Developmental Therapeutics Recent Publications

• Efficient standardization of clinical T(2)-weighted images: Phase-conjugacy e-CAMP with projected gradient descent.Zhang HZ, Elsaid NMH, Sun H, Tagare HD, Galiana G. Magn Reson Med. 2024 Dec; 2024 Jul 10. PMID: 38988054.
• Branching in poly(amine-co-ester) polyplexes impacts mRNA transfection.Shin K, Suh HW, Suberi A, Whang CH, Ene M, Grundler J, Grun MK, Saltzman WM. Biomaterials. 2024 Dec; 2024 Jun 27. PMID: 38986360.
• Chitinase 3-like-1 (CHI3L1) in the pathogenesis of epidermal growth factor receptor mutant non-small cell lung cancer.Kamle S, Ma B, Schor G, Bailey M, Pham B, Cho I, Khan H, Azzoli C, Hofstetter M, Sadanaga T, Herbst R, Politi K, Lee CG, Elias JA. Transl Oncol. 2024 Nov; 2024 Aug 22. PMID: 39178575.
• Enantioselective S-Alkylation of Sulfenamides by Phase-Transfer Catalysis.Champlin AT, Kwon NY, Ellman JA. Angew Chem Int Ed Engl. 2024 Oct 14; 2024 Sep 12. PMID: 39058627.
• Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer.Santin AD, Corr BR, Spira A, Willmott L, Butrynski J, Tse KY, Patel J, Mekan S, Wu T, Lin KW, Kuo P, Dumbrava EE. J Clin Oncol. 2024 Oct 10; 2024 Jul 31. PMID: 39083724.
• Bacterial small molecule metabolites implicated in gastrointestinal cancer development.Turocy T, Crawford JM. Nat Rev Microbiol. 2024 Oct 7; 2024 Oct 7. PMID: 39375475.
• Targeted therapies for myelodysplastic Syndromes/Neoplasms (MDS): current landscape and future directions.Bidikian A, Bewersdorf JP, Shallis RM, Getz TM, Stempel JM, Kewan T, Stahl M, Zeidan AM. Expert Rev Anticancer Ther. 2024 Oct 5; 2024 Oct 5. PMID: 39367718.
• Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma.Botta GP, Abdelrahim M, Drengler RL, Aushev VN, Esmail A, Laliotis G, Brewer CM, George GV, Abbate SM, Chandana SR, Tejani MA, Malla M, Bansal D, Rivero-Hinojosa S, Spickard E, McCormick N, Cecchini M, Lacy J, Fei N, Kasi PM, Kasi A, Dayyani F, Hanna DL, Sharma S, Malhotra M, Aleshin A, Liu MC, Jurdi A. Oncologist. 2024 Oct 3. PMID: 39022993.
• Topography of mutational signatures in non-small cell lung cancer: emerging concepts, clinical applications, and limitations.Jayakrishnan R, Kwiatkowski DJ, Rose MG, Nassar AH. Oncologist. 2024 Oct 3. PMID: 38907669.
• Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients.Wang JZ, Landry AP, Raleigh DR, Sahm F, Walsh KM, Goldbrunner R, Yefet LS, Tonn JC, Gui C, Ostrom QT, Barnholtz-Sloan J, Perry A, Ellenbogen Y, Hanemann CO, Jungwirth G, Jenkinson MD, Tabatabai G, Mathiesen TI, McDermott MW, Tatagiba M, la Fougère C, Maas SLN, Galldiks N, Albert NL, Brastianos PK, Ehret F, Minniti G, Lamszus K, Ricklefs FL, Schittenhelm J, Drummond KJ, Dunn IF, Pathmanaban ON, Cohen-Gadol AA, Sulman EP, Tabouret E, Le Rhun E, Mawrin C, Moliterno J, Weller M, Bi WL, Gao A, Yip S, Niyazi M, Aldape K, Wen PY, Short S, Preusser M, Nassiri F, Zadeh G. Neuro Oncol. 2024 Oct 3. PMID: 38695575.
• NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion.Noronha KJ, Lucas KN, Paradkar S, Edmonds J, Friedman S, Murray MA, Liu S, Sajed DP, Sachs C, Spurrier J, Raponi M, Liang J, Zeng H, Sundaram RK, Shuch B, Vasquez JC, Bindra RS. Mol Cancer Res. 2024 Oct 2. PMID: 38949523.
• CYP2E1 in 1,4-dioxane metabolism and liver toxicity: insights from CYP2E1 knockout mice study.Wang Y, Charkoftaki G, Orlicky DJ, Davidson E, Aalizadeh R, Sun N, Ginsberg G, Thompson DC, Vasiliou V, Chen Y. Arch Toxicol. 2024 Oct; 2024 Aug 27. PMID: 39192018.
• Prevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis.Muradashvili T, Yu M, Browning SL, Bar N, Gorshein E, Parker TL, Neparidze N. Leukemia. 2024 Oct; 2024 Aug 20. PMID: 39164408.
• Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma.Tripathi A, Tangen CM, Plets M, Li X, Tretiakova M, Humphrey PA, Adeniran A, Barata PC, Gulati S, Bergerot CD, Pruthi DK, Thompson IM, Lara PN Jr, Lerner SP, Pal SK, Shuch BM. BJU Int. 2024 Oct; 2024 Jul 16. PMID: 39014969.
• Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma.McNamara B, Greenman M, Bellone S, Santin LA, Demirkiran C, Mutlu L, Hartwich TMP, Yang-Hartwich Y, Ratner E, Schwartz PE, Santin AD. Gynecol Oncol. 2024 Oct; 2024 Jul 8. PMID: 38981151.
• Risk Factors and Contemporary Management Options for Pain and Discomfort Experienced During a Prostate Biopsy.Diaz GM, Webb LT, Rabil MJ, Lokeshwar SD, Choksi AU, Leapman MS, Sprenkle PC. Curr Urol Rep. 2024 Oct; 2024 Jun 19. PMID: 38896314.
• Automated graded prognostic assessment for patients with hepatocellular carcinoma using machine learning.Gross M, Haider SP, Ze'evi T, Huber S, Arora S, Kucukkaya AS, Iseke S, Gebauer B, Fleckenstein F, Dewey M, Jaffe A, Strazzabosco M, Chapiro J, Onofrey JA. Eur Radiol. 2024 Oct; 2024 Mar 27. PMID: 38536464.
• Synthesis of Monodehydro-Diketopiperazines Enabled by Cp*Rh(III)-Catalyzed Amine-Directed N-H Functionalization.Molas JC, Poag EM, Ellman JA. Org Lett. 2024 Sep 27; 2024 Sep 27. PMID: 39332014.
• Unmet needs in cervical cancer - can biological therapies plug the gap?Greenman M, Chang YE, McNamara B, Mutlu L, Santin AD. Expert Opin Biol Ther. 2024 Sep 25; 2024 Sep 25. PMID: 39311611.
• Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML.Bewersdorf JP, Shimony S, Shallis RM, Liu Y, Berton G, Schaefer EJ, Zeidan AM, Goldberg AD, Stein EM, Marcucci G, Bystrom RP, Lindsley RC, Chen EC, Ramos Perez J, Stein A, Pullarkat V, Aldoss I, DeAngelo DJ, Neuberg DS, Stone RM, Garciaz S, Ball B, Stahl M. Blood Adv. 2024 Sep 24. PMID: 38941537.
• Contemporary Approach to The Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes- Recommendations from The International Consortium for MDS (icMDS).Aakash F, Gisriel SD, Zeidan AM, Bennett JM, Bejar R, Bewersdorf JP, Borate UM, Boultwood J, Brunner AM, Buckstein R, Carraway H, Churpek JE, Daver NG, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Garcia-Manero G, Gore SD, Greenberg PL, Griffiths EA, Halene S, Hourigan CS, Kim TK, Kim N, Komrokji RS, Kutchroo V, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Platzbecker U, Della Porta MG, Roboz GJ, Sallman DA, Santini V, Sanz G, Savona MR, Sekeres MA, Stahl M, Starczynowski DT, Steensma DP, Taylor J, Abdel-Wahab O, Wei AH, Zhuoer X, Xu ML, Hasserjian RP, Loghavi S. Mod Pathol. 2024 Sep 23; 2024 Sep 23. PMID: 39322118.
• IL-1β Induces Human Endothelial Surface Expression of IL-15 by Relieving let-7c-3p Suppression of Protein Translation.Mullan CW, Summer L, Lopez-Giraldez F, Tobiasova Z, Manes TD, Yasothan S, Song G, Jane-Wit D, Saltzman WM, Pober JS. J Immunol. 2024 Sep 20; 2024 Sep 20. PMID: 39302113.
• Disulfide Tethering to Map Small Molecule Binding Sites Transcriptome-wide.Moon MH, Vock IW, Streit AD, Connor LJ, Senkina J, Ellman JA, Simon MD. ACS Chem Biol. 2024 Sep 20; 2024 Aug 28. PMID: 39192734.
• Prodrug nanotherapy demonstrates in vivo anticryptosporidial efficacy in a mouse model of chronic Cryptosporidium infection.Ranjan AP, Czyzyk DJ, Martinez-Traverso G, Sadiqova A, Valhondo M, Schaefer DA, Spasov KA, Jorgensen WL, Vishwanatha JK, Riggs MW, Castellanos-Gonzalez A, Anderson KS. RSC Pharm. 2024 Sep 19; 2024 Sep 19. PMID: 39372445.
• Microbial transformation of dietary xenobiotics shapes gut microbiome composition.Culp EJ, Nelson NT, Verdegaal AA, Goodman AL. Cell. 2024 Sep 19; 2024 Sep 19. PMID: 39321800.
• A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients With Small Cell Lung Cancer.Morgensztern D, Ready N, Johnson ML, Dowlati A, Choudhury N, Carbone DP, Schaefer E, Arnold SM, Puri S, Piotrowska Z, Hegde A, Chiang AC, Iams W, Tolcher A, Nosaki K, Kozuki T, Li T, Santana-Davila R, Akamatsu H, Murakami H, Yokouchi H, Wang S, Zha J, Li R, Robinson RR, Hingorani P, Jeng EE, Furqan M. Clin Cancer Res. 2024 Sep 17; 2024 Sep 17. PMID: 39287821.
• High-quality lipid suppression and B0 shimming for human brain (1)H MRSI.Kumaragamage C, McIntyre S, Nixon TW, De Feyter HM, de Graaf RA. Neuroimage. 2024 Sep 12; 2024 Sep 12. PMID: 39276817.
• Development of Ligands and Degraders Targeting MAGE-A3.Li K, Krone MW, Butrin A, Bond MJ, Linhares BM, Crews CM. J Am Chem Soc. 2024 Sep 11; 2024 Aug 27. PMID: 39190582.
• Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC.Nassar AH, Jayakrishnan R, Feng J, Shepherd F, Adib E, Cheung JM, Lin JJ, Liu Y, Lin SH, Parikh K, Sridhar A, Shakya P, Dilling TJ, Kaldas D, Gray JE, Lobachov A, Bar J, Luders H, Grohe C, Gupta S, Leal T, Fitzgerald B, Crowley F, Fujiwara Y, Marron TU, Wilgucki M, Reuss J, Chen L, Sankar K, Aredo JV, Neal JW, Wakelee HA, Thummalapalli R, Yu H, Whitaker R, Velazquez A, Ragavan M, Cortellini A, Kwiatkowski DJ, Naqash AR, Goldberg SB, Kim SY. J Thorac Oncol. 2024 Sep 10; 2024 Sep 10. PMID: 39260522.
• Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma.Barata P, Tangen C, Plets M, Thompson IM Jr, Narayan V, George DJ, Heng DYC, Shuch B, Stein M, Gulati S, Tretiakova M, Tripathi A, Bjarnason GA, Humphrey P, Adeniran A, Vaishampayan U, Alva A, Zhang T, Cole S, Lara PN Jr, Lerner SP, Balzer-Haas N, Pal SK. J Clin Oncol. 2024 Sep 10; 2024 Sep 10. PMID: 39255440.
• Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma.Straining R, Foss F, Schiffer M, Amin K, Agarwal S, Isufi I, Huntington S, Kothari S, Seropian S, Girardi M, Sethi T. Clin Lymphoma Myeloma Leuk. 2024 Sep 8; 2024 Sep 8. PMID: 39368885.
• Portal Fibrosis and the Ductular Reaction: Pathophysiological Role in the Progression of Liver Disease and Translational Opportunities.Gupta V, Sehrawat TS, Pinzani M, Strazzabosco M. Gastroenterology. 2024 Sep 7; 2024 Sep 7. PMID: 39251168.
• Dynamic and structural insights into allosteric regulation on MKP5 a dual-specificity phosphatase.Skeens E, Maschietto F, Manjula R, Shillingford S, Lolis EJ, Batista VS, Bennett AM, Lisi GP. bioRxiv. 2024 Sep 5; 2024 Sep 5. PMID: 39282375.
• Pancreatic Cysts.Gonda TA, Cahen DL, Farrell JJ. N Engl J Med. 2024 Sep 5. PMID: 39231345.
• Aplastic anemia in association with multiple myeloma: clinical and pathophysiological insights.Muradashvili T, Liu Y, VanOudenhove J, Gu SX, Krause DS, Montanari F, Carlino MJ, Mancuso R, Stempel JM, Halene S, Zeidan AM, Podoltsev NA, Neparidze N. Leuk Lymphoma. 2024 Sep 3; 2024 Sep 3. PMID: 39225418.
• Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors.Choi Y, Dharia NV, Jun T, Chang J, Royer-Joo S, Yau KK, Assaf ZJ, Aimi J, Sivakumar S, Montesion M, Sacher A, LoRusso P, Desai J, Schutzman JL, Shi Z. Clin Cancer Res. 2024 Sep 3. PMID: 38995268.
• Management of recurrent and persistent malignant ovarian germ cell tumors: a narrative review.Nasioudis D, Pashankar FD. Int J Gynecol Cancer. 2024 Sep 2; 2024 Sep 2. PMID: 38991656.
• Preclinical evaluation of avutometinib and defactinib in high-grade endometrioid endometrial cancer.Hartwich TMP, Mansolf M, Demirkiran C, Greenman M, Bellone S, McNamara B, Nandi SP, Alexandrov LB, Yang-Hartwich Y, Coma S, Pachter J, Santin AD. Cancer Med. 2024 Sep. PMID: 39240189.
• Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.Robichaux JP, Elamin YY, Tan Z, Carter BW, Zhang S, Liu S, Li S, Chen T, Poteete A, Estrada-Bernal A, Le AT, Truini A, Nilsson MB, Sun H, Roarty E, Goldberg SB, Brahmer JR, Altan M, Lu C, Papadimitrakopoulou V, Politi K, Doebele RC, Wong KK, Heymach JV. Nat Med. 2024 Sep. PMID: 39164519.
• Akt is a mediator of artery specification during zebrafish development.Zhou W, Ghersi JJ, Ristori E, Semanchik N, Prendergast A, Zhang R, Carneiro P, Baldissera G, Sessa WC, Nicoli S. Development. 2024 Sep 1; 2024 Sep 2. PMID: 39101673.
• Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial.Della Porta MG, Garcia-Manero G, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcárcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Pilot R, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Prebet T, Lai Y, Degulys A, Paolini S, Cluzeau T, Fenaux P, Platzbecker U. Lancet Haematol. 2024 Sep; 2024 Jul 19. PMID: 39038479.
• Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial.Dzienis M, Cundom J, Fuentes CS, Spreafico A, Nordlinger M, Pastor AV, Alesi E, Neki A, Fung AS, Figueiredo Lima IP, Oppelt P, da Cunha Junior GF, Burtness B, Franke FA, Tseng JE, Joshi A, McCarthy J, Swaby R, Sidi Y, Gumuscu B, Naicker N, de Castro G Jr. J Clin Oncol. 2024 Sep 1; 2024 Jul 22. PMID: 39038265.
• Enterococcus faecalis-derived adenine enhances enterohaemorrhagic Escherichia coli Type 3 Secretion System-dependent virulence.Martins FH, Rosay T, Rajan A, Carter HE, Turocy T, Mejia A, Crawford JM, Maresso AW, Sperandio V. Nat Microbiol. 2024 Sep; 2024 Jul 4. PMID: 38965331.
• Quantitative Measurement of HER2 Expression in Non-Small Cell Lung Cancer With a High-Sensitivity Assay.Liu M, Vathiotis I, Robbins CJ, Chan NNN, Moutafi M, Burela S, Xirou V, Schalper KA, Herbst RS, Syrigos K, Rimm DL. Mod Pathol. 2024 Sep; 2024 Jul 2. PMID: 38964502.
• Patterns of brain metastases response to immunotherapy with pembrolizumab.Mahajan A, Goldberg SL, Weiss SA, Tran T, Singh K, Joshi K, Aboian MS, Kluger HM, Chiang VL. J Neurooncol. 2024 Sep; 2024 Jul 4. PMID: 38963658.
• Outcomes Following Implementation of an Electronic Model for Perioperative Hematologic Consultation.Su DG, Rehman S, Wang K, Deng Y, Rose MG, Dosani T, Kunstman JW. J Surg Res. 2024 Sep; 2024 Jun 20. PMID: 38905768.
• ZFYVE21 promotes endothelial nitric oxide signaling and vascular barrier function in the kidney during aging.Jiang Q, Song G, He L, Li X, Jiang B, Wang Q, Wang S, Kim C, Barkestani MN, Lopez R, Fan M, Wanniarachchi K, Quaranta M, Tian X, Mani A, Gonzalez A, Goodwin JE, Sessa WC, Ishibe S, Jane-Wit D. Kidney Int. 2024 Sep; 2024 May 24. PMID: 38797325.
• Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208).Hochster HS, Catalano P, Weitz M, Mitchell EP, Cohen D, O'Dwyer PJ, Faller BA, Kortmansky JS, O'Hara MH, Kricher SM, Lacy J, Lenz HJ, Verma U, Benson AB. J Natl Cancer Inst. 2024 Sep 1. PMID: 38775718.
• Modifying the Backbone Chemistry of PEG-Based Bottlebrush Block Copolymers for the Formation of Long-Circulating Nanoparticles.Grundler J, Whang CH, Shin K, Savan NA, Zhong M, Saltzman WM. Adv Healthc Mater. 2024 Sep; 2024 May 22. PMID: 38734871.
• Challenges in management of older patients with chronic myeloid leukemia.Stempel JM, Shallis RM, Wong R, Podoltsev NA. Leuk Lymphoma. 2024 Sep; 2024 Apr 23. PMID: 38652861.
• Practical utilization of nonlinear spatial encoding: Fast field mapping and FRONSAC-wave.Zhang HZ, Constable RT, Galiana G. Magn Reson Med. 2024 Sep; 2024 Apr 23. PMID: 38651264.
• Prominent role of gut dysbiosis in the pathogenesis of cystic fibrosis-related liver disease in mice.Bertolini A, Nguyen M, Zehra SA, Taleb SA, Bauer-Pisani T, Palm N, Strazzabosco M, Fiorotto R. J Hepatol. 2024 Sep; 2024 Mar 28. PMID: 38554847.
• Variations in the genomic profiles and clinical behavior of meningioma by racial and ethnic group.Tabor JK, Dincer A, O'Brien J, Lei H, Vetsa S, Vasandani S, Jalal MI, Yalcin K, Morales-Valero SF, Marianayagam N, Alanya H, Elsamadicy AA, Millares Chavez MA, Aguilera SM, Mishra-Gorur K, McGuone D, Fulbright RK, Jin L, Erson-Omay EZ, Günel M, Moliterno J. J Neurosurg. 2024 Sep 1; 2024 Mar 22. PMID: 38518289.
• Cathepsin B Nuclear Flux in a DNA-Guided "Antinuclear Missile" Cancer Therapy.Cao F, Tang C, Chen X, Tu Z, Jin Y, Turk OM, Nishimura RN, Ebens A, Dubljevic V, Campbell JA, Zhou J, Hansen JE. ACS Cent Sci. 2024 Aug 28; 2024 Jul 15. PMID: 39220699.
• Clinical Presentation, Management, and Outcome in Neurolymphomatosis: A Systematic Review.Kaulen LD, Hielscher T, Doubrovinskaia S, Hoffmann DC, Kessler T, Traub BL, Baehring JM, Wick W. Neurology. 2024 Aug 27; 2024 Aug 5. PMID: 39102613.
• Prognostic implications of margin status in association with systemic treatment in a cohort study of patients with resection of colorectal liver metastases.Moaven O, Mainali BB, Valenzuela CD, Russell G, Cheung T, Corvera CU, Wisneski AD, Cha CH, Stauffer JA, Shen P. J Surg Oncol. 2024 Aug 25; 2024 Aug 25. PMID: 39183490.
• Use of Mitotic Activity and the Size of Any Dedifferentiated Component for Risk Assessment in MDM2-Amplified Liposarcoma.Wu H, Sukhanova M, Tang H, Lu X, Zhong M, Deshpande H, Pollack SM, Laskin WB, Alexiev BA. Arch Pathol Lab Med. 2024 Aug 21; 2024 Aug 21. PMID: 39164013.
• Impact of Social Needs and Identity Experiences on the Burden of Illness in Patients with Multiple Myeloma: A Mixed-Methods Study.Neparidze N, Godara A, Lin D, Le HH, Fixler K, Shea L, Everson S, Brittle C, Brunisholz KD. Healthcare (Basel). 2024 Aug 20; 2024 Aug 20. PMID: 39201218.
• Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes.Tentori CA, Gregorio C, Robin M, Gagelmann N, Gurnari C, Ball S, Caballero Berrocal JC, Lanino L, D'Amico S, Spreafico M, Maggioni G, Travaglino E, Sauta E, Meggendorfer M, Zhao LP, Campagna A, Savevski V, Santoro A, Al Ali N, Sallman D, Sole F, Garcia-Manero G, Germing U, Kroger N, Kordasti S, Santini V, Sanz G, Kern W, Platzbecker U, Diez-Campelo M, Maciejewski JP, Ades L, Fenaux P, Haferlach T, Zeidan AM, Castellani G, Komrokji R, Ieva F, Della Porta MG. J Clin Oncol. 2024 Aug 20; 2024 May 9. PMID: 38723212.
• Catalytic Enantioselective Sulfoxidation of Functionalized Thioethers Mediated by Aspartic Acid-Containing Peptides.Huth SE, Tampellini N, Guerrero MD, Miller SJ. Org Lett. 2024 Aug 16; 2024 Aug 5. PMID: 39102356.
• Regulated induced proximity targeting chimeras-RIPTACs-A heterobifunctional small molecule strategy for cancer selective therapies.Raina K, Forbes CD, Stronk R, Rappi JP Jr, Eastman KJ, Zaware N, Yu X, Li H, Bhardwaj A, Gerritz SW, Forgione M, Hundt A, King MP, Posner ZM, Correia AD, McGovern A, Puleo DE, Chenard R, Mousseau JJ, Vergara JI, Garvin E, Macaluso J, Martin M, Bassoli K, Jones K, Garcia M, Howard K, Yaggi M, Smith LM, Chen JM, Mayfield AB, De Leon CA, Hines J, Kayser-Bricker KJ, Crews CM. Cell Chem Biol. 2024 Aug 15; 2024 Aug 7. PMID: 39116881.
• Spatially Informed Gene Signatures for Response to Immunotherapy in Melanoma.Aung TN, Warrell J, Martinez-Morilla S, Gavrielatou N, Vathiotis I, Yaghoobi V, Kluger HM, Gerstein M, Rimm DL. Clin Cancer Res. 2024 Aug 15. PMID: 38837895.
• Monte Carlo simulations for free energies of hydration: Past to present.Jorgensen WL. J Chem Phys. 2024 Aug 14. PMID: 39136662.
• Parkinsonism Following Chimeric Antigen Receptor T Cell Therapy.Gudera JA, Baehring JM, Karschnia P. JAMA Neurol. 2024 Aug 12; 2024 Aug 12. PMID: 39133506.
• Addressing platelet insecurity - A national call to action.Gehrie EA, Young PP, Basavaraju SV, Bracey AW, Cap AP, Culler L, Dunbar NM, Homer M, Isufi I, Macedo R, Petraszko T, Ramsey G, Tormey CA, Kaufman RM, Snyder EL. Transfusion. 2024 Aug 12; 2024 Aug 12. PMID: 39133194.
• Progression of Femoral Osteolytic Metastases after Intramedullary Nailing and Subsequent Salvage Techniques.Jiang W, Latich I, Lindskog D, Friedlaender G, Lee FY. Cancers (Basel). 2024 Aug 10; 2024 Aug 10. PMID: 39199585.
• Patient Perspectives on Social and Identity Factors Affecting Multiple Myeloma Care: Barriers and Opportunities.Neparidze N, Godara A, Lin D, Le HH, Fixler K, Shea L, Everson S, Brittle C, Brunisholz KD. Healthcare (Basel). 2024 Aug 9; 2024 Aug 9. PMID: 39201146.
• Human AKR1C3 binds agonists of GPR84 and participates in an expanded polyamine pathway.Dudkina N, Park HB, Song D, Jain A, Khan SA, Flavell RA, Johnson CH, Palm NW, Crawford JM. Cell Chem Biol. 2024 Aug 9; 2024 Aug 9. PMID: 39163853.
• Enhanced Intratumoral Delivery of Immunomodulator Monophosphoryl Lipid A through Hyperbranched Polyglycerol-Coated Biodegradable Nanoparticles.Chang J, Shin K, Lewis JM, Suh HW, Lee J, Damsky W, Xu S, Bosenberg M, Saltzman WM, Girardi M. J Invest Dermatol. 2024 Aug 8; 2024 Aug 8. PMID: 39122142.
• Factors influencing timely diagnosis in neurolymphomatosis.Doubrovinskaia S, Egert A, Karschnia P, Scheffler GT, Traub BL, Galluzzo D, Huttner A, Fulbright RK, Baehring JM, Kaulen LD. J Neurooncol. 2024 Aug 8; 2024 Aug 8. PMID: 39115616.
• TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3.Perales O, Jilaveanu L, Adeniran A, Su DG, Hurwitz M, Braun DA, Kluger HM, Schoenfeld DA. Cancer Immunol Immunother. 2024 Aug 6; 2024 Aug 6. PMID: 39105820.
• GP100 expression is variable in intensity in melanoma.Mann JE, Hasson N, Su DG, Adeniran AJ, Smalley KSM, Djureinovic D, Jilaveanu LB, Schoenfeld DA, Kluger HM. Cancer Immunol Immunother. 2024 Aug 6; 2024 Aug 6. PMID: 39105816.
• A Th17 cell-intrinsic glutathione/mitochondrial-IL-22 axis protects against intestinal inflammation.Bonetti L, Horkova V, Grusdat M, Longworth J, Guerra L, Kurniawan H, Franchina DG, Soriano-Baguet L, Binsfeld C, Verschueren C, Spath S, Ewen A, Koncina E, Gérardy JJ, Kobayashi T, Dostert C, Farinelle S, Härm J, Fan YT, Chen Y, Harris IS, Lang PA, Vasiliou V, Waisman A, Letellier E, Becher B, Mittelbronn M, Brenner D. Cell Metab. 2024 Aug 6; 2024 Jul 9. PMID: 38986617.
• Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400).Kozono D, Hua X, Wu MC, Tolba KA, Waqar SN, Dragnev KH, Cheng H, Hirsch FR, Mack PC, Gray JE, Kelly K, Borghaei H, Herbst RS, Gandara DR, Redman MW. J Thorac Oncol. 2024 Aug 5; 2024 Aug 5. PMID: 39111731.
• Next generation triplex-forming PNAs for site-specific genome editing of the F508del CFTR mutation.Gupta A, Barone C, Quijano E, Piotrowski-Daspit AS, Perera JD, Riccardi A, Jamali H, Turchick A, Zao W, Saltzman WM, Glazer PM, Egan ME. J Cyst Fibros. 2024 Aug 5; 2024 Aug 5. PMID: 39107154.
• Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting.Leapman MS, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot JA, Davicioni E, Martin DT, An Y, Seibert TM, Lin DW, Spratt DE, Cooperberg MR, Sprenkle PC, Ross AE. Eur Urol Oncol. 2024 Aug 3; 2024 Aug 3. PMID: 39098389.
• Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape.Weller M, Remon J, Rieken S, Vollmuth P, Ahn MJ, Minniti G, Le Rhun E, Westphal M, Brastianos PK, Soo RA, Kirkpatrick JP, Goldberg SB, Öhrling K, Hegi-Johnson F, Hendriks LEL. Cancer Treat Rev. 2024 Aug 2; 2024 Aug 2. PMID: 39151281.
• Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors.Schoenfeld AJ, Lee SM, Doger de Spéville B, Gettinger SN, Häfliger S, Sukari A, Papa S, Rodríguez-Moreno JF, Graf Finckenstein F, Fiaz R, Catlett M, Chen G, Qi R, Masteller EL, Gontcharova V, He K. Cancer Discov. 2024 Aug 2. PMID: 38563600.
• CRISPR-based dissection of microRNA-23a ~ 27a ~ 24-2 cluster functionality in hepatocellular carcinoma.Cui M, Liu Z, Wang S, Bae S, Guo H, Zhou J, Liu R, Wang L. Oncogene. 2024 Aug; 2024 Aug 7. PMID: 39112518.
• Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer.Greenman M, Bellone S, Demirkiran C, Max Philipp Hartwich T, Santin AD. Gynecol Oncol Rep. 2024 Aug; 2024 Jul 13. PMID: 39108617.
• Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study.Philip PA, Sahai V, Bahary N, Mahipal A, Kasi A, Rocha Lima CMS, Alistar AT, Oberstein PE, Golan T, Metges JP, Lacy J, Fountzilas C, Lopez CD, Ducreux M, Hammel P, Salem M, Bajor D, Benson AB, Luther S, Pardee T, Van Cutsem E. J Clin Oncol. 2024 Aug 1; 2024 Aug 1. PMID: 39088774.
• Burnout and career satisfaction in young neuro-oncology investigators: Results of the Society for Neuro-Oncology Young Investigator Survey.Youssef G, Acquaye-Mallory A, Vera E, Chheda MG, Dunn GP, Moliterno J, O'Brien BJ, Venere M, Yust-Katz S, Lee EQ, Armstrong TS. Neurooncol Pract. 2024 Aug; 2024 Mar 13. PMID: 39006527.
• Pancreatic Cancer Surveillance and Survival of High-Risk Individuals.Blackford AL, Canto MI, Dbouk M, Hruban RH, Katona BW, Chak A, Brand RE, Syngal S, Farrell J, Kastrinos F, Stoffel EM, Rustgi A, Klein AP, Kamel I, Fishman EK, He J, Burkhart R, Shin EJ, Lennon AM, Goggins M. JAMA Oncol. 2024 Aug 1. PMID: 38959011.
• Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER(+)HER2(-) metastatic breast cancer: a phase 1 trial.Mukohara T, Park YH, Sommerhalder D, Yonemori K, Hamilton E, Kim SB, Kim JH, Iwata H, Yamashita T, Layman RM, Mita M, Clay T, Chae YS, Oakman C, Yan F, Kim GM, Im SA, Lindeman GJ, Rugo HS, Liyanage M, Saul M, Le Corre C, Skoura A, Liu L, Li M, LoRusso PM. Nat Med. 2024 Aug. PMID: 38914862.
• Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial.Cecchini M, Salem RR, Robert M, Czerniak S, Blaha O, Zelterman D, Rajaei M, Townsend JP, Cai G, Chowdhury S, Yugawa D, Tseng R, Mejia Arbelaez C, Jiao J, Shroyer K, Thumar J, Kortmansky J, Zaheer W, Fischbach N, Persico J, Stein S, Khan SA, Cha C, Billingsley KG, Kunstman JW, Johung KL, Wiess C, Muzumdar MD, Spickard E, Aushev VN, Laliotis G, Jurdi A, Liu MC, Escobar-Hoyos L, Lacy J. JAMA Oncol. 2024 Aug 1. PMID: 38900452.
• Latrophilin-2 mediates fluid shear stress mechanotransduction at endothelial junctions.Tanaka K, Chen M, Prendergast A, Zhuang Z, Nasiri A, Joshi D, Hintzen J, Chung M, Kumar A, Mani A, Koleske A, Crawford J, Nicoli S, Schwartz MA. EMBO J. 2024 Aug; 2024 Jun 17. PMID: 38886581.
• Inhibition of lysine acetyltransferase KAT6 in ER(+)HER2(-) metastatic breast cancer: a phase 1 trial.Mukohara T, Park YH, Sommerhalder D, Yonemori K, Hamilton E, Kim SB, Kim JH, Iwata H, Yamashita T, Layman RM, Mita M, Clay T, Chae YS, Oakman C, Yan F, Kim GM, Im SA, Lindeman GJ, Rugo HS, Liyanage M, Saul M, Le Corre C, Skoura A, Liu L, Li M, LoRusso PM. Nat Med. 2024 Aug; 2024 Jun 1. PMID: 38824244.
• Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study.Bewersdorf JP, Shimony S, Shallis RM, Liu Y, Berton G, Schaefer EJ, Zeidan AM, Goldberg A, Stein E, Marcucci G, Bystrom RP, Lindsley RC, Chen EC, Ramos J, Stein A, Pullarkat V, Aldoss I, DeAngelo DJ, Neuberg DS, Stone RM, Garciaz S, Ball B, Stahl M. Am J Hematol. 2024 Aug; 2024 May 15. PMID: 38751104.
• Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas.Demirkiran C, Greenman M, Bellone S, McNamara B, Hartwich TMP, Manavella D, Mutlu L, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz PE, Coma S, Pachter J, Santin AD. Gynecol Oncol. 2024 Aug; 2024 May 3. PMID: 38703673.
• Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update Clinical Insights.Rose MG, Kennedy EB, Abou-Alfa GK, Finn RS, Gade T, Kelley RK, Taddei T, Gordan JD. JCO Oncol Pract. 2024 Aug; 2024 Apr 25. PMID: 38662970.
• Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice.Chojecki A, Boselli D, Dortilus A, Hamadeh I, Begley S, Chen T, Bose R, Podoltsev N, Zeidan AM, Balmaceda NB, Yacoub A, Ai J, Knight TG, Ragon BK, Shah NA, Sanikommu SR, Symanowski J, Mesa R, Grunwald MR. Ann Hematol. 2024 Aug; 2024 Apr 25. PMID: 38662203.
• Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia.Bewersdorf JP, Patel KK, Shallis RM, Podoltsev NA, Kewan T, Stempel J, Mendez L, Stahl M, Stein EM, Huntington SF, Goshua G, Zeidan AM. Leuk Lymphoma. 2024 Aug; 2024 Apr 22. PMID: 38648559.
• Identifying Opportunities to Deliver High-Quality Cancer Care Across a Health System: A Clinical Responsibility.Shah HP, Cohen O, Bourdillon AT, Burtness BA, Boffa DJ, Young M, Judson BL, Mehra S. Otolaryngol Head Neck Surg. 2024 Aug; 2024 Apr 12. PMID: 38606669.
• Automated MRI liver segmentation for anatomical segmentation, liver volumetry, and the extraction of radiomics.Gross M, Huber S, Arora S, Ze'evi T, Haider SP, Kucukkaya AS, Iseke S, Kuhn TN, Gebauer B, Michallek F, Dewey M, Vilgrain V, Sartoris R, Ronot M, Jaffe A, Strazzabosco M, Chapiro J, Onofrey JA. Eur Radiol. 2024 Aug; 2024 Jan 13. PMID: 38217704.
• Patients' perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms.Zeidan AM, Perepezko K, Salimi T, Washington T, Epstein RS. Ther Adv Hematol. 2024; 2024 Jul 30. PMID: 39091323.
• Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era.Lee DY, McNamara M, Yang A, Yaskolko M, Kluger H, Tran T, Olino K, Clune J, Sznol M, Ishizuka JJ. Pigment Cell Melanoma Res. 2024 Jul 28; 2024 Jul 28. PMID: 39073002.
• Rh(II)-Catalyzed Enantioselective S-Alkylation of Sulfenamides with Acceptor-Acceptor Diazo Compounds Enables the Synthesis of Sulfoximines Displaying Diverse Functionality.Patel S, Greenwood NS, Mercado BQ, Ellman JA. Org Lett. 2024 Jul 26; 2024 Jul 14. PMID: 39004842.
• Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.Litzow MR, Sun Z, Mattison RJ, Paietta EM, Roberts KG, Zhang Y, Racevskis J, Lazarus HM, Rowe JM, Arber DA, Wieduwilt MJ, Liedtke M, Bergeron J, Wood BL, Zhao Y, Wu G, Chang TC, Zhang W, Pratz KW, Dinner SN, Frey N, Gore SD, Bhatnagar B, Atallah EL, Uy GL, Jeyakumar D, Lin TL, Willman CL, DeAngelo DJ, Patel SB, Elliott MA, Advani AS, Tzachanis D, Vachhani P, Bhave RR, Sharon E, Little RF, Erba HP, Stone RM, Luger SM, Mullighan CG, Tallman MS. N Engl J Med. 2024 Jul 25. PMID: 39047240.
• Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC).Pike LRG, Miao E, Boe LA, Patil T, Imber BS, Myall NJ, Pollom EL, Hui C, Qu V, Langston J, Chiang V, Grant M, Goldberg SB, Palmer JD, Prasad RN, Wang TJC, Lee A, Shu CA, Chen LN, Thomas NJ, Braunstein SE, Kavanagh BD, Camidge DR, Rusthoven CG. J Clin Oncol. 2024 Jul 24; 2024 Jul 24. PMID: 39047224.
• The Xenorhabdus nematophila LrhA transcriptional regulator modulates production of γ-keto-N-acyl amides with inhibitory activity against mutualistic host nematode egg hatching.Lam YC, Hamchand R, Mucci NC, Kauffman SJ, Dudkina N, Reagle EV, Casanova-Torres ÁM, DeCuyper J, Chen H, Song D, Thomas MG, Palm NW, Goodrich-Blair H, Crawford JM. Appl Environ Microbiol. 2024 Jul 24; 2024 Jun 25. PMID: 38916293.
• Glutathione synthesis in the mouse liver supports lipid abundance through NRF2 repression.Asantewaa G, Tuttle ET, Ward NP, Kang YP, Kim Y, Kavanagh ME, Girnius N, Chen Y, Rodriguez K, Hecht F, Zocchi M, Smorodintsev-Schiller L, Scales TQ, Taylor K, Alimohammadi F, Duncan RP, Sechrist ZR, Agostini-Vulaj D, Schafer XL, Chang H, Smith ZR, O'Connor TN, Whelan S, Selfors LM, Crowdis J, Gray GK, Bronson RT, Brenner D, Rufini A, Dirksen RT, Hezel AF, Huber AR, Munger J, Cravatt BF, Vasiliou V, Cole CL, DeNicola GM, Harris IS. Nat Commun. 2024 Jul 21; 2024 Jul 21. PMID: 39034312.
• Tumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making.Sobirey R, Matuschewski N, Gross M, Lin M, Kao T, Kasolowsky V, Strazzabosco M, Stein S, Savic LJ, Gebauer B, Jaffe A, Duncan J, Madoff DC, Chapiro J. Eur Radiol. 2024 Jul 20; 2024 Jul 20. PMID: 39033181.
• PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer.Barlesi F, Cho BC, Goldberg SB, Yoh K, Zimmer Gelatti AC, Mann H, Gopinathan A, Bielecka ZF, Newton M, Aggarwal C. Future Oncol. 2024 Jul 18; 2024 Jul 18. PMID: 39023287.
• Intramolecular Oxyalkylation of Unactivated Alkenes.Xu Z, Airan Y, Tomanik M, Yang AT, Bhak N, Herzon SB. Tetrahedron. 2024 Jul 17; 2024 May 31. PMID: 38911481.
• Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer.Sundaresan VM, Wang R, Long JB, Sprenkle PC, Seibert TM, Loeb S, Cooperberg MR, Catalona WJ, Ma X, Gross CP, Leapman MS. Urol Pract. 2024 Jul 16; 2024 Jul 16. PMID: 39196719.
• Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement.Sundaresan VM, Smani S, Rajwa P, Renzulli J, Sprenkle PC, Kim IY, Leapman MS. Urol Oncol. 2024 Jul 16; 2024 Jul 16. PMID: 39019723.
• Androgen deprivation increases frontopolar cortical thickness in prostate cancer patients: an effect of early neurodegeneration?Chaudhary S, Roy A, Summers C, Ahles T, Li CR, Chao HH. Am J Cancer Res. 2024; 2024 Jul 15. PMID: 39113873.
• Association of Crowd-Sourced Assessment of Technical Skills and Outcomes of Robotic-assisted Radical Prostatectomy.Rabil MJ, Jalfon M, Heckscher D, Song Z, Li F, Martin T, Sprenkle PC, Hesse D, Kim IY, Leapman MS, Cavallo JA. Urology. 2024 Jul 15; 2024 Jul 15. PMID: 39019332.
• Risk Prediction for Clonal Cytopenia: Multicenter Real-World Evidence.Xie Z, Komrokji RS, Al-Ali N, Regelson A, Geyer S, Patel AA, Saygin C, Zeidan AM, Bewersdorf JP, Mendez LM, Kishtagari A, Zeidner JF, Coombs CC, Madanat YF, Chung SS, Badar T, Foran JM, Desai P, Tsai C, Griffiths EA, Al Malki MM, Amanam I, Lai C, Deeg HJ, Ades L, Arana-Yi C, Osman AE, Dinner SN, Abaza Y, Taylor J, Chandhok NS, Soong D, Brunner AM, Carraway HE, Singh A, Elena C, Ferrari J, Galli A, Pozzi S, Padron E, Patnaik MM, Malcovati L, Savona MR, Al-Kali A. Blood. 2024 Jul 12; 2024 Jul 12. PMID: 38996210.
• A crisis in clinical research.Hong DS, LoRusso P, Sznol M. J Immunother Cancer. 2024 Jul 11; 2024 Jul 11. PMID: 38991727.
• Mechanism of Action of KL-50, a Candidate Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers.Huseman ED, Lo A, Fedorova O, Elia JL, Gueble SE, Lin K, Sundaram RK, Oh J, Liu J, Menges F, Rees MG, Ronan MM, Roth JA, Batista VS, Crawford JM, Pyle AM, Bindra RS, Herzon SB. J Am Chem Soc. 2024 Jul 10; 2024 May 30. PMID: 38815248.
• Risk of Pancreatitis After Endoscopic Ultrasound-Guided Fine-Needle Aspiration of Pancreatic Cystic Lesions: A Systematic Review and Meta-Analysis.Magahis PT, Chhoda A, Berzin TM, Farrell JJ, Wright DN, Rizvi A, Hanscom M, Carr-Locke DL, Sampath K, Sharaiha RZ, Mahadev S. Am J Gastroenterol. 2024 Jul 5; 2024 Jul 5. PMID: 38976379.
• Acute myeloid leukemia (AML) with chromosome 3 inversion: biology, management, and clinical outcome.Alhajahjeh A, Bewersdorf JP, Bystrom RP, Zeidan AM, Shimony S, Stahl M. Leuk Lymphoma. 2024 Jul 4; 2024 Jul 4. PMID: 38962996.
• Age-related reduction in anxiety and neural encoding of negative emotional memory.Chaudhary S, Zhang S, Chen Y, Dominguez JC, Chao HH, Li CR. Front Aging Neurosci. 2024; 2024 Jul 3. PMID: 39021704.
• Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas.Di M, Potnis KC, Long JB, Isufi I, Foss F, Seropian S, Gross CP, Huntington SF. JNCI Cancer Spectr. 2024 Jul 1. PMID: 39115391.
• Prognostic Understanding, Goals of Care, and Quality of Life in Hospitalized Patients with Leukemia or Multiple Myeloma.Shimer S, Allen OS, Yang C, Canavan M, Westvold S, Kim N, Morillo J, Parker T, Wallace N, Smith CB, Adelson KB. J Palliat Med. 2024 Jul; 2024 Jul 11. PMID: 38990245.
• Phase II Trial of Afatinib in Patients With EGFR-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A.Gettinger SN, Song Z, Reckamp KL, Moscow JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Kong XT, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. JCO Precis Oncol. 2024 Jul. PMID: 38986051.
• A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).Maldonado E, Rathmell WK, Shapiro GI, Takebe N, Rodon J, Mahalingam D, Trikalinos NA, Kalebasty AR, Parikh M, Boerner SA, Balido C, Krings G, Burns TF, Bergsland EK, Munster PN, Ashworth A, LoRusso P, Aggarwal RR. Cancer Res Commun. 2024 Jul 1. PMID: 38920407.
• A small-molecule allele-selective transcriptional inhibitor of the MIF immune susceptibility locus.Li J, Leng L, Pantouris G, Manjula R, Piecychna M, Abriola L, Hu B, Lolis E, Armstrong ME, Donnelly SC, Bucala R. J Biol Chem. 2024 Jul; 2024 Jun 3. PMID: 38838773.
• Assessing readiness to use electronic health record data for outcome ascertainment in clinical trials - A case study.Esserman D, Greene EJ, Latham NK, Kane M, Lu C, Peduzzi PN, Gill TM, Ganz DA. Contemp Clin Trials. 2024 Jul; 2024 May 11. PMID: 38740298.
• Sarcomatoid and Rhabdoid Renal Cell Carcinoma: Clinical, Pathologic, and Molecular Genetic Features.Adeniran AJ, Shuch B, Humphrey PA. Am J Surg Pathol. 2024 Jul 1; 2024 May 13. PMID: 38736105.
• Constrained alternating minimization for parameter mapping (CAMP).Elsaid NMH, Dispenza NL, Hu C, Peters DC, Constable RT, Tagare HD, Galiana G. Magn Reson Imaging. 2024 Jul; 2024 Apr 23. PMID: 38657714.
• Validation of a Rule-Based ICD-10-CM Algorithm to Detect Fall Injuries in Medicare Data.Ganz DA, Esserman D, Latham NK, Kane M, Min LC, Gill TM, Reuben DB, Peduzzi P, Greene EJ. J Gerontol A Biol Sci Med Sci. 2024 Jul 1. PMID: 38566617.
• Disparities in race, ethnicity, sex, and age inclusion in pancreatic cancer screening studies: a systematic review and meta-analysis.Silva-Santisteban A, Hernandez Woodbine MJ, Noriega MA, Rabinowitz LG, Grimshaw A, Farrell JJ, Chhoda A, Sawhney MS. Gastrointest Endosc. 2024 Jul; 2024 Mar 1. PMID: 38432492.
• Low-Field, Low-Cost, Point-of-Care Magnetic Resonance Imaging.Samardzija A, Selvaganesan K, Zhang HZ, Sun H, Sun C, Ha Y, Galiana G, Constable RT. Annu Rev Biomed Eng. 2024 Jul; 2024 Jun 20. PMID: 38211326.
• A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer.Verma N, Johung KL, Kortmansky J, Zaheer W, Lacy J, Cecchini M, Stein S, Cheng YC, Lam W, Liu SH, Reddy V, Hochster H, Higgins SA. J Gastrointest Oncol. 2024 Jun 30; 2024 Jun 25. PMID: 38989411.
• Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity.Locke FL, Siddiqi T, Jacobson CA, Ghobadi A, Ahmed S, Miklos DB, Perales MA, Munoz J, Fingrut WB, Pennisi M, Gauthier J, Shadman M, Gowda L, Mirza AS, Abid MB, Hong S, Majhail NS, Kharfan-Dabaja MA, Khurana A, Badar T, Lin Y, Bennani NN, Herr MM, Hu ZH, Wang HL, Baer A, Baro E, Miao H, Spooner C, Xu H, Pasquini MC. Blood. 2024 Jun 27. PMID: 38635762.
• β-Amino Acids Reduce Ternary Complex Stability and Alter the Translation Elongation Mechanism.Cruz-Navarrete FA, Griffin WC, Chan YC, Martin MI, Alejo JL, Brady RA, Natchiar SK, Knudson IJ, Altman RB, Schepartz A, Miller SJ, Blanchard SC. ACS Cent Sci. 2024 Jun 26; 2024 Jun 4. PMID: 38947208.
• Fe/Thiol Cooperative Hydrogen Atom Transfer Olefin Hydrogenation: Mechanistic Insights That Inform Enantioselective Catalysis.Buzsaki SR, Mason SM, Kattamuri PV, Serviano JMI, Rodriguez DN, Wilson CV, Hood DM, Ellefsen JD, Lu YC, Kan J, West JG, Miller SJ, Holland PL. J Am Chem Soc. 2024 Jun 26; 2024 Jun 14. PMID: 38875703.
• Neutrophils insert elastase into hepatocytes to regulate calcium signaling in alcohol-associated hepatitis.Ogino N, Leite MF, Guerra MT, Kruglov E, Asashima H, Hafler DA, Ito T, Pereira JP, Peiffer BJ, Sun Z, Ehrlich BE, Nathanson MH. J Clin Invest. 2024 Jun 25; 2024 Jun 25. PMID: 38916955.
• Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2.Mutlu L, McNamara B, Bellone S, Manavella DD, Demirkiran C, Greenman M, Verzosa MSZ, Buza N, Hui P, Hartwich TMP, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang GS, Clark M, Andikyan V, Azodi M, Schwartz PE, Santin AD. Clin Exp Metastasis. 2024 Jun 22; 2024 Jun 22. PMID: 38909139.
• Procoagulant phenotype of virus-infected pericytes is associated with portal thrombosis and intrapulmonary vascular dilations in fatal COVID-19.Cadamuro M, Lasagni A, Radu CM, Calistri A, Pilan M, Valle C, Bonaffini PA, Vitiello A, Toffanin S, Venturin C, Friòn-Herrera Y, Sironi S, Alessio MG, Previtali G, Seghezzi M, Gianatti A, Strazzabosco M, Strain AJ, Campello E, Spiezia L, Palù G, Frigo AC, Tosoni A, Nebuloni M, Parolin C, Sonzogni A, Simioni P, Fabris L. J Hepatol. 2024 Jun 20; 2024 Jun 20. PMID: 38908437.
• Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine.Zeidan AM, Bewersdorf JP, Hasle V, Shallis RM, Thompson E, de Menezes DL, Rose S, Boss I, Halene S, Haferlach T, Fox BA. Ther Adv Hematol. 2024; 2024 Jun 15. PMID: 38883163.
• Targetable ERBB2/HER2 Mutations in Gynecologic Malignancies: Clinicopathological, Immunohistochemical, and Molecular Correlations.Manrai PA, McHenry A, Sun T, Santin AD, Ratner E, Lin DI, Elvin JA, Hui P, Buza N. Int J Gynecol Pathol. 2024 Jun 10; 2024 Jun 10. PMID: 38914011.
• Bifunctional Molecules That Induce Both Targeted Degradation and Transcytosis of Extracellular Proteins in Brain Cells.Howell RA, Wang S, Khambete M, McDonald DM, Spiegel DA. J Am Chem Soc. 2024 Jun 10; 2024 Jun 10. PMID: 38855935.
• Cost-effectiveness analysis: The missing factor in the management of HCC.Njei B, Yi I, Strazzabosco M. Clin Liver Dis (Hoboken). 2024 Jan-Jun; 2024 Jun 7. PMID: 38860130.
• Copper-Catalyzed Three-Component Synthesis of Highly Substituted Morpholines.Chu D, Zoll AJ, Ellman JA. Org Lett. 2024 Jun 7; 2024 May 29. PMID: 38810982.
• Development of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage.Leapman MS, Ho J, Liu Y, Filson CP, Zhao X, Hakansson A, Proudfoot JA, Davicioni E, Martin DT, An Y, Seibert TM, Lin DW, Spratt DE, Cooperberg MR, Ross AE, Sprenkle PC. JAMA Netw Open. 2024 Jun 3; 2024 Jun 3. PMID: 38874922.
• A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol.Neal JW, Minichiello K, Brennick R, Huang RSP, Hiemenz MC, Amler C, Patel J, Herbst R, Reckamp KL, Borghaei H, Highleyman L, Redman MW, Pasquina LW, Kozono DE. Oncologist. 2024 Jun 3. PMID: 38597608.
• Favorable Radiographic Response in a Patient With an Oligodendroglioma Treated With Azacitidine and Venetoclax for Acute Myeloid Leukemia.Perez M, Barrionuevo V, Arias C, Baehring JM. Cureus. 2024 Jun; 2024 Jun 2. PMID: 38957232.
• Association between pelvic lymph node dissection and survival among patients with prostate cancer treated with radical prostatectomy.Kim IE Jr, Wang AH, Corpuz GS, Sprenkle PC, Leapman MS, Brito JM, Renzulli J, Kim IY. Prostate Int. 2024 Jun; 2024 Feb 7. PMID: 39036758.
• Big Decisions on Small Cell Lung Cancer: A Focus on Clinical Care Updates and Patient Perspectives.Wang X, Chiang AC. Am Soc Clin Oncol Educ Book. 2024 Jun. PMID: 38830134.
• Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates.Ascione L, Guidi L, Prakash A, Trapani D, LoRusso P, Lou E, Curigliano G. Am Soc Clin Oncol Educ Book. 2024 Jun 1. PMID: 38828973.
• Navigating the Complexities of Brain Metastases Management.Amouzegar A, Haig S, Kahn AM, Tawbi HA, Jones JA, Goldberg SB. Am Soc Clin Oncol Educ Book. 2024 Jun. PMID: 38781565.
• Pragmaticism in Cancer Clinical Trials.Sankar K, Redman MW, Dragnev KH, Henick BS, Iams WT, Blanke CD, Herbst RS, Gray JE, Reckamp KL. Am Soc Clin Oncol Educ Book. 2024 Jun. PMID: 38771997.
• Correction to: Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities.Kewan T, Stahl M, Bewersdorf JP, Zeidan AM. Curr Hematol Malig Rep. 2024 Jun. PMID: 38761360.
• Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis.Pasta A, Calabrese F, Jaffe A, Labanca S, Marenco S, Pieri G, Plaz Torres MC, Strazzabosco M, Giannini EG. Liver Cancer. 2024 Jun; 2023 Oct 14. PMID: 38756146.
• Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities.Kewan T, Stahl M, Bewersdorf JP, Zeidan AM. Curr Hematol Malig Rep. 2024 Jun; 2024 Apr 18. PMID: 38632155.
• Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review.Haumschild R, Kennerly-Shah J, Barbarotta L, Zeidan AM. J Oncol Pharm Pract. 2024 Jun; 2024 Mar 21. PMID: 38509812.
• Ligand-gated ion channels as potential biomarkers for ADT-mediated cognitive decline in prostate cancer patients.Verma S, Singh V, Nagampalli V, Ponsky LE, Li CR, Chao H, Gupta S. Mol Carcinog. 2024 Jun; 2024 Mar 14. PMID: 38482990.
• Providing 0.1 Full-Time Equivalent (FTE) Support to Fellowship Core Faculty Improves Faculty Involvement in Fellowship Education and Recruitment.Butt A, Christian J, Kress A, Lu BY, Hurwitz ME, Goldberg SB, Podoltsev NA, Gilkes L, Lee AI. J Cancer Educ. 2024 Jun; 2024 Mar 2. PMID: 38430454.
• Multiplexable and Scalable Aqueous Synthesis Platform for Oleate-Based, Bilayer-Coated Gold Nanoparticles.Backhaus A, Albrecht J, Alzhanova G, Long A, Arnold W, Lee J, Tse HY, Su TT, Cruz-Gomez S, Lee SSS, Menges F, Parent LR, Ratjen L, Burtness B, Fortner JD, Zimmerman JB. Small. 2024 Jun; 2024 Feb 20. PMID: 38377304.
• Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial.Roussos Torres ET, Ho WJ, Danilova L, Tandurella JA, Leatherman J, Rafie C, Wang C, Brufsky A, LoRusso P, Chung V, Yuan Y, Downs M, O'Connor A, Shin SM, Hernandez A, Engle EL, Piekarz R, Streicher H, Talebi Z, Rudek MA, Zhu Q, Anders RA, Cimino-Mathews A, Fertig EJ, Jaffee EM, Stearns V, Connolly RM. Nat Cancer. 2024 Jun; 2024 Feb 14. PMID: 38355777.
• Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.Nassar AH, Kim SY, Aredo JV, Feng J, Shepherd F, Xu C, Kaldas D, Gray JE, Dilling TJ, Neal JW, Wakelee HA, Liu Y, Lin SH, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron TU, Thummalapalli R, Yu H, Owen DH, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris JP, Nagasaka M, Ayanambakkam A, Velazquez AI, Ragavan M, Lin JJ, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar SR, Gupta S, Leal T, Kwiatkowski DJ, Mak RH, Adib E, Naqash AR, Goldberg SB. J Thorac Oncol. 2024 Jun; 2024 Jan 24. PMID: 38278303.
• Prognostic impact of 'multi-hit' versus 'single hit' TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases.Badar T, Nanaa A, Atallah E, Shallis RM, Craver EC, Li Z, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, Duvall A, Burkart M, Bradshaw D, Abaza Y, Stahl M, Palmisiano N, Murthy GSG, Zeidan AM, Kota V, Patnaik MM, Litzow MR. Haematologica. 2024 May 30; 2024 May 30. PMID: 38813716.
• A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling.Wei W, Blaha O, Esserman D, Zelterman D, Kane M, Liu R, Lin J. Stat Med. 2024 May 30; 2024 Apr 9. PMID: 38594809.
• Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials.Montesinos P, Fathi AT, de Botton S, Stein EM, Zeidan AM, Zhu Y, Prebet T, Vigil CE, Bluemmert I, Yu X, DiNardo CD. Blood Adv. 2024 May 28. PMID: 38507688.
• Scaffold-Oriented Asymmetric Catalysis: Conformational Modulation of Transition State Multivalency during a Catalyst-Controlled Assembly of a Pharmaceutically Relevant Atropisomer.Tampellini N, Mercado BQ, Miller SJ. Chemistry. 2024 May 28; 2024 Apr 11. PMID: 38507249.
• Author Correction: Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients.Uhlig J, Uhlig A, Deshpande H, Ströbel P, Trojan L, Lotz J, Hurwitz M, Hafez O, Humphrey P, Grünwald V, Kim HS. Sci Rep. 2024 May 24; 2024 May 24. PMID: 38789511.
• Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS).Efficace F, Buckstein R, Abel GA, Giesinger JM, Fenaux P, Bewersdorf JP, Brunner AM, Bejar R, Borate U, DeZern AE, Greenberg P, Roboz GJ, Savona MR, Sparano F, Boultwood J, Komrokji R, Sallman DA, Xie Z, Sanz G, Carraway HE, Taylor J, Nimer SD, Della Porta MG, Santini V, Stahl M, Platzbecker U, Sekeres MA, Zeidan AM. Hemasphere. 2024 May; 2024 May 21. PMID: 38774655.
• Entering the golden age for antibody-drug conjugates in gynecologic cancer.Greenman M, McNamara B, Mutlu L, Santin AD. Oncoscience. 2024; 2024 May 20. PMID: 38770444.
• Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update.Gordan JD, Kennedy EB, Abou-Alfa GK, Beal E, Finn RS, Gade TP, Goff L, Gupta S, Guy J, Hoang HT, Iyer R, Jaiyesimi I, Jhawer M, Karippot A, Kaseb AO, Kelley RK, Kortmansky J, Leaf A, Remak WM, Sohal DPS, Taddei TH, Wilson Woods A, Yarchoan M, Rose MG. J Clin Oncol. 2024 May 20; 2024 Mar 19. PMID: 38502889.
• Enhancing in vivo cell and tissue targeting by modulation of polymer nanoparticles and macrophage decoys.Piotrowski-Daspit AS, Bracaglia LG, Eaton DA, Richfield O, Binns TC, Albert C, Gould J, Mortlock RD, Egan ME, Pober JS, Saltzman WM. Nat Commun. 2024 May 18; 2024 May 18. PMID: 38762483.
• Hepatotoxicity assessment of innovative nutritional supplements based on olive-oil formulations enriched with natural antioxidants.Prodromou SI, Chatzopoulou F, Saiti A, Giannopoulos-Dimitriou A, Koudoura LA, Pantazaki AA, Chatzidimitriou D, Vasiliou V, Vizirianakis IS. Front Nutr. 2024; 2024 May 15. PMID: 38812942.
• CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials.Segal NH, Melero I, Moreno V, Steeghs N, Marabelle A, Rohrberg K, Rodriguez-Ruiz ME, Eder JP, Eng C, Manji GA, Waterkamp D, Leutgeb B, Bouseida S, Flinn N, Das Thakur M, Elze MC, Koeppen H, Jamois C, Martin-Facklam M, Lieu CH, Calvo E, Paz-Ares L, Tabernero J, Argilés G. Nat Commun. 2024 May 15; 2024 May 15. PMID: 38750034.
• Approach to immunotherapy for HCC in the liver transplant population.Block PD, Strazzabosco M, Jaffe A. Clin Liver Dis (Hoboken). 2024 Jan-Jun; 2024 May 3. PMID: 38707244.
• The effect of a fermented soy beverage among patients with localized prostate cancer prior to radical prostatectomy.Lokeshwar SD, Ali A, Weiss TR, Reynolds J, Shuch BM, Ferencz T, Kyriakides TC, Mehal WZ, Brito J, Renzulli J, Leapman MS. BMC Urol. 2024 May 3; 2024 May 3. PMID: 38702664.
• Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients.Uhlig J, Uhlig A, Deshpande H, Ströbel P, Trojan L, Lotz J, Hurwitz M, Hafez O, Humphrey P, Grünwald V, Kim HS. Sci Rep. 2024 May 2; 2024 May 2. PMID: 38693188.
• Response letter by Nassar et al.Nassar AH, Kim SY, Adib E, Naqash AR, Goldberg SB. J Thorac Oncol. 2024 May. PMID: 38719428.
• Long-term exposure to ambient fine particulate matter and risk of liver cancer in the NIH-AARP Diet and Health Study.Ma X, Fisher JA, McGlynn KA, Liao LM, Vasiliou V, Sun N, Kaufman JD, Silverman DT, Jones RR. Environ Int. 2024 May; 2024 Apr 5. PMID: 38636274.
• Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147).Sheth SS, Oh JE, Bellone S, Siegel ER, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim DJ, Iwasaki A, Levi AW, Buza N, Hui P, Flaherty S, Schwartz PE, Santin AD. Clin Cancer Res. 2024 May 1. PMID: 38592381.
• Essential data variables for a minimum dataset for head and neck cancer trials and clinical research: HNCIG consensus recommendations and database.Baliga S, Abou-Foul AK, Parente P, Szturz P, Thariat J, Shreenivas A, Nankivell P, Bertolini F, Biau J, Blakaj D, Brennan S, Brunet A, De Oliveira TB, Burtness B, Maseda AC, Chow VL, Chua ML, de Ridder M, Garikipati S, Hanai N, Ho FCH, Huang SH, Kiyota N, Klinghammer K, Kowalski LP, Kwong DL, McDowell LJ, Merlano MC, Nair S, Economopoulou P, Overgaard J, Psyrri A, Tribius S, Waldron J, Yom SS, Mehanna H. Eur J Cancer. 2024 May; 2024 Mar 30. PMID: 38579517.
• NCS-1 protein regulates TRPA1 channel through the PI3K pathway in breast cancer and neuronal cells.Sánchez JC, Alemán A, Henao JF, Olaya JC, Ehrlich BE. J Physiol Biochem. 2024 May; 2024 Apr 2. PMID: 38564162.
• Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał M, Delord JP, Mesía R, Taberna M, Waldron JN, Simon C, Grégoire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL. Lancet Oncol. 2024 May; 2024 Mar 29. PMID: 38561010.
• An algorithm for standardization of tumor Infiltrating lymphocyte evaluation in head and neck cancers.Xirou V, Moutafi M, Bai Y, Nwe Aung T, Burela S, Liu M, Kimple RJ, Shabbir Ahmed F, Schultz B, Flieder D, Connolly DC, Psyrri A, Burtness B, Rimm DL. Oral Oncol. 2024 May; 2024 Mar 27. PMID: 38547779.
• Clinical physiology: the crucial role of MRI in evaluation of peripheral artery disease.Elsaid NMH, Peters DC, Galiana G, Sinusas AJ. Am J Physiol Heart Circ Physiol. 2024 May 1; 2024 Mar 22. PMID: 38517227.
• Impact of (18)F-FDG PET Intensity Normalization on Radiomic Features of Oropharyngeal Squamous Cell Carcinomas and Machine Learning-Generated Biomarkers.Haider SP, Zeevi T, Sharaf K, Gross M, Mahajan A, Kann BH, Judson BL, Prasad ML, Burtness B, Aboian M, Canis M, Reichel CA, Baumeister P, Payabvash S. J Nucl Med. 2024 May 1; 2024 May 1. PMID: 38514087.
• Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103).Garralda E, Oh DY, Italiano A, Bedard PL, Delord JP, Calvo E, LoRusso P, Wainberg Z, Cervantes A, Rodriguez-Vida A, Shemesh CS, Sane R, Mendus D, Ding H, Hendricks R, Meng R, Cho BC, Kim TW, Wu B. J Clin Pharmacol. 2024 May; 2024 Jan 17. PMID: 38105505.
• Clinical predictive value of renalase in post-ERCP pancreatitis.Muniraj T, Desir G, Gorelick FS, Guo X, Ciarleglio MM, Deng Y, Jamidar PA, Farrell J, Aslanian HR, Laine L. Gastrointest Endosc. 2024 May; 2023 Dec 14. PMID: 38103747.
• Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix.Bellone S, Jeong K, Halle MK, Krakstad C, McNamara B, Greenman M, Mutlu L, Demirkiran C, Hartwich TMP, Yang-Hartwich Y, Zipponi M, Buza N, Hui P, Raspagliesi F, Lopez S, Paolini B, Milione M, Perrone E, Scambia G, Altwerger G, Ravaggi A, Bignotti E, Huang GS, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz PE, Quick CM, Angioli R, Terranova C, Zaidi S, Nandi S, Alexandrov LB, Siegel ER, Choi J, Schlessinger J, Santin AD. Proc Natl Acad Sci U S A. 2024 Apr 23; 2024 Apr 16. PMID: 38625939.
• Proof-of-concept studies with a computationally designed M(pro) inhibitor as a synergistic combination regimen alternative to Paxlovid.Papini C, Ullah I, Ranjan AP, Zhang S, Wu Q, Spasov KA, Zhang C, Mothes W, Crawford JM, Lindenbach BD, Uchil PD, Kumar P, Jorgensen WL, Anderson KS. Proc Natl Acad Sci U S A. 2024 Apr 23; 2024 Apr 15. PMID: 38621119.
• Vascular mimicry as a facilitator of melanoma brain metastasis.Provance OK, Oria VO, Tran TT, Caulfield JI, Zito CR, Aguirre-Ducler A, Schalper KA, Kluger HM, Jilaveanu LB. Cell Mol Life Sci. 2024 Apr 18; 2024 Apr 18. PMID: 38635031.
• ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts.Hu B, Wiesehöfer M, de Miguel FJ, Liu Z, Chan LH, Choi J, Melnick MA, Arnal Estape A, Walther Z, Zhao D, Lopez-Giraldez F, Wurtz A, Cai G, Fan R, Gettinger S, Xiao A, Yan Q, Homer R, Nguyen DX, Politi K. Cancer Res. 2024 Apr 15. PMID: 38359163.
• Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial.Parra ER, Zhang J, Duose DY, Gonzalez-Kozlova E, Redman MW, Chen H, Manyam GC, Kumar G, Zhang J, Song X, Lazcano R, Marques-Piubelli ML, Laberiano-Fernandez C, Rojas F, Zhang B, Taing L, Jhaveri A, Geisberg J, Altreuter J, Michor F, Provencher J, Yu J, Cerami E, Moravec R, Kannan K, Luthra R, Alatrash G, Huang HH, Xie H, Patel M, Nie K, Harris J, Argueta K, Lindsay J, Biswas R, Van Nostrand S, Kim-Schulze S, Gray JE, Herbst RS, Wistuba II, Gettinger S, Kelly K, Bazhenova L, Gnjatic S, Lee JJ, Zhang J, Haymaker C. Clin Cancer Res. 2024 Apr 15. PMID: 38277235.
• pHLIP targeted intracellular delivery of calicheamicin.DuPont M, Klumpp C, Iraca M, Allababidi D, Visca H, Engelman DM, Andreev OA, Moshnikova A, Reshetnyak YK. Int J Pharm. 2024 Apr 10; 2024 Feb 28. PMID: 38428548.
• Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors.Kahn AM, Perry CJ, Etts K, Kluger H, Sznol M. Oncologist. 2024 Apr 4. PMID: 37971411.
• Development of a Small Molecule Downmodulator for the Transcription Factor Brachyury.Chase DH, Bebenek AM, Nie P, Jaime-Figueroa S, Butrin A, Castro DA, Hines J, Linhares BM, Crews CM. Angew Chem Int Ed Engl. 2024 Apr 2; 2024 Feb 28. PMID: 38348945.
• Differential Effect of Consolidative Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer Based on Sex.Jairam V, Soulos PR, K C M, Gross CP, Slotman BJ, Chiang AC, Park HS. Adv Radiat Oncol. 2024 Apr; 2023 Dec 3. PMID: 38778819.
• Melanocortin-1 Receptor Expression as a Marker of Progression in Melanoma.Su DG, Djureinovic D, Schoenfeld D, Marquez-Nostra B, Olino K, Jilaveanu L, Kluger H. JCO Precis Oncol. 2024 Apr. PMID: 38662983.
• The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals.Zogopoulos G, Haimi I, Sanoba SA, Everett JN, Wang Y, Katona BW, Farrell JJ, Grossberg AJ, Paiella S, Klute KA, Bi Y, Wallace MB, Kwon RS, Stoffel EM, Wadlow RC, Sussman DA, Merchant NB, Permuth JB, Golan T, Raitses-Gurevich M, Lowy AM, Liau J, Jeter JM, Lindberg JM, Chung DC, Earl J, Brentnall TA, Schrader KA, Kaul V, Huang C, Chandarana H, Smerdon C, Graff JJ, Kastrinos F, Kupfer SS, Lucas AL, Sears RC, Brand RE, Parmigiani G, Simeone DM. J Natl Compr Canc Netw. 2024 Apr. PMID: 38626807.
• Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer.McNamara B, Demirkiran C, Hartwich TMP, Bellone S, Manavella D, Mutlu L, Greenman M, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz PE, Coma S, Pachter JA, Santin AD. Gynecol Oncol. 2024 Apr; 2024 Mar 15. PMID: 38493021.
• VEGF-C prophylaxis favors lymphatic drainage and modulates neuroinflammation in a stroke model.Boisserand LSB, Geraldo LH, Bouchart J, El Kamouh MR, Lee S, Sanganahalli BG, Spajer M, Zhang S, Lee S, Parent M, Xue Y, Skarica M, Yin X, Guegan J, Boyé K, Saceanu Leser F, Jacob L, Poulet M, Li M, Liu X, Velazquez SE, Singhabahu R, Robinson ME, Askenase MH, Osherov A, Sestan N, Zhou J, Alitalo K, Song E, Eichmann A, Sansing LH, Benveniste H, Hyder F, Thomas JL. J Exp Med. 2024 Apr 1; 2024 Mar 5. PMID: 38442272.
• Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.Roque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader JC, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD. Br J Cancer. 2024 Apr. PMID: 38438590.
• Compartmentalized ocular lymphatic system mediates eye-brain immunity.Yin X, Zhang S, Lee JH, Dong H, Mourgkos G, Terwilliger G, Kraus A, Geraldo LH, Poulet M, Fischer S, Zhou T, Mohammed FS, Zhou J, Wang Y, Malloy S, Rohner N, Sharma L, Salinas I, Eichmann A, Thomas JL, Saltzman WM, Huttner A, Zeiss C, Ring A, Iwasaki A, Song E. Nature. 2024 Apr; 2024 Feb 28. PMID: 38418880.
• Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.Shimony S, Bewersdorf JP, Shallis RM, Liu Y, Schaefer EJ, Zeidan AM, Goldberg AD, Stein EM, Marcucci G, Lindsley RC, Chen EC, Ramos Perez J, Stein A, DeAngelo DJ, Neuberg DS, Stone RM, Ball B, Stahl M. Leukemia. 2024 Apr; 2024 Feb 20. PMID: 38378841.
• The dementia care study (D-CARE): Recruitment strategies and demographic characteristics of participants in a pragmatic randomized trial of dementia care.Yang M, Samper-Ternent R, Volpi E, Green AN, Lichtenstein M, Araujo K, Borek P, Charpentier P, Dziura J, Gill TM, Galloway R, Greene EJ, Lenoir K, Peduzzi P, Meng C, Reese J, Shelton A, Skokos EA, Summapund J, Unger E, Reuben DB, Williamson JD, Stevens AB. Alzheimers Dement. 2024 Apr; 2024 Feb 15. PMID: 38358084.
• CD70 is Consistently Expressed in Primary and Metastatic Clear Cell Renal Cell Carcinoma.Huang RR, Chen Z, Kroeger N, Pantuck A, Said J, Kluger HM, Shuch B, Ye H. Clin Genitourin Cancer. 2024 Apr; 2023 Dec 13. PMID: 38195301.
• Self-Assembled nanoparticles of natural bioactive molecules enhance the delivery and efficacy of paclitaxel in glioblastoma.Li Y, Zhao Q, Zhu X, Zhou L, Song P, Liu B, Tian D, Chen Q, Zhou J, Deng G. CNS Neurosci Ther. 2024 Apr; 2023 Dec 4. PMID: 38044793.
• Implementation of a health system intervention to reduce time from presentation to surgical intervention for pediatric testicular torsion.Heckscher D, Jalfon M, Buck MB, Abello A, Nguyen JV, Casilla-Lennon M, Leapman MS, Hittelman AB, Teitelbaum J, Emerson BL, Kenney PA, Cavallo JA, Lambert S. J Pediatr Urol. 2024 Apr; 2023 Nov 2. PMID: 38030428.
• Effect of a Personalized Tobacco Treatment Intervention on Smoking Abstinence in Individuals Eligible for Lung Cancer Screening.Cartmel B, Fucito LM, Bold KW, Neveu S, Li F, Rojewski AM, Gueorguieva R, O'Malley SS, Herbst RS, Toll BA. J Thorac Oncol. 2024 Apr; 2023 Nov 15. PMID: 37977486.
• Unresolved issues with noninferiority pragmatic trials: Results of a literature survey.Ciarleglio MM, Li J, Peduzzi P. Clin Trials. 2024 Apr; 2023 Nov 5. PMID: 37927102.
• It could happen in your backyard.Strazzabosco M. Hepatology. 2024 Apr 1; 2023 Sep 18. PMID: 37722133.
• De-Escalated Therapy and Early Treatment of Recurrences in HPV-Associated Head and Neck Cancer: The Potential for Biomarkers to Revolutionize Personalized Therapy.Yarbrough WG, Schrank TP, Burtness BA, Issaeva N. Viruses. 2024 Mar 29; 2024 Mar 29. PMID: 38675879.
• Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series.Yamamoto N, Tolcher A, Hafez N, Lugowska I, Ramlau R, Macarulla T, Geng J, Li J, Teufel M, Märten A, LoRusso P. Onco Targets Ther. 2024; 2024 Mar 29. PMID: 38567193.
• EGFR targeting PhosTACs as a dual inhibitory approach reveals differential downstream signaling.Hu Z, Chen PH, Li W, Krone M, Zheng S, Saarbach J, Velasco IU, Hines J, Liu Y, Crews CM. Sci Adv. 2024 Mar 29; 2024 Mar 27. PMID: 38536914.
• Iguratimod, an allosteric inhibitor of macrophage migration inhibitory factor (MIF), prevents mortality and oxidative stress in a murine model of acetaminophen overdose.Bloom J, Pantouris G, He M, Aljabari B, Mishra L, Manjula R, Parkins A, Lolis EJ, Al-Abed Y. Mol Med. 2024 Mar 27; 2024 Mar 27. PMID: 38539088.
• Enantioselective Sulfonimidamide Acylation via a Cinchona Alkaloid-Catalyzed Desymmetrization: Scope, Data Science, and Mechanistic Investigation.Haas BC, Lim NK, Jermaks J, Gaster E, Guo MC, Malig TC, Werth J, Zhang H, Toste FD, Gosselin F, Miller SJ, Sigman MS. J Am Chem Soc. 2024 Mar 27; 2024 Mar 13. PMID: 38480482.
• Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma.Su DG, Schoenfeld DA, Ibrahim W, Cabrejo R, Djureinovic D, Baumann R, Rimm DL, Khan SA, Halaban R, Kluger HM, Olino K, Galan A, Clune J. J Immunother Cancer. 2024 Mar 21; 2024 Mar 21. PMID: 38519058.
• CML and the WHO: Why?Berman E, Shah NP, Deninger M, Altman JK, Amaya M, Begna K, Bhatia R, Chan O, Collins R, Curtin P, DeAngelo DJ, Drazer M, Maness L, Metheny L, Mohan S, Moore J, Oehler V, Pratz K, Pusic I, Rose M, Shomali W, Smith BD, Styler M, Sweet K, Talpaz M, Tanaka T, Tantravahi S, Tsai S, Vaughn J, Welborn J, Yang D, Mauro M, Cortes J, Radich J, Druker B. J Clin Oncol. 2024 Mar 20; 2023 Dec 12. PMID: 38086008.
• Reply to Pisan et al.: Pathogenicity of inherited TRAF7 mutations in congenital heart disease.Mishra-Gorur K, Barak T, Kaulen LD, Henegariu O, Jin SC, Aguilera SM, Yalbir E, Goles G, Nishimura S, Miyagishima D, Djenoune L, Altinok S, Rai DK, Viviano S, Prendergast A, Zerillo C, Ozcan K, Baran B, Sencar L, Goc N, Yarman Y, Ercan-Encicek AG, Bilguvar K, Lifton RP, Moliterno J, Louvi A, Yuan S, Deniz E, Brueckner M, Gunel M. Proc Natl Acad Sci U S A. 2024 Mar 19; 2024 Mar 11. PMID: 38466853.
• The role of surgery and deescalation for HPV-related oropharyngeal cancer.Contrera KJ, Patel MR, Burtness B, Mehra R, Ferris RL. Cancer. 2024 Mar 18; 2024 Mar 18. PMID: 38497569.
• Aiming the magic bullet: targeted delivery of imaging and therapeutic agents to solid tumors by pHLIP peptides.Reshetnyak YK, Andreev OA, Engelman DM. Front Pharmacol. 2024; 2024 Mar 13. PMID: 38545547.
• Correction: pH-Responsive fluorescent graphene quantum dots for fluorescence-guided cancer surgery and diagnosis.Fan Z, Zhou S, Garcia C, Fan L, Zhou J. Nanoscale. 2024 Mar 7; 2024 Mar 7. PMID: 38372010.
• A Single Arm Phase 2 Trial of Trametinib in Patients With Locally Advanced or Metastatic Epithelioid Hemangioendothelioma.Schuetze SM, Ballman KV, Heise R, Ganjoo KN, Davis EJ, George S, Burgess MA, Choy E, Shepard DR, Tinoco G, Hirbe A, Kelly CM, Attia S, Deshpande HA, Schwartz GK, Siontis BL, Riedel RF, von Mehren M, Kozlowski E, Chen HX, Astbury C, Rubin BP. Clin Cancer Res. 2024 Mar 6; 2024 Mar 6. PMID: 38446990.
• Enthalpies and entropies of hydration from Monte Carlo simulations.Jorgensen WL. Phys Chem Chem Phys. 2024 Mar 6; 2024 Mar 6. PMID: 38412420.
• Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the Malignant Germ Cell International Consortium perspective.Pashankar F, Murray MJ, Gell J, MacDonald N, Shamash J, Billmire DF, Klosterkemper L, Olson T, Hirsch MS, Lockley M, Stoneham S, Frazier AL. EClinicalMedicine. 2024 Mar; 2024 Feb 6. PMID: 38544795.
• Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Bonanno L, Dómine M, Poole L, Bolanos A, Rukazenkov Y, Wu YL. Target Oncol. 2024 Mar; 2024 Mar 11. PMID: 38466534.
• Targeting cervical cancer with anti-PD-1 antibodies: what is new?Greenman M, McNamara B, Mutlu L, Santin AD. Expert Opin Biol Ther. 2024 Mar; 2024 Feb 27. PMID: 38391293.
• IL-10 constrains sphingolipid metabolism to limit inflammation.York AG, Skadow MH, Oh J, Qu R, Zhou QD, Hsieh WY, Mowel WK, Brewer JR, Kaffe E, Williams KJ, Kluger Y, Smale ST, Crawford JM, Bensinger SJ, Flavell RA. Nature. 2024 Mar; 2024 Feb 21. PMID: 38383790.
• Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients.Brahmer JR, Long GV, Hamid O, Garon EB, Herbst RS, Andre T, Armand P, Bajorin D, Bellmunt J, Burtness B, Choueiri TK, Cohen EEW, Diaz LA Jr, Shitara K, Kulkarni G, McDermott D, Shah M, Tabernero J, Vogel A, Zinzani PL, Jafari N, Bird S, Snyder E, Gause C, Bracco OL, Pietanza MC, Gruber T, Ribas A. Eur J Cancer. 2024 Mar; 2024 Jan 11. PMID: 38295556.
• Normal Erythroid Precursors in Diamond-Blackfan Anemia: A Rare Case Highlighting Challenges That Remain.Prior D, Sowa A, Pashankar F. J Pediatr Hematol Oncol. 2024 Mar 1; 2024 Jan 25. PMID: 38277626.
• A new prognostic model in chemotherapy-treated patients with recurrent or metastatic head and neck cancer: An analysis of ECOG-ACRIN E1305.Argiris A, Flamand Y, Savvides P, Johnson JM, Vathiotis I, Levine M, Li S, Forastiere AA, Burtness B. Eur J Cancer. 2024 Mar; 2023 Dec 29. PMID: 38215573.
• Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US.Kerekes DM, Frey AE, Prsic EH, Tran TT, Clune JE, Sznol M, Kluger HM, Forman HP, Becher RD, Olino KL, Khan SA. JAMA Oncol. 2024 Mar 1. PMID: 38175659.
• Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs).Zeidan AM, Mearns ES, Ng CD, Shah A, Lamarre N, Yellow-Duke A, Alrawashdh N, Yang B, Cheng WH, Bui CN, Svensson A. Clin Lymphoma Myeloma Leuk. 2024 Mar; 2023 Oct 30. PMID: 37996264.
• Educational Review: Clinical Application of Immune Checkpoint Blockade for the Treatment of Melanoma.Su D, Kluger H, Olino K. Ann Surg Oncol. 2024 Mar; 2023 Nov 21. PMID: 37989956.
• K-t PCA accelerated in-plane balanced steady-state free precession phase-contrast (PC-SSFP) for all-in-one diastolic function evaluation.Xiang J, Lamy J, Qiu M, Galiana G, Peters DC. Magn Reson Med. 2024 Mar; 2023 Nov 6. PMID: 37927206.
• Cytologic evaluation of upper urinary tract specimens: An institutional retrospective study using The Paris System for Reporting Urine Cytology second edition with histopathologic follow-up.Khajir G, Sun T, Wang H, Sprenkle PC, Adeniran AJ, Cai G, Levi AW. Cytopathology. 2024 Mar; 2023 Nov 2. PMID: 37916579.
• Circulating Tumor Reactive KIR+CD8+ T cells Suppress Anti-Tumor Immunity in Patients with Melanoma.Hafler D, Lu B, Lucca L, Lewis W, Wang J, Nogeuira C, Heer S, Axisa PP, Buitrago-Pocasangre N, Pham G, Kojima M, Wei W, Aizenbud L, Bacchiocchi A, Zhang L, Walewski J, Chiang V, Olino K, Clune J, Halaban R, Kluger Y, Coyle A, Kisielow J, Obermair FJ, Kluger H. Res Sq. 2024 Feb 28; 2024 Feb 28. PMID: 38464315.
• β-amino acids reduce ternary complex stability and alter the translation elongation mechanism.Cruz-Navarrete FA, Griffin WC, Chan YC, Martin MI, Alejo JL, Natchiar SK, Knudson IJ, Altman RB, Schepartz A, Miller SJ, Blanchard SC. bioRxiv. 2024 Feb 27; 2024 Feb 27. PMID: 38464221.
• An oxidative photocyclization approach to the synthesis of Securiflustra securifrons alkaloids.Alexander BW, Bartfield NM, Gupta V, Mercado BQ, Del Campo M, Herzon SB. Science. 2024 Feb 23; 2024 Feb 22. PMID: 38386756.
• Precision needle-punch tumor enrichment from paraffin blocks improves the detection of clinically actionable genomic alterations and biomarkers.Lin DI, Huang RSP, Ladas I, Keller RB, Patel NR, Lakis S, Decker B, Janovitz T, Mata DA, Ross JS, Vergilio JA, Elvin JA, Herbst RS, Mack PC, Killian JK. Front Oncol. 2024; 2024 Feb 20. PMID: 38444675.
• Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).Badar T, Nanaa A, Atallah E, Shallis RM, Guilherme SCC, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, DuVall AS, Bradshaw D, Abaza Y, Murthy GSG, Palmisiano N, Zeidan AM, Kota V, Litzow MR. Blood Cancer J. 2024 Feb 20; 2024 Feb 20. PMID: 38378617.
• Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, Faries M, Tran TT, Cowey CL, Pecora A, Shaheen M, Segar J, Medina T, Atkinson V, Gibney GT, Luke JJ, Thomas S, Buchbinder EI, Healy JA, Huang M, Morrissey M, Feldman I, Sehgal V, Robert-Tissot C, Hou P, Zhu L, Brown M, Aanur P, Meehan RS, Zaks T. Lancet. 2024 Feb 17; 2024 Jan 18. PMID: 38246194.
• The European Union Ban on Microplastics Includes Artificial Turf Crumb Rubber Infill: Other Nations Should Follow Suit.Zuccaro P, Thompson DC, de Boer J, Llompart M, Watterson A, Bilott R, Birnbaum LS, Vasiliou V. Environ Sci Technol. 2024 Feb 13; 2024 Feb 1. PMID: 38301275.
• Encoding scheme design for gradient-free, nonlinear projection imaging using Bloch-Siegert RF spatial encoding in a low-field, open MRI system.Selvaganesan K, Ha Y, Sun H, Zhang Z, Sun C, Samardzija A, Galiana G, Constable RT. Sci Rep. 2024 Feb 8; 2024 Feb 8. PMID: 38332252.
• Immunotherapy utilization in stage IIIA melanoma: less may be more.Frey AE, Kerekes DM, Khan SA, Tran TT, Kluger HM, Clune JE, Ariyan S, Sznol M, Ishizuka JJ, Olino KL. Front Oncol. 2024; 2024 Feb 6. PMID: 38380358.
• Community-Level Factors Associated with Hepatocellular Carcinoma Incidence and Mortality: An Observational Registry Study.Mezzacappa C, Rossi R, Jaffe A, Taddei TH, Strazzabosco M. Cancer Epidemiol Biomarkers Prev. 2024 Feb 6. PMID: 38059831.
• A comprehensive trial on PFAS remediation: hemp phytoextraction and PFAS degradation in harvested plants.Nason SL, Thomas S, Stanley C, Silliboy R, Blumenthal M, Zhang W, Liang Y, Jones JP, Zuverza-Mena N, White JC, Haynes CL, Vasiliou V, Timko MP, Berger BW. Env Sci Adv. 2024 Feb 5; 2024 Jan 5. PMID: 38322792.
• Clinical Outcomes Among Immunotherapy-Treated Patients With Primary Cardiac Soft Tissue Sarcomas: A Multicenter Retrospective Study.Nassar AH, El-Am E, Denu R, Abou Alaiwi S, El Zarif T, Macaron W, Abdel-Wahab N, Desai A, Smith C, Parikh K, Abbasi M, Bou Farhat E, Williams JM, Collins JD, Al-Hader A, McKay RR, Malvar C, Sabra M, Zhong C, El Alam R, Chehab O, Lima J, Phan M, Dalla Pria HF, Trevino A, Neilan TG, Kwan JM, Ravi V, Deshpande H, Demetri G, Choueiri TK, Naqash AR. JACC CardioOncol. 2024 Feb; 2024 Jan 16. PMID: 38510282.
• Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country.Awidi A, Alzu'bi M, Odeh N, Alrawabdeh J, Al Zyoud M, Hamadneh Y, Bawa'neh H, Magableh A, Alshorman A, Al-Fararjeh F, Aladily T, Zeidan AM. JCO Glob Oncol. 2024 Feb. PMID: 38422464.
• Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors.Hu Y, Narayan A, Xu Y, Wolfe J, Vu D, Trinh T, Kantak C, Ivy SP, Eder JP, Deng Y, LoRusso P, Kim JW, Patel AA. JCO Precis Oncol. 2024 Feb. PMID: 38412387.
• The importance of considering competing risks in recurrence analysis of intracranial meningioma.Mirian C, Jensen LR, Juratli TA, Maier AD, Torp SH, Shih HA, Morshed RA, Young JS, Magill ST, Bertero L, Stummer W, Spille DC, Brokinkel B, Oya S, Miyawaki S, Saito N, Proescholdt M, Kuroi Y, Gousias K, Simon M, Moliterno J, Prat-Acin R, Goutagny S, Prabhu VC, Tsiang JT, Wach J, Güresir E, Yamamoto J, Kim YZ, Lee JH, Koshy M, Perumal K, Baskaya MK, Cannon DM, Shrieve DC, Suh CO, Chang JH, Kamenova M, Straumann S, Soleman J, Eyüpoglu IY, Catalan T, Lui A, Theodosopoulos PV, McDermott MW, Wang F, Guo F, Góes P, de Paiva Neto MA, Jamshidi A, Komotar R, Ivan M, Luther E, Souhami L, Guiot MC, Csonka T, Endo T, Barrett OC, Jensen R, Gupta T, Patel AJ, Klisch TJ, Kim JW, Maiuri F, Barresi V, Tabernero MD, Skyrman S, Broechner A, Bach MJ, Law I, Scheie D, Kristensen BW, Munch TN, Meling T, Fugleholm K, Blanche P, Mathiesen T. J Neurooncol. 2024 Feb; 2024 Feb 10. PMID: 38336917.
• May we actually help clinicians select the best systemic treatment for patients with intermediate-stage hepatocellular carcinoma?Giannini EG, Strazzabosco M. Liver Int. 2024 Feb. PMID: 38289589.
• Increased von Willebrand and Factor VIII plasma levels in gynecologic patients with Post-Acute-COVID-Sequela (PASC)/Long COVID.Bellone S, Siegel ER, Scheim DE, Santin AD. Gynecol Oncol Rep. 2024 Feb; 2024 Jan 4. PMID: 38273933.
• Racial differences in treatment and survival among older patients with multiple myeloma.Wang R, Neparidze N, Ma X, Colditz GA, Chang SH, Wang SY. Cancer Med. 2024 Feb; 2024 Jan 17. PMID: 38234237.
• Association between sociodemographic factors and diagnosis of lethal prostate cancer in early life.Smani S, Novosel M, Sutherland R, Jeong F, Jalfon M, Marks V, Rajwa P, Nolazco JI, Washington SL, Renzulli JF II,, Sprenkle P, Kim IY, Leapman MS. Urol Oncol. 2024 Feb; 2023 Dec 31. PMID: 38161105.
• NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.Cecchini M, Cleary JM, Shyr Y, Chao J, Uboha N, Cho M, Shields A, Pant S, Goff L, Spencer K, Kim E, Stein S, Kortmansky JS, Canosa S, Sklar J, Swisher EM, Radke M, Ivy P, Boerner S, Durecki DE, Hsu CY, LoRusso P, Lacy J. Br J Cancer. 2024 Feb; 2023 Dec 22. PMID: 38135713.
• PD-1H/VISTA mediates immune evasion in acute myeloid leukemia.Kim TK, Han X, Hu Q, Vandsemb EN, Fielder CM, Hong J, Kim KW, Mason EF, Plowman RS, Wang J, Wang Q, Zhang JP, Badri T, Sanmamed MF, Zheng L, Zhang T, Alawa J, Lee SW, Zeidan AM, Halene S, Pillai MM, Chandhok NS, Lu J, Xu ML, Gore SD, Chen L. J Clin Invest. 2024 Feb 1; 2024 Feb 1. PMID: 38060328.
• Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy.Iqbal M, Jagadeesh D, Chavez J, Khurana A, Rosenthal A, Craver E, Epperla N, Li Z, Isufi I, Awan FT, Dholaria BR, Maakaron JE, Sandoval-Sus JD, Mishra R, Saha A, Annunzio K, Bhaskar ST, Sumransub N, Fijalka A, Ivanov SA, Lin Y, Kharfan-Dabaja MA. Bone Marrow Transplant. 2024 Feb; 2023 Nov 16. PMID: 37973893.
• Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer.Stockhammer P, Grant M, Wurtz A, Foggetti G, Expósito F, Gu J, Zhao H, Choi J, Chung S, Li F, Walther Z, Dietz J, Duffield E, Gettinger S, Politi K, Goldberg SB. J Thorac Oncol. 2024 Feb; 2023 Oct 6. PMID: 37806385.
• A Physics-Based Algorithm to Universally Standardize Routinely Obtained Clinical T(2)-Weighted Images.Elsaid NMH, Tagare HD, Galiana G. Acad Radiol. 2024 Feb; 2023 Jul 6. PMID: 37407374.
• The Fanconi anemia pathway repairs colibactin-induced DNA interstrand cross-links.Altshuller M, He X, MacKrell EJ, Wernke KM, Wong JWH, Sellés-Baiget S, Wang TY, Chou TF, Duxin JP, Balskus EP, Herzon SB, Semlow DR. bioRxiv. 2024 Jan 31; 2024 Jan 31. PMID: 38352618.
• Integrating the gut microbiome and pharmacology.Verdegaal AA, Goodman AL. Sci Transl Med. 2024 Jan 31; 2024 Jan 31. PMID: 38295186.
• European Society for Organ Transplantation (ESOT) Consensus Statement on Outcome Measures in Liver Transplantation According to Value-Based Health Care.Carbone M, Neuberger J, Rowe I, Polak WG, Forsberg A, Fondevila C, Mantovani L, Nardi A, Colli A, Rockell K, Schick L, Cristoferi L, Oniscu GC, Strazzabosco M, Cillo U. Transpl Int. 2023; 2024 Jan 25. PMID: 38332850.
• Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.Platzbecker U, Santini V, Fenaux P, Sekeres MA, Savona MR, Madanat YF, Díez-Campelo M, Valcárcel D, Illmer T, Jonášová A, Bělohlávková P, Sherman LJ, Berry T, Dougherty S, Shah S, Xia Q, Sun L, Wan Y, Huang F, Ikin A, Navada S, Feller F, Komrokji RS, Zeidan AM. Lancet. 2024 Jan 20; 2023 Dec 1. PMID: 38048786.
• Synthesis of N-Acylsulfenamides from (Hetero)Aryl Iodides and Boronic Acids by One-Pot Sulfur-Arylation and Dealkylation.Greenwood NS, Cerny NP, Deziel AP, Ellman JA. Angew Chem Int Ed Engl. 2024 Jan 15; 2023 Dec 12. PMID: 38015869.
• The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results.Lewis GD, Li G, Guo J, Yu SF, Fields CT, Lee G, Zhang D, Dragovich PS, Pillow T, Wei B, Sadowsky J, Leipold D, Wilson T, Kamath A, Mamounas M, Lee MV, Saad O, Choeurng V, Ungewickell A, Monemi S, Crocker L, Kalinsky K, Modi S, Jung KH, Hamilton E, LoRusso P, Krop I, Schutten MM, Commerford R, Sliwkowski MX, Cho E. Nat Commun. 2024 Jan 11; 2024 Jan 11. PMID: 38212321.
• OPLS/2020 Force Field for Unsaturated Hydrocarbons, Alcohols, and Ethers.Jorgensen WL, Ghahremanpour MM, Saar A, Tirado-Rives J. J Phys Chem B. 2024 Jan 11; 2023 Dec 21. PMID: 38127719.
• Novel Approach to Accelerate Lung Cancer Research: Lung-MAP and the Potential of Public-Private Partnerships.Herbst RS, Blanke CD, Sigal EV. Clin Cancer Res. 2024 Jan 5. PMID: 37903180.
• A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy.Weiss SA, Sznol M, Shaheen M, Berciano-Guerrero MÁ, Couselo EM, Rodríguez-Abreu D, Boni V, Schuchter LM, Gonzalez-Cao M, Arance A, Wei W, Ganti AK, Hauke RJ, Berrocal A, Iannotti NO, Hsu FJ, Kluger HM. Clin Cancer Res. 2024 Jan 5. PMID: 37535056.
• A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid Tumors.Garralda E, Schram AM, Bedard PL, Schwartz GK, Yuen E, McNeely SC, Ribeiro S, Cunningham J, Wang Y, Urunuela A, Xu X, LoRusso P. Oncologist. 2024 Jan 5. PMID: 37531083.
• Dynamic metabolism of endothelial triglycerides protects against atherosclerosis in mice.Boutagy NE, Gamez-Mendez A, Fowler JW, Zhang H, Chaube BK, Esplugues E, Kuo A, Lee S, Horikami D, Zhang J, Citrin KM, Singh AK, Coon BG, Lee MY, Suarez Y, Fernandez-Hernando C, Sessa WC. J Clin Invest. 2024 Jan 4; 2024 Jan 4. PMID: 38175710.
• Celebrating 20 years of human genomics: a journey of discovery.Vasiliou V. Hum Genomics. 2024 Jan 2; 2024 Jan 2. PMID: 38163870.
• Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy.Smani S, Sundaresan V, Lokeshwar SD, Choksi AU, Carbonella J, Brito J, Renzulli J, Sprenkle P, Leapman MS. Explor Target Antitumor Ther. 2024; 2024 Jul 30. PMID: 39280242.
• Microtubule-Targeting Agents: Disruption of the Cellular Cytoskeleton as a Backbone of Ovarian Cancer Therapy.Danziger M, Noble H, Roque DM, Xu F, Rao GG, Santin AD. Adv Exp Med Biol. 2024. PMID: 38805122.
• Telemedicine and Cancer: Shifting a Paradigm of Care.Chiang AC. Cancer J. 2024 Jan-Feb 01. PMID: 38265918.
• Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, Deeg HJ, Patel PA, Sabloff M, Keating MM, Zhu N, Gabrail NY, Fazal S, Maly J, Odenike O, Kantarjian H, DeZern AE, O'Connell CL, Roboz GJ, Busque L, Buckstein R, Amin H, Randhawa J, Leber B, Shastri A, Dao KH, Oganesian A, Hao Y, Keer HN, Azab M, Savona MR. Lancet Haematol. 2024 Jan. PMID: 38135371.
• Traditional Medicare or Medicare Advantage? The Leukemia and Cancer Perspective.Kantarjian H, Zeidan AM, Fathi AT, Stein E, Rajkumar V, Tefferi A. Mayo Clin Proc. 2024 Jan; 2023 Dec 16. PMID: 38108685.
• Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review.Majem M, Basch E, Cella D, Garon EB, Herbst RS, Leighl NB. Lung Cancer. 2024 Jan; 2023 Nov 10. PMID: 38070301.
• Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial.Zeidan AM, Ando K, Rauzy O, Turgut M, Wang MC, Cairoli R, Hou HA, Kwong YL, Arnan M, Meers S, Pullarkat V, Santini V, Malek K, Kiertsman F, Niolat J, Ramos PM, Menssen HD, Fenaux P, Miyazaki Y, Platzbecker U. Lancet Haematol. 2024 Jan; 2023 Dec 5. PMID: 38065203.
• Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.Desai J, Alonso G, Kim SH, Cervantes A, Karasic T, Medina L, Shacham-Shmueli E, Cosman R, Falcon A, Gort E, Guren T, Massarelli E, Miller WH Jr, Paz-Ares L, Prenen H, Amatu A, Cremolini C, Kim TW, Moreno V, Ou SI, Passardi A, Sacher A, Santoro A, Stec R, Ulahannan S, Arbour K, Lorusso P, Luo J, Patel MR, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Jun T, Dharia NV, Schutzman JL, Han SW. Nat Med. 2024 Jan; 2023 Dec 5. PMID: 38052910.
• A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.Bewersdorf JP, Shallis RM, Sharon E, Park S, Ramaswamy R, Roe CE, Irish JM, Caldwell A, Wei W, Yacoub A, Madanat YF, Zeidner JF, Altman JK, Odenike O, Yerrabothala S, Kovacsovics T, Podoltsev NA, Halene S, Little RF, Piekarz R, Gore SD, Kim TK, Zeidan AM. Ann Hematol. 2024 Jan; 2023 Dec 1. PMID: 38036712.
• A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.Garcia-Manero G, Podoltsev NA, Othus M, Pagel JM, Radich JP, Fang M, Rizzieri DA, Marcucci G, Strickland SA, Litzow MR, Savoie ML, Medeiros BC, Sekeres MA, Lin TL, Uy GL, Powell BL, Kolitz JE, Larson RA, Stone RM, Claxton D, Essell J, Luger SM, Mohan SR, Moseley A, Appelbaum FR, Erba HP. Leukemia. 2024 Jan; 2023 Nov 7. PMID: 37935977.
• Post-transplantation cyclophosphamide is associated with increased bacterial infections.Ustun C, Chen M, Kim S, Auletta JJ, Batista MV, Battiwalla M, Cerny J, Gowda L, Hill JA, Liu H, Munshi PN, Nathan S, Seftel MD, Wingard JR, Chemaly RF, Dandoy CE, Perales MA, Riches M, Papanicolaou GA. Bone Marrow Transplant. 2024 Jan; 2023 Oct 31. PMID: 37903992.
• Long-term super-resolution inner mitochondrial membrane imaging with a lipid probe.Zheng S, Dadina N, Mozumdar D, Lesiak L, Martinez KN, Miller EW, Schepartz A. Nat Chem Biol. 2024 Jan; 2023 Oct 19. PMID: 37857992.
• A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.Merryman RW, Redd RA, Freedman AS, Ahn IE, Brown JR, Crombie JL, Davids MS, Fisher DC, Jacobsen ED, Kim AI, LaCasce AS, Ng S, Odejide OO, Parry EM, Isufi I, Kline J, Cohen JB, Mehta-Shah N, Bartlett NL, Mei M, Kuntz TM, Wolff J, Rodig SJ, Armand P, Jacobson CA. Ann Hematol. 2024 Jan; 2023 Oct 18. PMID: 37851072.
• Surveillance of Individuals at High Risk of Developing Pancreatic Cancer: A Prevalence Meta-analysis to Estimate the Rate of Low-yield Surgery.Paiella S, Secchettin E, Lionetto G, Archibugi L, Azzolina D, Casciani F, Simeone DM, Overbeek KA, Goggins M, Farrell J, Ponz de Leon Pisani R, Tridenti M, Corciulo MA, Malleo G, Arcidiacono PG, Falconi M, Gregori D, Bassi C, Salvia R, Capurso G. Ann Surg. 2024 Jan 1; 2023 Sep 8. PMID: 37681303.
• Leptomeningeal disease in melanoma: An update on the developments in pathophysiology and clinical care.Smalley I, Boire A, Brastianos P, Kluger HM, Hernando-Monge E, Forsyth PA, Ahmed KA, Smalley KSM, Ferguson S, Davies MA, Glitza Oliva IC. Pigment Cell Melanoma Res. 2024 Jan; 2023 Aug 25. PMID: 37622466.
• Colchicine reduces inflammation in a humanized transgenic murine model of sickle cell disease.Fouda RT, Cherukury HM, Kiven SB, Garcia NR, Argueta DA, Velasco GJ, Gupta K, Roberts JD. Haematologica. 2024 Jan 1; 2024 Jan 1. PMID: 37534545.
• Living Donor Liver Transplantation for Hepatocellular Carcinoma Within and Outside Traditional Selection Criteria: A Multicentric North American Experience.Ivanics T, Claasen MPAW, Samstein B, Emond JC, Fox AN, Pomfret E, Pomposelli J, Tabrizian P, Florman SS, Mehta N, Roberts JP, Emamaullee JA, Genyk Y, Hernandez-Alejandro R, Tomiyama K, Sasaki K, Hashimoto K, Nagai S, Abouljoud M, Olthoff KM, Hoteit MA, Heimbach J, Taner T, Liapakis AH, Mulligan DC, Sapisochin G, Halazun KJ. Ann Surg. 2024 Jan 1; 2023 Jul 31. PMID: 37522174.
• Visible-Light-Mediated, Diastereoselective Epimerization of Exocyclic Amines.Vargas-Rivera MA, Liu AS, Ellman JA. Org Lett. 2023 Dec 29; 2023 Dec 19. PMID: 38114418.
• Introduction: Remote and Late Stage Functionalization.Miller SJ, Ritter T. Chem Rev. 2023 Dec 27. PMID: 38148744.
• Application of novel PACS-based informatics platform to identify imaging based predictors of CDKN2A allelic status in glioblastomas.Tillmanns N, Lost J, Tabor J, Vasandani S, Vetsa S, Marianayagam N, Yalcin K, Erson-Omay EZ, von Reppert M, Jekel L, Merkaj S, Ramakrishnan D, Avesta A, de Oliveira Santo ID, Jin L, Huttner A, Bousabarah K, Ikuta I, Lin M, Aneja S, Turowski B, Aboian M, Moliterno J. Sci Rep. 2023 Dec 22; 2023 Dec 22. PMID: 38135704.
• Gut microbes modulate (p)ppGpp during a time-restricted feeding regimen.Ontai-Brenning A, Hamchand R, Crawford JM, Goodman AL. mBio. 2023 Dec 19; 2023 Nov 16. PMID: 37971266.
• Covalent and noncovalent strategies for targeting Lys102 in HIV-1 reverse transcriptase.Prucha GR, Henry S, Hollander K, Carter ZJ, Spasov KA, Jorgensen WL, Anderson KS. Eur J Med Chem. 2023 Dec 15; 2023 Oct 20. PMID: 37883896.
• Ensemble Geometric Deep Learning of Aqueous Solubility.Ghahremanpour MM, Saar A, Tirado-Rives J, Jorgensen WL. J Chem Inf Model. 2023 Dec 11; 2023 Nov 21. PMID: 37990484.
• Sex differences in the effects of trait anxiety and age on resting-state functional connectivities of the amygdala.Chaudhary S, Hu S, Hu K, Dominguez JC, Chao HH, Li CR. J Affect Disord Rep. 2023 Dec; 2023 Aug 28. PMID: 38105798.
• When to use which molecular prognostic scoring system in the management of patients with MDS?Kewan T, Bewersdorf JP, Gurnari C, Xie Z, Stahl M, Zeidan AM. Best Pract Res Clin Haematol. 2023 Dec; 2023 Oct 17. PMID: 38092484.
• Sialylated Glycan Bindings from SARS-CoV-2 Spike Protein to Blood and Endothelial Cells Govern the Severe Morbidities of COVID-19.Scheim DE, Vottero P, Santin AD, Hirsh AG. Int J Mol Sci. 2023 Dec 1; 2023 Dec 1. PMID: 38069362.
• Increased serum 1,25-dihydroxyvitamin D levels in gynecologic cancer patients with Post-Acute-Covid-Sequela (PASC)/Long COVID.Bellone S, Siegel EE, Santin AD. Gynecol Oncol Rep. 2023 Dec; 2023 Nov 2. PMID: 38029227.
• Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT).Burns L, Hsu CY, Whisenant JG, Marmarelis ME, Presley CJ, Reckamp KL, Khan H, Jo Fidler M, Bestvina CM, Brahmer J, Puri S, Patel JD, Halmos B, Hirsch FR, Liu SV, Costa DB, Goldberg SB, Feldman LE, Mamdani H, Puc M, Mansfield AS, Islam N, Scilla KA, Garassino MC, Horn L, Peters S, Wakelee HA, Charlot M, Tapan U. Lung Cancer. 2023 Dec; 2023 Nov 13. PMID: 37995456.
• Treatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists.Madanat YF, Zeidan AM. Clin Lab Med. 2023 Dec; 2023 Aug 8. PMID: 37865511.
• Metformin inhibits digestive proteases and impairs protein digestion in mice.Kelly CJ, Verdegaal AA, Anderson BW, Shaw WL, Bencivenga-Barry NA, Folta-Stogniew E, Goodman AL. J Biol Chem. 2023 Dec; 2023 Oct 19. PMID: 37863262.
• Exploring novel HIV-1 reverse transcriptase inhibitors with drug-resistant mutants: A double mutant surprise.Hollander K, Chan AH, Frey KM, Hunker O, Ippolito JA, Spasov KA, Yeh YJ, Jorgensen WL, Ho YC, Anderson KS. Protein Sci. 2023 Dec. PMID: 37861472.
• Changes in Older Adult Trauma Quality When Evaluated Using Longer-Term Outcomes vs In-Hospital Mortality.Zogg CK, Cooper Z, Peduzzi P, Falvey JR, Castillo-Angeles M, Kodadek LM, Staudenmayer KL, Davis KA, Tinetti ME, Lichtman JH. JAMA Surg. 2023 Dec 1; 2023 Dec 13. PMID: 37792354.
• EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)-A Podcast Discussion Between Patients and Oncologists.Liu SV, Elkins IB, Feldman J, Goldberg SB. Oncol Ther. 2023 Dec; 2023 Sep 26. PMID: 37750968.
• In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma.Mutlu L, Manavella DD, Bellone S, McNamara B, Harold JA, Mauricio D, Siegel ER, Buza N, Hui P, Hartwich TMP, Yang-Hartwich Y, Demirkiran C, Verzosa MSZ, Altwerger G, Ratner ES, Huang GS, Clark M, Andikyan V, Azodi M, Dottino PR, Schwartz PE, Santin AD. Mol Cancer Ther. 2023 Dec 1. PMID: 37676984.
• A systematic review and individual participant data meta-analysis of gonadal steroid hormone receptors in meningioma.Miyagishima DF, Sundaresan V, Gutierrez AG, Barak T, Yeung J, Moliterno J, McGuone D, Claus EB, Günel M. J Neurosurg. 2023 Dec 1; 2023 May 26. PMID: 37243565.
• Clinical and genomic differences in supratentorial versus infratentorial NF2 mutant meningiomas.Tabor JK, O'Brien J, Vasandani S, Vetsa S, Lei H, Jalal MI, Marianayagam NJ, Jin L, Millares Chavez M, Haynes J, Dincer A, Yalcin K, Aguilera SM, Omay SB, Mishra-Gorur K, McGuone D, Morales-Valero SF, Fulbright RK, Gunel M, Erson-Omay EZ, Moliterno J. J Neurosurg. 2023 Dec 1; 2023 May 26. PMID: 37243548.
• Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis.Murthy HS, Zhang MJ, Chen K, Ahmed S, Deotare U, Ganguly S, Kansagra A, Michelis FV, Nishihori T, Patnaik M, Abid MB, Aljurf M, Arai Y, Bacher U, Badar T, Badawy SM, Ballen K, Battiwalla M, Beitinjaneh A, Bejanyan N, Bhatt VR, Brown VI, Martino R, Cahn JY, Castillo P, Cerny J, Chhabra S, Copelan E, Daly A, Dholaria B, Diaz Perez MA, Freytes CO, Grunwald MR, Hashmi S, Hildebrandt GC, Jamy O, Joseph J, Kanakry CG, Khera N, Krem MM, Kuwatsuka Y, Lazarus HM, Lekakis LJ, Liu H, Modi D, Munshi PN, Mussetti A, Palmisiano N, Patel SS, Rizzieri DA, Seo S, Shah MV, Sharma A, Sohl M, Solomon SR, Ulrickson M, Ustun C, van der Poel M, Verdonck LF, Wagner JL, Wang T, Wirk B, Zeidan A, Litzow M, Kebriaei P, Hourigan CS, Weisdorf DJ, Saber W, Kharfan-Dabaja MA. Blood Adv. 2023 Nov 28. PMID: 37792849.
• Assessing Metadynamics and Docking for Absolute Binding Free Energy Calculations Using Severe Acute Respiratory Syndrome Coronavirus 2 Main Protease Inhibitors.Saar A, Ghahremanpour MM, Tirado-Rives J, Jorgensen WL. J Chem Inf Model. 2023 Nov 27; 2023 Nov 7. PMID: 37934762.
• Emerging Prognostic and Predictive Significance of Stress Keratin 17 in HPV-Associated and Non HPV-Associated Human Cancers: A Scoping Review.Lozar T, Wang W, Gavrielatou N, Christensen L, Lambert PF, Harari PM, Rimm DL, Burtness B, Grasic Kuhar C, Carchman EH. Viruses. 2023 Nov 25; 2023 Nov 25. PMID: 38140561.
• How Healthcare Systems Negatively Impact Environmental Health? The Need for Institutional Commitment to Reduce the Ecological Footprint of Medical Services.Piscitelli P, Karaj S, Miani A, Kyriakides TC, Greco E, Colicino E, Bray A, Simón F, Vasiliou V, Baccarelli AA. Epidemiologia (Basel). 2023 Nov 22; 2023 Nov 22. PMID: 38131675.
• Imaging Proteins Sensitive to Direct Fusions Using Transient Peptide-Peptide Interactions.Gidden Z, Oi C, Johnston EJ, Konieczna Z, Bhaskar H, Mendive-Tapia L, de Moliner F, Rosser SJ, Mochrie SGJ, Vendrell M, Horrocks MH, Regan L. Nano Lett. 2023 Nov 22; 2023 Nov 2. PMID: 37916770.
• Plant MDL proteins synergize with the cytokine MIF at CXCR2 and CXCR4 receptors in human cells.Spiller L, Manjula R, Leissing F, Basquin J, Bourilhon P, Sinitski D, Brandhofer M, Levecque S, Gerra S, Sabelleck B, Zhang L, Feederle R, Flatley A, Hoffmann A, Panstruga R, Bernhagen J, Lolis E. Sci Signal. 2023 Nov 21; 2023 Nov 21. PMID: 37988455.
• A High-Throughput, High-Containment Human Primary Epithelial Airway Organ-on-Chip Platform for SARS-CoV-2 Therapeutic Screening.Fisher CR, Mba Medie F, Luu RJ, Gaibler RB, Mulhern TJ, Miller CR, Zhang CJ, Rubio LD, Marr EE, Vijayakumar V, Gabriel EP, Lopez Quezada L, Zhang CH, Anderson KS, Jorgensen WL, Alladina JW, Medoff BD, Borenstein JT, Gard AL. Cells. 2023 Nov 16; 2023 Nov 16. PMID: 37998374.
• Loss of cis-PTase function in the liver promotes a highly penetrant form of fatty liver disease that rapidly transitions to hepatocellular carcinoma.Singh AK, Chaube B, Citrin KM, Fowler JW, Lee S, Catarino J, Knight J, Lowery S, Shree S, Boutagy N, Ruz-Maldonado I, Harry K, Shanabrough M, Ross TT, Malaker S, Suárez Y, Fernández-Hernando C, Grabinska K, Sessa WC. bioRxiv. 2023 Nov 15; 2023 Nov 15. PMID: 38014178.
• Endothelial nitric oxide synthase (eNOS) S1176 phosphorylation status governs atherosclerotic lesion formation.Nguyen TD, Rahman NT, Sessa WC, Lee MY. Front Cardiovasc Med. 2023; 2023 Nov 14. PMID: 38034389.
• A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better.Djureinovic D, Weiss SA, Krykbaeva I, Qu R, Vathiotis I, Moutafi M, Zhang L, Perdigoto AL, Wei W, Anderson G, Damsky W, Hurwitz M, Johnson B, Schoenfeld D, Mahajan A, Hsu F, Miller-Jensen K, Kluger Y, Sznol M, Kaech SM, Bosenberg M, Jilaveanu LB, Kluger HM. Mol Cancer. 2023 Nov 14; 2023 Nov 14. PMID: 37964379.
• Are We Ready For "Triplet" Therapy in Higher-Risk MDS?Brunner AM, Platzbecker U, DeZern AE, Zeidan AM. Clin Hematol Int. 2023; 2023 Nov 3. PMID: 37933301.
• Antibody-Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors.McNamara B, Greenman M, Pebley N, Mutlu L, Santin AD. Molecules. 2023 Nov 2; 2023 Nov 2. PMID: 37959808.
• Clinical Trials and Climate Change: Doing Our Part While Pursuing Progress.Rahman S, Ryan S, Kim J, Kenney P, Ghali F. Eur Urol Focus. 2023 Nov; 2023 Dec 1. PMID: 38042649.
• Intrathecal delivery of nanoparticle PARP inhibitor to the cerebrospinal fluid for the treatment of metastatic medulloblastoma.Khang M, Lee JH, Lee T, Suh HW, Lee S, Cavaliere A, Rushing A, Geraldo LH, Belitzky E, Rossano S, de Feyter HM, Shin K, Huttner A, Roussel MF, Thomas JL, Carson RE, Marquez-Nostra B, Bindra RS, Saltzman WM. Sci Transl Med. 2023 Nov; 2023 Nov 1. PMID: 37910601.
• Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.Ledermann JA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, Raspagliesi F, Sonke GS, Birrer M, Provencher DM, Sehouli J, Colombo N, González-Martín A, Oaknin A, Ottevanger PB, Rudaitis V, Kobie J, Nebozhyn M, Edmondson M, Sun Y, Cristescu R, Jelinic P, Keefe SM, Matulonis UA. Gynecol Oncol. 2023 Nov; 2023 Oct 18. PMID: 37862791.
• Radiotherapy Plus Cisplatin With or Without Lapatinib for Non-Human Papillomavirus Head and Neck Carcinoma: A Phase 2 Randomized Clinical Trial.Wong SJ, Torres-Saavedra PA, Saba NF, Shenouda G, Bumpous JM, Wallace RE, Chung CH, El-Naggar AK, Gwede CK, Burtness B, Tennant PA, Dunlap NE, Redman R, Stokes WA, Rudra S, Mell LK, Sacco AG, Spencer SA, Nabell L, Yao M, Cury FL, Mitchell DL, Jones CU, Firat S, Contessa JN, Galloway T, Currey A, Harris J, Curran WJ Jr, Le QT. JAMA Oncol. 2023 Nov 1. PMID: 37768670.
• Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.Kim TW, Bedard PL, LoRusso P, Gordon MS, Bendell J, Oh DY, Ahn MJ, Garralda E, D'Angelo SP, Desai J, Hodi FS, Wainberg Z, Delord JP, Cassier PA, Cervantes A, Gil-Martin M, Wu B, Patil NS, Jin Y, Hoang T, Mendus D, Wen X, Meng R, Cho BC. JAMA Oncol. 2023 Nov 1. PMID: 37768658.
• Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts.Platzbecker U, Santini V, Komrokji RS, Zeidan AM, Garcia-Manero G, Buckstein R, Miteva D, Keeperman K, Holot N, Nadal JA, Lai Y, Vodala S, Rosettani B, Giuseppi AC, Yucel A, Fenaux P. Leukemia. 2023 Nov; 2023 Sep 26. PMID: 37752285.
• Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).Stahl M, Bewersdorf JP, Xie Z, Porta MGD, Komrokji R, Xu ML, Abdel-Wahab O, Taylor J, Steensma DP, Starczynowski DT, Sekeres MA, Sanz G, Sallman DA, Roboz GJ, Platzbecker U, Patnaik MM, Padron E, Odenike O, Nimer SD, Nazha A, Majeti R, Loghavi S, Little RF, List AF, Kim TK, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Gore SD, Greenberg P, Figueroa ME, Fenaux P, Efficace F, DeZern AE, Daver NG, Churpek JE, Carraway HE, Buckstein R, Brunner AM, Boultwood J, Borate U, Bejar R, Bennett JM, Wei AH, Santini V, Savona MR, Zeidan AM. Blood Rev. 2023 Nov; 2023 Aug 19. PMID: 37704469.
• Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia.Croucher PJP, Ridinger M, Becker PS, Lin TL, Silberman SL, Wang ES, Zeidan AM. Ann Hematol. 2023 Nov; 2023 Sep 13. PMID: 37702821.
• Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution.Santinelli E, Pascale MR, Xie Z, Badar T, Stahl MF, Bewersdorf JP, Gurnari C, Zeidan AM. Blood Rev. 2023 Nov; 2023 Aug 29. PMID: 37679263.
• Microvascular Decompression for Treatment of Simultaneous Arterial and Venous Conflict Causing Trigeminal Neuralgia: 2-Dimensional Operative Video.Morales-Valero SF, Tabor JK, Moliterno J. Oper Neurosurg (Hagerstown). 2023 Nov 1; 2023 Jul 25. PMID: 37499238.
• Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis.Blue BJ, Brazauskas R, Chen K, Patel J, Zeidan AM, Steinberg A, Ballen K, Kwok J, Rotz SJ, Perez MAD, Kelkar AH, Ganguly S, Wingard JR, Lad D, Sharma A, Badawy SM, Lazarus HM, Hashem H, Szwajcer D, Knight JM, Bhatt NS, Page K, Beattie S, Arai Y, Liu H, Arnold SD, Freytes CO, Abid MB, Beitinjaneh A, Farhadfar N, Wirk B, Winestone LE, Agrawal V, Preussler JM, Seo S, Hashmi S, Lehmann L, Wood WA, Rangarajan HG, Saber W, Majhail NS. Transplant Cell Ther. 2023 Nov; 2023 Jul 22. PMID: 37482244.
• Prostate cancer risk stratification using magnetic resonance imaging-ultrasound fusion vs systematic prostate biopsy.Khajir G, Press B, Lokeshwar S, Ghabili K, Rahman S, Gardezi M, Washington S, Cooperberg MR, Sprenkle P, Leapman MS. JNCI Cancer Spectr. 2023 Oct 31. PMID: 38085220.
• Scientific evidence supporting the newly developed one-health labeling tool "Med-Index": an umbrella systematic review on health benefits of mediterranean diet principles and adherence in a planeterranean perspective.Zupo R, Castellana F, Piscitelli P, Crupi P, Desantis A, Greco E, Severino FP, Pulimeno M, Guazzini A, Kyriakides TC, Vasiliou V, Trichopoulou A, Soldati L, La Vecchia C, De Gaetano G, Donati MB, Colao A, Miani A, Corbo F, Clodoveo ML. J Transl Med. 2023 Oct 26; 2023 Oct 26. PMID: 37885010.
• Peripheral Blasts in a Patient Receiving Chemotherapy.Kshattry S, Parker TL, Huntington SF. JAMA. 2023 Oct 24. PMID: 37801303.
• DNA recognition and induced genome modification by a hydroxymethyl-γ tail-clamp peptide nucleic acid.Oyaghire SN, Quijano E, Perera JDR, Mandl HK, Saltzman WM, Bahal R, Glazer PM. Cell Rep Phys Sci. 2023 Oct 18. PMID: 37920723.
• An Asymmetric Aromatic Finkelstein Reaction: A Platform for Remote Diarylmethane Desymmetrization.Morack T, Myers TE, Karas LJ, Hardy MA, Mercado BQ, Sigman MS, Miller SJ. J Am Chem Soc. 2023 Oct 18; 2023 Oct 3. PMID: 37788150.
• Associations between per- and polyfluoroalkyl substances, liver function, and daily alcohol consumption in a sample of U.S. adults.Ma X, Fisher JA, VoPham T, Vasiliou V, Jones RR. Environ Res. 2023 Oct 15; 2023 Jul 13. PMID: 37451576.
• Determinants of overall survival in patients with metastatic uveal melanoma.Demkowicz P, Pointdujour-Lim R, Miguez S, Lee Y, Jones BSCL, Barker CA, Bosenberg M, Abramson DH, Shoushtari AN, Kluger H, Francis JH, Sznol M, Bakhoum MF. Cancer. 2023 Oct 15; 2023 Jun 29. PMID: 37382208.
• The room where it happens: addressing diversity, equity, and inclusion in National Clinical Trials Network clinical trial leadership.Snyder RA, Burtness B, Cho M, Del Rivero J, Doroshow DB, Hitchcock KE, Kalyan A, Kim CA, Lukovic J, Parikh AR, Sanford NN, Singh B, Shen C, Shroff RT, Vijayvergia N, Goodman KA, Kunz PL. J Natl Cancer Inst. 2023 Oct 9. PMID: 37364007.
• Super-enhancer hijacking drives ectopic expression of hedgehog pathway ligands in meningiomas.Youngblood MW, Erson-Omay Z, Li C, Najem H, Coșkun S, Tyrtova E, Montejo JD, Miyagishima DF, Barak T, Nishimura S, Harmancı AS, Clark VE, Duran D, Huttner A, Avşar T, Bayri Y, Schramm J, Boetto J, Peyre M, Riche M, Goldbrunner R, Amankulor N, Louvi A, Bilgüvar K, Pamir MN, Özduman K, Kilic T, Knight JR, Simon M, Horbinski C, Kalamarides M, Timmer M, Heimberger AB, Mishra-Gorur K, Moliterno J, Yasuno K, Günel M. Nat Commun. 2023 Oct 7; 2023 Oct 7. PMID: 37805627.
• Atypical presentation of dysembryoplastic neuroepithelial tumor in an adult without epilepsy: a case report.Vivanco RA, Aguirre AS, Montero M, Perez-Davila M, Baehring J. Int J Neurosci. 2023 Oct 6; 2023 Oct 6. PMID: 37800586.
• Osimertinib in Resected EGFR-Mutated NSCLC. Reply.Tsuboi M, Herbst RS, Wu YL. N Engl J Med. 2023 Oct 5. PMID: 37792623.
• YIV-818-A: a novel therapeutic agent in prostate cancer management through androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation, and enhancement of apalutamide, darolutamide, and enzalutamide efficacy.Lam W, Arammash M, Cai W, Guan F, Jiang Z, Liu SH, Cheng P, Cheng YC. Front Pharmacol. 2023; 2023 Oct 4. PMID: 37860121.
• Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance.Krykbaeva I, Bridges K, Damsky W, Pizzurro GA, Alexander AF, McGeary MK, Park K, Muthusamy V, Eyles J, Luheshi N, Turner N, Weiss SA, Olino K, Kaech SM, Kluger HM, Miller-Jensen K, Bosenberg M. Cancer Immunol Res. 2023 Oct 4. PMID: 37478171.
• Parallel detection of multi-contrast MRI and Deuterium Metabolic Imaging (DMI) for time-efficient characterization of neurological diseases.Liu Y, De Feyter HM, Corbin ZA, Fulbright RK, McIntyre S, Nixon TW, de Graaf RA. medRxiv. 2023 Oct 3; 2023 Oct 3. PMID: 37873422.
• Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell Leukemia.Park JH, Devlin S, Durham BH, Winer ES, Huntington S, von Keudell G, Vemuri S, Shukla M, Falco V, Cuello B, Gore S, Stone R, Abdel-Wahab O, Tallman MS. NEJM Evid. 2023 Oct; 2023 Sep 21. PMID: 38320179.
• Multi-omics profiling reveals cellular pathways and functions regulated by ALDH1B1 in colon cancer cells.Wang Y, Popovic Z, Charkoftaki G, Garcia-Milian R, Lam TT, Thompson DC, Chen Y, Vasiliou V. Chem Biol Interact. 2023 Oct 1; 2023 Sep 15. PMID: 37716420.
• 3D FRONSAC with PSF reconstruction.Rodriguez Y, Elsaid NMH, Keil B, Galiana G. J Magn Reson. 2023 Oct; 2023 Sep 1. PMID: 37672990.
• Surgical and oncologic outcomes in surgically treated women 80 years and older with endometrioid endometrial cancer as a function of their comorbidities.AlAshqar A, Ghazarian M, Webster EM, Upadhyay A, Azodi M, Schwartz PE, Ratner E, Altwerger G. Gynecol Oncol Rep. 2023 Oct; 2023 Jul 10. PMID: 37636496.
• Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: Systemic Before Local Therapy?Lu BY, Goldberg SB. J Clin Oncol. 2023 Oct 1; 2023 Aug 21. PMID: 37603819.
• Bidirectional processes linking social determinants of health and pediatric sickle cell anemia management: A qualitative study.Long KA, Blakey AO, Amaro CM, Eilenberg JS, Brochier A, Garg A, Drainoni ML, Pashankar F, Esrick EB, Kavanagh PL. Pediatr Blood Cancer. 2023 Oct; 2023 Jul 20. PMID: 37470711.
• Against the Waves: Blocking the EB3-IP3 Interaction Inhibits Calcium Waves in the Lung Endothelium.Takyar SS. Am J Respir Cell Mol Biol. 2023 Oct. PMID: 37348847.
• Microfluidic Immuno-Serolomic Assay Reveals Systems Level Association with COVID-19 Pathology and Vaccine Protection.Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan JM, Buitrago-Pocasangre NC, Lele N, Asashima H, Racke MK, Wilson JE, Givens TS, Tomayko MM, Schulz WL, Longbrake EE, Hafler DA, Halene S, Fan R. Small Methods. 2023 Oct; 2023 Jun 13. PMID: 37312418.
• Precision Medicine for Pancreas Cancer Treatment: A Multidisciplinary Challenge or Opportunity?Farrell JJ, Robert ME, Lacy J. Clin Gastroenterol Hepatol. 2023 Oct; 2023 Jan 12. PMID: 36640803.
• Digital spatial profiling of melanoma shows CD95 expression in immune cells is associated with resistance to immunotherapy.Martinez-Morilla S, Moutafi M, Fernandez AI, Jessel S, Divakar P, Wong PF, Garcia-Milian R, Schalper KA, Kluger HM, Rimm DL. Oncoimmunology. 2023; 2023 Sep 27. PMID: 37781235.
• Data Science-Enabled Palladium-Catalyzed Enantioselective Aryl-Carbonylation of Sulfonimidamides.van Dijk L, Haas BC, Lim NK, Clagg K, Dotson JJ, Treacy SM, Piechowicz KA, Roytman VA, Zhang H, Toste FD, Miller SJ, Gosselin F, Sigman MS. J Am Chem Soc. 2023 Sep 27; 2023 Sep 1. PMID: 37656964.
• MicroRNA-1 protects the endothelium in acute lung injury.Korde A, Haslip M, Pednekar P, Khan A, Chioccioli M, Mehta S, Lopez-Giraldez F, Bermejo S, Rojas M, Dela Cruz C, Matthay MA, Pober JS, Pierce RW, Takyar SS. JCI Insight. 2023 Sep 22; 2023 Sep 22. PMID: 37737266.
• Melanocortin 1 receptor (MC1R) expression as a marker of progression in melanoma.Su D, Djureinovic D, Schoenfeld D, Marquez-Nostra B, Olino K, Jilaveanu L, Kluger H. Res Sq. 2023 Sep 19; 2023 Sep 19. PMID: 37790306.
• TNFα increases the degradation of pyruvate dehydrogenase kinase 4 by the Lon protease to support proinflammatory genes.Boutagy NE, Fowler JW, Grabinska KA, Cardone R, Sun Q, Vazquez KR, Whalen MB, Zhu X, Chakraborty R, Martin KA, Simons M, Romanoski CE, Kibbey RG, Sessa WC. Proc Natl Acad Sci U S A. 2023 Sep 19; 2023 Sep 11. PMID: 37695914.
• Reply to D. Wu et al.Herbst RS, Wu YL, Tsuboi M. J Clin Oncol. 2023 Sep 10; 2023 Jun 30. PMID: 37390374.
• Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.Pratz KW, Cherry M, Altman JK, Cooper BW, Podoltsev NA, Cruz JC, Lin TL, Schiller GJ, Jurcic JG, Asch A, Wu R, Hill JE, Gill SC, James AJ, Rich ES, Hasabou N, Perl AE, Levis MJ. J Clin Oncol. 2023 Sep 10; 2023 Jun 28. PMID: 37379495.
• Atezolizumab for Advanced Alveolar Soft Part Sarcoma.Chen AP, Sharon E, O'Sullivan-Coyne G, Moore N, Foster JC, Hu JS, Van Tine BA, Conley AP, Read WL, Riedel RF, Burgess MA, Glod J, Davis EJ, Merriam P, Naqash AR, Fino KK, Miller BL, Wilsker DF, Begum A, Ferry-Galow KV, Deshpande HA, Schwartz GK, Ladle BH, Okuno SH, Beck JC, Chen JL, Takebe N, Fogli LK, Rosenberger CL, Parchment RE, Doroshow JH. N Engl J Med. 2023 Sep 7. PMID: 37672694.
• Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial.Stockton S, Catalano P, Cohen SJ, Burtness BA, Mitchell EP, Dotan E, Lubner SJ, Kumar P, Mulcahy MF, Fisher GA, Crandall TL, Benson A. Oncologist. 2023 Sep 7. PMID: 37104870.
• Updates on risk stratification and management of lower-risk myelodysplastic syndromes/neoplasms.Badar T, Madanat YF, Zeidan AM. Future Oncol. 2023 Sep; 2023 Sep 26. PMID: 37750305.
• Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia.Podoltsev NA, Wang R, Shallis RM, Stempel JM, Di M, Neparidze N, Zeidan AM, Huntington SF, Giri S, Hull SC, Gore SD, Ma X. Cancer Med. 2023 Sep; 2023 Sep 13. PMID: 37702132.
• Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP).Vaidya R, Unger JM, Qian L, Minichiello K, Herbst RS, Gandara DR, Neal JW, Leal TA, Patel JD, Dragnev KH, Waqar SN, Edelman MJ, Sigal EV, Adam SJ, Malik S, Blanke CD, LeBlanc ML, Kelly K, Gray JE, Redman MW. JCO Precis Oncol. 2023 Sep. PMID: 37677122.
• Reply to: Amniote metabolism and the evolution of endothermy.Wiemann J, Menéndez I, Crawford JM, Fabbri M, Gauthier JA, Hull PM, Norell MA, Briggs DEG. Nature. 2023 Sep. PMID: 37673991.
• Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.Ettinger DS, Wood DE, Stevenson J, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Mullikin TC, Ng T, Otterson GA, Patel SP, Patil T, Polanco PM, Riely GJ, Riess J, Shapiro TA, Singh AP, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory KM, Hughes M. J Natl Compr Canc Netw. 2023 Sep. PMID: 37673108.
• Frailty and postoperative outcomes in brain tumor patients: a systematic review subdivided by tumor etiology.Qureshi HM, Tabor JK, Pickens K, Lei H, Vasandani S, Jalal MI, Vetsa S, Elsamadicy A, Marianayagam N, Theriault BC, Fulbright RK, Qin R, Yan J, Jin L, O'Brien J, Morales-Valero SF, Moliterno J. J Neurooncol. 2023 Sep; 2023 Aug 25. PMID: 37624530.
• Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.Shallis RM, Daver N, Altman JK, Komrokji RS, Pollyea DA, Badar T, Bewersdorf JP, Bhatt VR, de Botton S, de la Fuente Burguera A, Carraway HE, Desai P, Dillon R, Duployez N, El Chaer F, Fathi AT, Freeman SD, Gojo I, Grunwald MR, Jonas BA, Konopleva M, Lin TL, Mannis GN, Mascarenhas J, Michaelis LC, Mims AS, Montesinos P, Pozdnyakova O, Pratz KW, Schuh AC, Sekeres MA, Smith CC, Stahl M, Subklewe M, Uy GL, Voso MT, Walter RB, Wang ES, Zeidner JF, Žučenka A, Zeidan AM. Lancet Haematol. 2023 Sep; 2023 Aug 9. PMID: 37572683.
• On the Ability of the N-O Bond to Support a Stable Stereogenic Axis: Peptide-Catalyzed Atroposelective N-Oxidation.Huth SE, Stone EA, Crotti S, Miller SJ. J Org Chem. 2023 Sep 1; 2023 Aug 10. PMID: 37561942.
• Platinum Sensitivity in IDH1/2 Mutated Intrahepatic Cholangiocarcinoma: Not All "BRCAness" Is Created Equal.Doroshow DB, Wei W, Mehrotra M, Sia D, Eder JP, Bindra R, Houldsworth J, LoRusso P, Walther Z. Cancer Invest. 2023 Sep; 2023 Aug 17. PMID: 37505929.
• The microbial genotoxin colibactin exacerbates mismatch repair mutations in colorectal tumors.Dougherty MW, Valdés-Mas R, Wernke KM, Gharaibeh RZ, Yang Y, Brant JO, Riva A, Muehlbauer M, Elinav E, Puschhof J, Herzon SB, Jobin C. Neoplasia. 2023 Sep; 2023 Jul 25. PMID: 37499275.
• Integrated genetic analyses of immunodeficiency-associated Epstein-Barr virus- (EBV) positive primary CNS lymphomas.Kaulen LD, Denisova E, Hinz F, Hai L, Friedel D, Henegariu O, Hoffmann DC, Ito J, Kourtesakis A, Lehnert P, Doubrovinskaia S, Karschnia P, von Baumgarten L, Kessler T, Baehring JM, Brors B, Sahm F, Wick W. Acta Neuropathol. 2023 Sep; 2023 Jul 26. PMID: 37495858.
• Development of an orally bioavailable selective inhibitor of the menin-MLL.Zhong HJ, Wang W, Zhou W, Liang JX, Cheng YC, Ma DL, Leung CH. Genes Dis. 2023 Sep; 2022 Oct 18. PMID: 37492738.
• Children's Oncology Group's 2023 blueprint for research: Germ cell tumors.Bhuta R, Shah R, Gell JJ, Poynter JN, Bagrodia A, Dicken BJ, Pashankar F, Frazier AL, Shaikh F. Pediatr Blood Cancer. 2023 Sep; 2023 Jul 14. PMID: 37449938.
• Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.Gelissen JH, Adjei NN, McNamara B, Mutlu L, Harold JA, Clark M, Altwerger G, Dottino PR, Huang GS, Santin AD, Azodi M, Ratner E, Schwartz PE, Andikyan V. Ann Surg Oncol. 2023 Sep; 2023 Jun 26. PMID: 37358686.
• Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies.Patel MR, Donnellan W, Byrne M, Asch AS, Zeidan AM, Baer MR, Fathi AT, Kuykendall AT, Zheng F, Walker C, Cheng L, Marando C, Savona MR. Clin Lymphoma Myeloma Leuk. 2023 Sep; 2023 May 15. PMID: 37290996.
• Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial.John T, Grohé C, Goldman JW, Shepherd FA, de Marinis F, Kato T, Wang Q, Su WC, Choi JH, Sriuranpong V, Melotti B, Fidler MJ, Chen J, Albayaty M, Stachowiak M, Taggart S, Wu YL, Tsuboi M, Herbst RS, Majem M. J Thorac Oncol. 2023 Sep; 2023 May 24. PMID: 37236398.
• Humanized mouse liver reveals endothelial control of essential hepatic metabolic functions.Kaffe E, Roulis M, Zhao J, Qu R, Sefik E, Mirza H, Zhou J, Zheng Y, Charkoftaki G, Vasiliou V, Vatner DF, Mehal WZ, Yuval Kluger, Flavell RA. Cell. 2023 Aug 31; 2023 Aug 9. PMID: 37562401.
• CheckMate-915: does adjuvant CTLA-4 blockade play a role in resected melanoma?Su D, Kluger H, Weiss SA. Ann Transl Med. 2023 Aug 30; 2023 Mar 6. PMID: 37675335.
• An AI-powered patient triage platform for future viral outbreaks using COVID-19 as a disease model.Charkoftaki G, Aalizadeh R, Santos-Neto A, Tan WY, Davidson EA, Nikolopoulou V, Wang Y, Thompson B, Furnary T, Chen Y, Wunder EA, Coppi A, Schulz W, Iwasaki A, Pierce RW, Cruz CSD, Desir GV, Kaminski N, Farhadian S, Veselkov K, Datta R, Campbell M, Thomaidis NS, Ko AI, Thompson DC, Vasiliou V. Hum Genomics. 2023 Aug 29; 2023 Aug 29. PMID: 37641126.
• Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals.McNamara B, Chang Y, Goreshnik A, Santin AD. Int J Womens Health. 2023; 2023 Aug 28. PMID: 37663226.
• Computation of Absolute Binding Free Energies for Noncovalent Inhibitors with SARS-CoV-2 Main Protease.Ghahremanpour MM, Saar A, Tirado-Rives J, Jorgensen WL. J Chem Inf Model. 2023 Aug 28; 2023 Aug 10. PMID: 37561001.
• A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors.Carducci MA, Wang D, Habermehl C, Bödding M, Rohdich F, Lignet F, Duecker K, Karpenko O, Pudelko L, Gimmi C, LoRusso P. Cancer Res Commun. 2023 Aug; 2023 Aug 24. PMID: 37637935.
• Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.Sacher A, LoRusso P, Patel MR, Miller WH Jr, Garralda E, Forster MD, Santoro A, Falcon A, Kim TW, Paz-Ares L, Bowyer S, de Miguel M, Han SW, Krebs MG, Lee JS, Cheng ML, Arbour K, Massarelli E, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Dharia NV, Schutzman JL, Desai J. N Engl J Med. 2023 Aug 24. PMID: 37611121.
• Progress on the Pharmacological Targeting of Janus Pseudokinases.Henry SP, Jorgensen WL. J Med Chem. 2023 Aug 24; 2023 Aug 14. PMID: 37578217.
• Polymer nanoparticles deliver mRNA to the lung for mucosal vaccination.Suberi A, Grun MK, Mao T, Israelow B, Reschke M, Grundler J, Akhtar L, Lee T, Shin K, Piotrowski-Daspit AS, Homer RJ, Iwasaki A, Suh HW, Saltzman WM. Sci Transl Med. 2023 Aug 16; 2023 Aug 16. PMID: 37585505.
• Finding activity through rigidity: syntheses of natural products containing tricyclic bridgehead carbon centers.Xu Z, Li X, Rose JA, Herzon SB. Nat Prod Rep. 2023 Aug 16; 2023 Aug 16. PMID: 37140079.
• HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma.McNamara B, Mutlu L, Greenman M, Harold J, Santin A. Cancers (Basel). 2023 Aug 14; 2023 Aug 14. PMID: 37627113.
• Noncanonical HPV carcinogenesis drives radiosensitization of head and neck tumors.Schrank TP, Kothari A, Weir WH, Stepp WH, Rehmani H, Liu X, Wang X, Sewell A, Li X, Tasoulas J, Kim S, Yarbrough G, Xie Y, Flamand Y, Marur S, Hayward MC, Wu D, Burtness B, Anderson KS, Baldwin AS, Yarbrough WG, Issaeva N. Proc Natl Acad Sci U S A. 2023 Aug 8; 2023 Jul 31. PMID: 37523561.
• The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study.LoRusso P, Yamamoto N, Patel MR, Laurie SA, Bauer TM, Geng J, Davenport T, Teufel M, Li J, Lahmar M, Gounder MM. Cancer Discov. 2023 Aug 4. PMID: 37269344.
• Costs of fall injuries in the STRIDE study: an economic evaluation of healthcare system heterogeneity and heterogeneity of treatment effect.Ganz DA, Gill TM, Reuben DB, Bhasin S, Latham NK, Peduzzi P, Greene EJ. Cost Eff Resour Alloc. 2023 Aug 2; 2023 Aug 2. PMID: 37533073.
• A pilot study of volumetric and density tumor analysis of ACC patients treated with vorinostat in a phase II clinical trial.Malarkey M, Toscano AP, Bagheri MH, Solomon J, Machado LB, LoRusso P, Chen A, Folio LR, Goncalves PH. Heliyon. 2023 Aug; 2023 Jul 31. PMID: 37593628.
• Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases.Schoenfeld DA, Moutafi M, Martinez S, Djureinovic D, Merkin RD, Adeniran A, Braun DA, Signoretti S, Choueiri TK, Parisi F, Hurwitz M, Rimm DL, Wei W, Jilaveanu L, Kluger HM. J Immunother Cancer. 2023 Aug. PMID: 37586773.
• ScRNA-seq defines dynamic T-cell subsets in longitudinal colon and peripheral blood samples in immune checkpoint inhibitor-induced colitis.Mann JE, Lucca L, Austin MR, Merkin RD, Robert ME, Al Bawardy B, Raddassi K, Aizenbud L, Joshi NS, Hafler DA, Abraham C, Herold KC, Kluger HM. J Immunother Cancer. 2023 Aug. PMID: 37586769.
• Precise, pragmatic and inclusive: the modern era of oncology clinical trials.Grant MJ, Goldberg SB. Nat Med. 2023 Aug. PMID: 37524954.
• Synthesis of N-Acylsulfenamides from Amides and N-Thiosuccinimides.Liu JT, Brandes DS, Greenwood NS, Ellman JA. Synthesis (Stuttg). 2023 Aug; 2022 Dec 20. PMID: 37457378.
• Rational nanoparticle design: Optimization using insights from experiments and mathematical models.Richfield O, Piotrowski-Daspit AS, Shin K, Saltzman WM. J Control Release. 2023 Aug; 2023 Jul 22. PMID: 37442201.
• SREBP2 regulates the endothelial response to cytokines via direct transcriptional activation of KLF6.Fowler JWM, Boutagy NE, Zhang R, Horikami D, Whalen MB, Romanoski CE, Sessa WC. J Lipid Res. 2023 Aug; 2023 Jul 10. PMID: 37437844.
• Correction to: Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.Zeidan AM, Pollyea DA, Borate U, Vasconcelos A, Potluri R, Rotter D, Kiendrebeogo Z, Gaugler L, Prebet T, Strocchia M, Bonifacio G, Chen C. Ann Hematol. 2023 Aug. PMID: 37341779.
• Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy.McNamara B, Bellone S, Demirkiran C, Max Philipp Hartwich T, Santin AD. Gynecol Oncol Rep. 2023 Aug; 2023 Jun 3. PMID: 37325296.
• Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy.McNamara B, Bellone S, Demirkiran C, Hartwich TMP, Santin AD. Gynecol Oncol Rep. 2023 Aug; 2023 Jun 4. PMID: 37325293.
• Age-related reduction in trait anxiety: Behavioral and neural evidence of automaticity in negative facial emotion processing.Chaudhary S, Zhang S, Zhornitsky S, Chen Y, Chao HH, Li CR. Neuroimage. 2023 Aug 1; 2023 May 30. PMID: 37263454.
• Disparities in COVID-19 vaccine hesitancy among a diverse community-based sample in Connecticut, United States.Eger WH, Suttiratana SC, Herbst RL, Behringer H, Ibrahim E, Jones BA. Prev Med Rep. 2023 Aug; 2023 May 24. PMID: 37252068.
• Adjuvant chemotherapy does not improve outcome in children with ovarian immature teratoma: A comparative analysis of clinical trial data from the Malignant Germ Cell International Consortium.Vieira AGS, Puthenpura V, Krailo M, Fallahazad N, Brougham MFH, Murray MJ, Frazier AL, Lopes LF, Pashankar F. Pediatr Blood Cancer. 2023 Aug; 2023 May 26. PMID: 37243320.
• Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma.Horowitch B, Lee DY, Ding M, Martinez-Morilla S, Aung TN, Ouerghi F, Wang X, Wei W, Damsky W, Sznol M, Kluger H, Rimm DL, Ishizuka JJ. Clin Cancer Res. 2023 Aug 1. PMID: 37233452.
• Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial.Garon EB, Spira AI, Goldberg SB, Chaft JE, Papadimitrakopoulou V, Cascone T, Antonia SJ, Brahmer JR, Camidge DR, Powderly JD, Wozniak AJ, Felip E, Wu S, Ascierto ML, Elgeioushi N, Awad MM. J Thorac Oncol. 2023 Aug; 2023 May 4. PMID: 37146752.
• Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer.Bauman JE, Saba NF, Roe D, Bauman JR, Kaczmar J, Bhatia A, Muzaffar J, Julian R, Wang S, Bearelly S, Baker A, Steuer C, Giri A, Burtness B, Centuori S, Caulin C, Klein R, Saboda K, Obara S, Chung CH. J Clin Oncol. 2023 Aug 1; 2023 Mar 28. PMID: 36977289.
• Celastrol attenuates hepatitis C virus translation and inflammatory response in mice by suppressing heat shock protein 90β.Chen SR, Li ZQ, Xu J, Ding MY, Shan YM, Cheng YC, Zhang GX, Sun YW, Wang YQ, Wang Y. Acta Pharmacol Sin. 2023 Aug; 2023 Mar 7. PMID: 36882503.
• Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis.Di M, Long JB, Kothari SK, Sethi T, Zeidan AM, Podoltsev NA, Shallis RM, Wang R, Ma X, Huntington SF. Haematologica. 2023 Aug 1; 2023 Aug 1. PMID: 36655436.
• Beyond In-hospital Mortality: Use of Postdischarge Quality-Metrics Provides a More Complete Picture of Older Adult Trauma Care.Zogg CK, Cooper Z, Peduzzi P, Falvey JR, Tinetti ME, Lichtman JH. Ann Surg. 2023 Aug 1; 2022 Sep 15. PMID: 36111845.
• Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.Platzbecker U, Della Porta MG, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcarcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Giuseppi AC, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Shetty JK, Hayati S, Vodala S, Prebet T, Degulys A, Paolini S, Cluzeau T, Fenaux P, Garcia-Manero G. Lancet. 2023 Jul 29; 2023 Jun 10. PMID: 37311468.
• Catalytic Asymmetric Hydrogen Atom Transfer: Enantioselective Hydroamination of Alkenes.Hejna BG, Ganley JM, Shao H, Tian H, Ellefsen JD, Fastuca NJ, Houk KN, Miller SJ, Knowles RR. J Am Chem Soc. 2023 Jul 26; 2023 Jul 11. PMID: 37432783.
• Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM.Wong S, Hamidi H, Costa LJ, Bekri S, Neparidze N, Vij R, Nielsen TG, Raval A, Sareen R, Wassner-Fritsch E, Cho HJ. Front Immunol. 2023; 2023 Jul 25. PMID: 37559718.
• IL-7R licenses a population of epigenetically poised memory CD8(+) T cells with superior antitumor efficacy that are critical for melanoma memory.Micevic G, Daniels A, Flem-Karlsen K, Park K, Talty R, McGeary M, Mirza H, Blackburn HN, Sefik E, Cheung JF, Hornick NI, Aizenbud L, Joshi NS, Kluger H, Iwasaki A, Bosenberg MW, Flavell RA. Proc Natl Acad Sci U S A. 2023 Jul 25; 2023 Jul 17. PMID: 37459511.
• COVID-19 annual update: a narrative review.Biancolella M, Colona VL, Luzzatto L, Watt JL, Mattiuz G, Conticello SG, Kaminski N, Mehrian-Shai R, Ko AI, Gonsalves GS, Vasiliou V, Novelli G, Reichardt JKV. Hum Genomics. 2023 Jul 24; 2023 Jul 24. PMID: 37488607.
• Response to Kochan et al., 2023.Ehrlich BE, Vahdat L, DeCillis AP, Seidman A. Support Care Cancer. 2023 Jul 22; 2023 Jul 22. PMID: 37480366.
• Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy.Wang Z, Muthusamy V, Petrylak DP, Anderson KS. NPJ Precis Oncol. 2023 Jul 21; 2023 Jul 21. PMID: 37479885.
• Computational Prediction of the Interaction of Ivermectin with Fibrinogen.Vottero P, Tavernini S, Santin AD, Scheim DE, Tuszynski JA, Aminpour M. Int J Mol Sci. 2023 Jul 14; 2023 Jul 14. PMID: 37511206.
• Considerations for Drug Development in Myelodysplastic Syndromes.Sekeres MA, Kim N, DeZern AE, Norsworthy KJ, Garcia JS, de Claro RA, Theoret MR, Jen EY, Ehrlich LA, Zeidan AM, Komrokji RS. Clin Cancer Res. 2023 Jul 14. PMID: 36688922.
• Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL. N Engl J Med. 2023 Jul 13; 2023 Jun 4. PMID: 37272535.
• Bone Mass Changes Following Percutaneous Radiofrequency Ablation, Osteoplasty, Reinforcement, and Internal Fixation of Periacetabular Osteolytic Metastases.Jiang W, Caruana DL, Dussik CM, Conway D, Latich I, Chapiro J, Lindskog DM, Friedlaender GE, Lee FY. J Clin Med. 2023 Jul 11; 2023 Jul 11. PMID: 37510728.
• Acetate controls endothelial-to-mesenchymal transition.Zhu X, Wang Y, Soaita I, Lee HW, Bae H, Boutagy N, Bostwick A, Zhang RM, Bowman C, Xu Y, Trefely S, Chen Y, Qin L, Sessa W, Tellides G, Jang C, Snyder NW, Yu L, Arany Z, Simons M. Cell Metab. 2023 Jul 11; 2023 Jun 15. PMID: 37327791.
• Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence.Shallis RM, Wang R, Zeidan AM, Huntington SF, Neparidze N, Stempel JM, Mendez LM, Di M, Ma X, Podoltsev NA. Blood Adv. 2023 Jul 11. PMID: 36939371.
• A Th17 cell-intrinsic glutathione/mitochondrial-IL-22 axis protects against intestinal inflammation.Bonetti L, Horkova V, Longworth J, Guerra L, Kurniawan H, Franchina DG, Soriano-Baguet L, Grusdat M, Spath S, Koncina E, Ewen A, Binsfeld C, Verschueren C, Gérardy JJ, Kobayashi T, Dostert C, Farinelle S, Härm J, Chen Y, Harris IS, Lang PA, Vasiliou V, Waisman A, Letellier E, Becher B, Mittelbronn M, Brenner D. bioRxiv. 2023 Jul 7; 2023 Jul 7. PMID: 37489135.
• Alzheimer's disease: using gene/protein network machine learning for molecule discovery in olive oil.Rita L, Neumann NR, Laponogov I, Gonzalez G, Veselkov D, Pratico D, Aalizadeh R, Thomaidis NS, Thompson DC, Vasiliou V, Veselkov K. Hum Genomics. 2023 Jul 7; 2023 Jul 7. PMID: 37420280.
• Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan AA, Blumenschein GR, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. Cancer Discov. 2023 Jul 7. PMID: 37068173.
• Case report: Metastatic Merkel cell carcinoma presenting seven years after loco-regional disease resection of primary tumor with interval in-transit and nodal metastases.Rusheen J, Clune J, Ariyan S, Baumann R, Kluger H, Olino K, Weiss S. Front Oncol. 2023; 2023 Jul 5. PMID: 37476373.
• Quantifying the impact of the COVID-19 pandemic on cancer center clinical trial operations.George TJ, Lin TL, Adrales Bentz T, Grant S, Houston CM, Nashawati MA, Pappu B, Peck H, Zafirovski A, Kerstann K, LoRusso P, Schnatterly A, Hofacker J, Cameron K, Honeycutt H, Werner TL. JNCI Cancer Spectr. 2023 Jul 3. PMID: 37467065.
• Autologous humanized PDX modeling for immuno-oncology recapitulates features of the human tumor microenvironment.Chiorazzi M, Martinek J, Krasnick B, Zheng Y, Robbins KJ, Qu R, Kaufmann G, Skidmore Z, Juric M, Henze LA, Brösecke F, Adonyi A, Zhao J, Shan L, Sefik E, Mudd J, Bi Y, Goedegebuure SP, Griffith M, Griffith O, Oyedeji A, Fertuzinhos S, Garcia-Milian R, Boffa D, Detterbeck F, Dhanasopon A, Blasberg J, Judson B, Gettinger S, Politi K, Kluger Y, Palucka K, Fields RC, Flavell RA. J Immunother Cancer. 2023 Jul. PMID: 37487666.
• Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development.Kluger HM, Tawbi H, Feltquate D, LaVallee T, Rizvi NA, Sharon E, Sosman J, Sullivan RJ. J Immunother Cancer. 2023 Jul. PMID: 37487665.
• Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress.Venugopal S, Shallis RM, Zeidan AM. Expert Rev Anticancer Ther. 2023 Jul-Dec; 2023 Jul 20. PMID: 37470508.
• Associations of race and socioeconomic status with outcomes after intracranial meningioma resection: a systematic review and meta-analysis.Lei H, Tabor JK, O'Brien J, Qin R, Pappajohn AF, Chavez MAM, Morales-Valero SF, Moliterno J. J Neurooncol. 2023 Jul; 2023 Jul 13. PMID: 37440095.
• NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023.Benson AB, D'Angelica MI, Abrams T, Abbott DE, Ahmed A, Anaya DA, Anders R, Are C, Bachini M, Binder D, Borad M, Bowlus C, Brown D, Burgoyne A, Castellanos J, Chahal P, Cloyd J, Covey AM, Glazer ES, Hawkins WG, Iyer R, Jacob R, Jennings L, Kelley RK, Kim R, Levine M, Palta M, Park JO, Raman S, Reddy S, Ronnekleiv-Kelly S, Sahai V, Singh G, Stein S, Turk A, Vauthey JN, Venook AP, Yopp A, McMillian N, Schonfeld R, Hochstetler C. J Natl Compr Canc Netw. 2023 Jul. PMID: 37433432.
• Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results.Gutierrez M, Lam WS, Hellmann MD, Gubens MA, Aggarwal C, Tan DSW, Felip E, Chiu JWY, Lee JS, Yang JC, Garon EB, Finocchiaro G, Ahn MJ, Luft A, Landers GA, Basso A, Ma H, Kobie J, Palcza J, Cristescu R, Fong L, Snyder A, Yuan J, Herbst RS. Nat Med. 2023 Jul; 2023 Jul 10. PMID: 37429923.
• Atomistic simulations of the Escherichia coli ribosome provide selection criteria for translationally active substrates.Watson ZL, Knudson IJ, Ward FR, Miller SJ, Cate JHD, Schepartz A, Abramyan AM. Nat Chem. 2023 Jul; 2023 Jun 12. PMID: 37308707.
• Expanding the substrate scope of pyrrolysyl-transfer RNA synthetase enzymes to include non-α-amino acids in vitro and in vivo.Fricke R, Swenson CV, Roe LT, Hamlish NX, Shah B, Zhang Z, Ficaretta E, Ad O, Smaga S, Gee CL, Chatterjee A, Schepartz A. Nat Chem. 2023 Jul; 2023 Jun 1. PMID: 37264106.
• Surveillance of Pancreatic Cystic Neoplasms.Chhoda A, Schmidt J, Farrell JJ. Gastrointest Endosc Clin N Am. 2023 Jul; 2023 Apr 24. PMID: 37245939.
• Calcium signaling in chemotherapy-induced neuropathy.Fonseca MC, Marazzi-Diniz PHS, Leite MF, Ehrlich BE. Cell Calcium. 2023 Jul; 2023 May 20. PMID: 37244172.
• Nanoparticles as a Therapeutic Delivery System for Skin Cancer Prevention and Treatment.Chang J, Yu B, Saltzman WM, Girardi M. JID Innov. 2023 Jul; 2023 Mar 16. PMID: 37205301.
• First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.Bendell J, LoRusso P, Overman M, Noonan AM, Kim DW, Strickler JH, Kim SW, Clarke S, George TJ, Grimison PS, Barve M, Amin M, Desai J, Wise-Draper T, Eck S, Jiang Y, Khan AA, Wu Y, Martin P, Cooper ZA, Elgeioushi N, Mueller N, Kumar R, Patel SP. Cancer Immunol Immunother. 2023 Jul; 2023 Apr 5. PMID: 37016126.
• Use of stereotactic radiosurgery in treatment of brain metastases from pediatric extracranial solid tumors.Xu S, Campbell A, Chiang V, Bindra R, Vasquez J, Pashankar F. Pediatr Blood Cancer. 2023 Jul; 2023 Mar 28. PMID: 36975152.
• Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1(st) International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS).Bewersdorf JP, Xie Z, Bejar R, Borate U, Boultwood J, Brunner AM, Buckstein R, Carraway HE, Churpek JE, Daver NG, Porta MGD, DeZern AE, Fenaux P, Figueroa ME, Gore SD, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim TK, Komrokji R, Kuchroo VK, List AF, Loghavi S, Majeti R, Odenike O, Patnaik MM, Platzbecker U, Roboz GJ, Sallman DA, Santini V, Sanz G, Sekeres MA, Stahl M, Starczynowski DT, Steensma DP, Taylor J, Abdel-Wahab O, Xu ML, Savona MR, Wei AH, Zeidan AM. Blood Rev. 2023 Jul; 2023 Mar 11. PMID: 36934059.
• Living donor liver transplant candidate and donor selection and engagement: Meeting report from the living donor liver transplant consensus conference.Jesse MT, Jackson WE, Liapakis A, Ganesh S, Humar A, Goldaracena N, Levitsky J, Mulligan D, Pomfret EA, Ladner DP, Roberts JP, Mavis A, Thiessen C, Trotter J, Winder GS, Griesemer AD, Pillai A, Kumar V, Verna EC, LaPointe Rudow D, Han HH. Clin Transplant. 2023 Jul; 2023 Mar 16. PMID: 36892182.
• Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS.Frumm SM, Shimony S, Stone RM, DeAngelo DJ, Bewersdorf JP, Zeidan AM, Stahl M. Blood Rev. 2023 Jul; 2023 Feb 12. PMID: 36805300.
• Survival Outcomes of Optimally Treated Colorectal Metastases: The Importance of R0 Status in Surgical Treatment of Hepatic and Peritoneal Surface Disease.Solsky I, Moaven O, Valenzuela CD, Lundy M, Stauffer JA, Del Piccolo NR, Cheung T, Corvera CU, Wisneski AD, Cha C, Zarandi NP, Dourado J, Russell G, Levine EA, Votanopoulos KI, Shen P. Ann Surg Oncol. 2023 Jul; 2023 Feb 8. PMID: 36754944.
• A Rare Cause of Gastrointestinal Bleeding After Pancreaticoduodenectomy.Block PD, Farrell JJ, Li DK. Gastroenterology. 2023 Jul; 2022 Dec 30. PMID: 36592728.
• Sense of mastery and attitude towards illness: Examining longitudinal benefits of a medical specialty camp for youth with sickle cell disease.Gillard A, Gagnon R, Pashankar F, Balsamo L, Grafft N, Miranda J, Boruchov D, Neri C, Sprinz P, Longyear C. Clin Child Psychol Psychiatry. 2023 Jul; 2022 Dec 11. PMID: 36503316.
• Treatment of myelodysplasia-associated reactive, non-interstitial granulomatous dermatitis with hydroxychloroquine.Choi R, Bhullar S, Glusac E, Podoltsev N, Leventhal J. Int J Dermatol. 2023 Jul; 2022 Oct 10. PMID: 36214463.
• Pre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer.Peters GW, Talcott W, Peters NV, Dhanasopan A, Lacy J, Cecchini M, Kortmansky J, Stein S, Lattanzi S, Park HS, Boffa D, Johung KL, Jethwa KR. J Gastrointest Oncol. 2023 Jun 30; 2023 Jun 26. PMID: 37435226.
• Sulfur-Arylation of Sulfenamides via Ullmann-Type Coupling with (Hetero)aryl Iodides.Greenwood NS, Ellman JA. Org Lett. 2023 Jun 30; 2023 Jun 20. PMID: 37338140.
• Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer.Cecchini M, Zhang JY, Wei W, Sklar J, Lacy J, Zhong M, Kong Y, Zhao H, DiPalermo J, Devine L, Stein SM, Kortmansky J, Johung KL, Bindra RS, LoRusso P, Schalper KA. Cancer Res Commun. 2023 Jun; 2023 Jun 28. PMID: 37387791.
• New approach methodologies to address population variability and susceptibility.To KT, Kleinstreuer N, Vasiliou V, Hogberg HT. Hum Genomics. 2023 Jun 28; 2023 Jun 28. PMID: 37381067.
• Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis.Ragon BK, Shah MV, D'Souza A, Estrada-Merly N, Gowda L, George G, de Lima M, Hashmi S, Kharfan-Dabaja MA, Majhail NS, Banerjee R, Saad A, Hildebrandt GC, Mian H, Abid MB, Battiwalla M, Lekakis LJ, Patel SS, Murthy HS, Nieto Y, Strouse C, Badawy SM, Al Hadidi S, Dholaria B, Aljurf M, Vesole DH, Lee CH, Pawarode A, Gergis U, Miller KC, Holmberg LA, Afrough A, Solh M, Munshi PN, Nishihori T, Anderson LD Jr, Wirk B, Kaur G, Qazilbash MH, Shah N, Kumar SK, Usmani SZ. Blood Adv. 2023 Jun 27. PMID: 36827681.
• An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS.Stahl M, Abdel-Wahab O, Wei AH, Savona MR, Xu ML, Xie Z, Taylor J, Starczynowski D, Sanz GF, Sallman DA, Santini V, Roboz GJ, Patnaik MM, Padron E, Odenike O, Nazha A, Nimer SD, Majeti R, Little RF, Gore S, List AF, Kutchroo V, Komrokji RS, Kim TK, Kim N, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Greenberg PL, Figueroa M, Fenaux P, Efficace F, DeZern AE, Della Porta MG, Daver NG, Churpek JE, Carraway HE, Brunner AM, Borate U, Bennett JM, Bejar R, Boultwood J, Loghavi S, Bewersdorf JP, Platzbecker U, Steensma DP, Sekeres MA, Buckstein RJ, Zeidan AM. Blood Adv. 2023 Jun 27. PMID: 36260702.
• NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors.Cecchini M, Walther Z, Wei W, Hafez N, Pilat MJ, Boerner SA, Durecki DE, Eder JP, Schalper KA, Chen AP, LoRusso P. Cancer Res Commun. 2023 Jun; 2023 Jun 26. PMID: 37377610.
• An optogenetic-phosphoproteomic study reveals dynamic Akt1 signaling profiles in endothelial cells.Zhou W, Li W, Wang S, Salovska B, Hu Z, Tao B, Di Y, Punyamurtula U, Turk BE, Sessa WC, Liu Y. Nat Commun. 2023 Jun 26; 2023 Jun 26. PMID: 37365174.
• Structure Elucidation of Secondary Metabolites: Current Frontiers and Lingering Pitfalls.DiBello M, Healy AR, Nikolayevskiy H, Xu Z, Herzon SB. Acc Chem Res. 2023 Jun 20; 2023 May 23. PMID: 37220079.
• Catalytic Asymmetric Synthesis of Atropisomeric N-Aryl 1,2,4-Triazoles.Choi S, Guo MC, Coombs GM, Miller SJ. J Org Chem. 2023 Jun 16; 2023 Jan 27. PMID: 36705994.
• Magnetic resonance imaging using a nonuniform Bo (NuBo) field-cycling magnet.Selvaganesan K, Wan Y, Ha Y, Wu B, Hancock K, Galiana G, Constable RT. PLoS One. 2023; 2023 Jun 15. PMID: 37319289.
• In utero delivery of miRNA induces epigenetic alterations and corrects pulmonary pathology in congenital diaphragmatic hernia.Ullrich SJ, Yung NK, Bauer-Pisani TJ, Maassel NL, Guerra ME, Freedman-Weiss M, Ahle SL, Ricciardi AS, Sauler M, Saltzman WM, Piotrowski-Daspit AS, Stitelman DH. Mol Ther Nucleic Acids. 2023 Jun 13; 2023 Apr 23. PMID: 37200861.
• Uncovering diffusive states of the yeast membrane protein, Pma1, and how labeling method can change diffusive behavior.Bailey MLP, Pratt SE, Hinrichsen M, Zhang Y, Bewersdorf J, Regan LJ, Mochrie SGJ. Eur Phys J E Soft Matter. 2023 Jun 9; 2023 Jun 9. PMID: 37294385.
• How I treat AML incorporating the updated classifications and guidelines.El Chaer F, Hourigan CS, Zeidan AM. Blood. 2023 Jun 8. PMID: 36758209.
• High-throughput determination of enantiopurity in atroposelective synthesis of aryl triazoles.Lim J, Guo M, Choi S, Miller SJ, Anslyn EV. Chem Sci. 2023 Jun 7; 2023 May 11. PMID: 37293656.
• Aspartyl β-Turn-Based Dirhodium(II) Metallopeptides for Benzylic C(sp(3))-H Amination: Enantioselectivity and X-ray Structural Analysis.van den Heuvel N, Mason SM, Mercado BQ, Miller SJ. J Am Chem Soc. 2023 Jun 7; 2023 May 22. PMID: 37216431.
• The clinical and genomic features of seizures in meningiomas.Dincer A, Jalal MI, Gupte TP, Vetsa S, Vasandani S, Yalcin K, Marianayagam N, Blondin N, Corbin Z, McGuone D, Fulbright RK, Erson-Omay Z, Günel M, Moliterno J. Neurooncol Adv. 2023 May; 2023 Jun 3. PMID: 37287582.
• Preparation of Sulfilimines by Sulfur-Alkylation of N-Acyl Sulfenamides with Alkyl Halides.Champlin AT, Ellman JA. J Org Chem. 2023 Jun 2; 2023 May 23. PMID: 37221855.
• Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform.Ko AH, Kim KP, Siveke JT, Lopez CD, Lacy J, O'Reilly EM, Macarulla T, Manji GA, Lee J, Ajani J, Alsina Maqueda M, Rha SY, Lau J, Al-Sakaff N, Allen S, Lu D, Shemesh CS, Gan X, Cha E, Oh DY. Oncologist. 2023 Jun 2. PMID: 36940261.
• Assessing extraction-analysis methodology to detect fluorotelomer alcohols (FTOH), a class of perfluoroalkyl and polyfluoroalkyl substances (PFAS), in artificial turf fibers and crumb rubber infill.Zuccaro P, Licato J, Davidson EA, Thompson DC, Vasiliou V. Case Stud Chem Environ Eng. 2023 Jun; 2022 Nov 30. PMID: 37575658.
• Immune Resistance Mechanisms and the Road to Personalized Immunotherapy.Piper M, Kluger H, Ruppin E, Hu-Lieskovan S. Am Soc Clin Oncol Educ Book. 2023 Jun. PMID: 37459578.
• Response to "NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng.Aizenbud L, Schoenfeld DA, Caulfield JI, Mann JE, Austin MR, Perdigoto AL, Herold KC, Kluger HM. J Immunother Cancer. 2023 Jun. PMID: 37349129.
• Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop.Clifton GT, Rothenberg M, Ascierto PA, Begley G, Cecchini M, Eder JP, Ghiringhelli F, Italiano A, Kochetkova M, Li R, Mechta-Grigoriou F, Pai SI, Provenzano P, Puré E, Ribas A, Schalper KA, Fridman WH. J Immunother Cancer. 2023 Jun. PMID: 37290925.
• The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021.Goyal G, Lau KW, Wang X, Davidoff AJ, Huntington SF, Jamy O, Calip G, Shah H, Stephens DM, Miksad R, Parikh RB, Takvorian S, Neparidze N, Seymour EK. JAMA Netw Open. 2023 Jun 1; 2023 Jun 1. PMID: 37273206.
• Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance.Katona BW, Klute K, Brand RE, Everett JN, Farrell JJ, Hawthorne K, Kaul V, Kupfer SS, Paiella S, Simeone DM, Sussman DA, Zogopoulos G, Lucas AL, Kastrinos F. Cancer Prev Res (Phila). 2023 Jun 1. PMID: 37259800.
• The effects of age on the severity of problem drinking: Mediating effects of positive alcohol expectancy and neural correlates.Chaudhary S, Chen Y, Zhornitsky S, Le TM, Zhang S, Chao HH, Dominguez JC, Li CR. Addict Biol. 2023 Jun. PMID: 37252876.
• Evaluating the medical management of locally advanced and metastatic basal cell carcinoma: A single institutional retrospective analysis investigating efficacy, safety, and tolerability.Belzer A, Pach J, Mortlock RD, Clune J, Olino K, Sznol M, Bhatia A, Burtness B, Christensen S, Leventhal JS. JAAD Int. 2023 Jun; 2023 Feb 26. PMID: 37252181.
• Author Correction: LACC1 bridges NOS2 and polyamine metabolism in inflammatory macrophages.Wei Z, Oh J, Flavell RA, Crawford JM. Nature. 2023 Jun. PMID: 37231312.
• First-Line Treatment of Driver-Negative Non-Small Cell Lung Cancer.Kim SY, Gettinger S. Hematol Oncol Clin North Am. 2023 Jun. PMID: 37150586.
• Screening for extranodal extension in HPV-associated oropharyngeal carcinoma: evaluation of a CT-based deep learning algorithm in patient data from a multicentre, randomised de-escalation trial.Kann BH, Likitlersuang J, Bontempi D, Ye Z, Aneja S, Bakst R, Kelly HR, Juliano AF, Payabvash S, Guenette JP, Uppaluri R, Margalit DN, Schoenfeld JD, Tishler RB, Haddad R, Aerts HJWL, Garcia JJ, Flamand Y, Subramaniam RM, Burtness BA, Ferris RL. Lancet Digit Health. 2023 Jun; 2023 Apr 21. PMID: 37087370.
• Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's Choice.Lorusso D, Colombo N, Herraez AC, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay SE, Ray-Coquard IL, Shapira-Frommer R, Kim YM, McCormack M, Massaad R, Nguyen AM, Zhao Q, McKenzie J, Prabhu VS, Makker V. Eur J Cancer. 2023 Jun; 2023 Mar 23. PMID: 37086595.
• Mapping N- to C-terminal allosteric coupling through disruption of a putative CD74 activation site in D-dopachrome tautomerase.Chen E, Widjaja V, Kyro G, Allen B, Das P, Prahaladan VM, Bhandari V, Lolis EJ, Batista VS, Lisi GP. J Biol Chem. 2023 Jun; 2023 Apr 18. PMID: 37080391.
• Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775.Makker V, Colombo N, Casado Herráez A, Monk BJ, Mackay H, Santin AD, Miller DS, Moore RG, Baron-Hay S, Ray-Coquard I, Ushijima K, Yonemori K, Kim YM, Guerra Alia EM, Sanli UA, Bird S, Orlowski R, McKenzie J, Okpara C, Barresi G, Lorusso D. J Clin Oncol. 2023 Jun 1; 2023 Apr 14. PMID: 37058687.
• Advances and Opportunities in the Management of Lung Cancer.Goldberg SB, Herbst RS. Hematol Oncol Clin North Am. 2023 Jun; 2023 Apr 4. PMID: 37024390.
• The Evolving Role for Systemic Therapy in Resectable Non-small Cell Lung Cancer.Grant MJ, Woodard GA, Goldberg SB. Hematol Oncol Clin North Am. 2023 Jun; 2023 Apr 4. PMID: 37024389.
• What Is New in Small Cell Lung Cancer.Matera R, Chiang A. Hematol Oncol Clin North Am. 2023 Jun; 2023 Apr 4. PMID: 37024387.
• Including International Medical Graduates in Diversity, Equity, and Inclusion Conversations Among Pathology Training Programs.Schukow CP, Zeidan AM, Loghavi S. Arch Pathol Lab Med. 2023 Jun 1. PMID: 36919991.
• Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations.Grant MJ, Aredo JV, Starrett JH, Stockhammer P, van Alderwerelt van Rosenburgh IK, Wurtz A, Piper-Valillo AJ, Piotrowska Z, Falcon C, Yu HA, Aggarwal C, Scholes D, Patil T, Nguyen C, Phadke M, Li FY, Neal J, Lemmon MA, Walther Z, Politi K, Goldberg SB. Clin Cancer Res. 2023 Jun 1. PMID: 36913537.
• Conditional Survival After Hepatectomy for Colorectal Liver Metastasis: Results from the Colorectal Liver Operative Metastasis International Collaborative (COLOMIC).Valenzuela CD, Moaven O, Solsky IB, Stauffer JA, Del Piccolo NR, Cheung T, Corvera CU, Wisneski AD, Cha CH, Pourhabibi Zarandi N, Dourado J, Perry KC, Russell G, Shen P. Ann Surg Oncol. 2023 Jun; 2023 Mar 1. PMID: 36859704.
• Preclinical evaluation of a brain penetrant PARP PET imaging probe in rat glioblastoma and nonhuman primates.Chen B, Ojha DP, Toyonaga T, Tong J, Pracitto R, Thomas MA, Liu M, Kapinos M, Zhang L, Zheng MQ, Holden D, Fowles K, Ropchan J, Nabulsi N, De Feyter H, Carson RE, Huang Y, Cai Z. Eur J Nucl Med Mol Imaging. 2023 Jun; 2023 Feb 28. PMID: 36849748.
• Validation of the Prognostic Usefulness of the Gene Expression Profiling Test in Patients with Uveal Melanoma.Miguez S, Lee RY, Chan AX, Demkowicz PC, Jones BSCL, Long CP, Abramson DH, Bosenberg M, Sznol M, Kluger H, Goldbaum MH, Francis JH, Pointdujour-Lim R, Bakhoum MF. Ophthalmology. 2023 Jun; 2023 Feb 4. PMID: 36739981.
• Reply: Novel antidiabetic drugs and the risk for HCC. What else to expect from these "wonderful" drug classes?Plaz Torres MC, Jaffe A, Perry R, Marabotto E, Strazzabosco M, Giannini EG. Hepatology. 2023 Jun 1; 2023 Feb 3. PMID: 36724446.
• Use of clinical chemistry health outcomes and PFAS chain length to predict 28-day rodent oral toxicity.Bellia GRM, Bilott RA, Sun N, Thompson D, Vasiliou V. Toxicol Mech Methods. 2023 Jun; 2022 Nov 29. PMID: 36446747.
• Benefit of Extended Surveillance of Low-Risk Pancreatic Cysts After 5-Year Stability: A Systematic Review and Meta-Analysis.Chhoda A, Singh S, Sheth AH, Grimshaw AA, Gunderson CG, Sharma P, Kunstman JW, Sharma A, Ahuja N, Gonda TA, Farrell JJ. Clin Gastroenterol Hepatol. 2023 Jun; 2022 May 11. PMID: 35568304.
• Adherence to Tumor Board Recommendations in the Treatment of Patients with Hepatocellular Carcinoma.Cao Y, Mezzacappa C, Jaffe A, Strazzabosco M, Taddei TH. J Multidiscip Healthc. 2023; 2023 May 31. PMID: 37283950.
• Management of patients with brain metastases from NSCLC without a genetic driver alteration: upfront radiotherapy or immunotherapy?Merkin RD, Chiang VL, Goldberg SB. Ther Adv Med Oncol. 2023; 2023 May 29. PMID: 37275964.
• On the Abundance and Stability of Diazo-Containing Secondary Metabolites: Enantioselective Synthesis of (-)-Nenestatin A.Frischling MC, Herzon SB. Org Lett. 2023 May 26; 2023 May 12. PMID: 37172275.
• Stereospecific Synthesis of Unprotected, α,β-Disubstituted Tryptamines and Phenethylamines from 1,2-Disubstituted Alkenes via a One-Pot Reaction Sequence.Chu D, Ellman JA. Org Lett. 2023 May 26; 2023 May 12. PMID: 37172224.
• Generality-oriented optimization of enantioselective aminoxyl radical catalysis.Rein J, Rozema SD, Langner OC, Zacate SB, Hardy MA, Siu JC, Mercado BQ, Sigman MS, Miller SJ, Lin S. Science. 2023 May 19; 2023 May 18. PMID: 37200427.
• Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers.Bellone S, McNamara B, Mutlu L, Demirkiran C, Hartwich TMP, Harold J, Yang-Hartwich Y, Siegel ER, Santin AD. Int J Mol Sci. 2023 May 17; 2023 May 17. PMID: 37240216.
• Loss to follow-up of minorities, adolescents, and young adults on clinical trials: A report from the Children's Oncology Group.Puthenpura V, Ji L, Xu X, Roth ME, Freyer DR, Frazier AL, Marks AM, Pashankar FD. Cancer. 2023 May 15; 2023 Feb 22. PMID: 36813754.
• Does ADT Influence the Risk of Suicidal Ideation among US Veteran Prostate Cancer Patients Pre-Exposed to PTSD?Brahmbhatt S, Chao HH, Verma S, Gupta S. Cancers (Basel). 2023 May 12; 2023 May 12. PMID: 37345076.
• Infection leaves a genetic and functional mark on the gut population of a commensal bacterium.Tawk C, Lim B, Bencivenga-Barry NA, Lees HJ, Ramos RJF, Cross J, Goodman AL. Cell Host Microbe. 2023 May 10; 2023 Apr 28. PMID: 37119822.
• The role of imaging and sentinel lymph node biopsy in patients with T3b-T4b melanoma with clinically negative disease.Papageorge MV, Maina RM, King ALO, Lee V, Baumann R, Pucar D, Ariyan S, Khan SA, Weiss SA, Clune J, Olino K. Front Oncol. 2023; 2023 May 8. PMID: 37223678.
• Integrated genomic analysis reveals aberrations in WNT signaling in germ cell tumors of childhood and adolescence.Xu L, Pierce JL, Sanchez A, Chen KS, Shukla AA, Fustino NJ, Stuart SH, Bagrodia A, Xiao X, Guo L, Krailo MD, Shaikh F, Billmire DF, Pashankar F, Bestrashniy J, Oosterhuis JW, Gillis AJM, Xie Y, Teot L, Mora J, Poynter JN, Rakheja D, Looijenga LHJ, Draper BW, Frazier AL, Amatruda JF. Nat Commun. 2023 May 6; 2023 May 6. PMID: 37149691.
• Genetic or therapeutic neutralization of ALK1 reduces LDL transcytosis and atherosclerosis in mice.Lee S, Schleer H, Park H, Jang E, Boyer M, Tao B, Gamez-Mendez A, Singh A, Folta-Stogniew E, Zhang X, Qin L, Xiao X, Xu L, Zhang J, Hu X, Pashos E, Tellides G, Shaul PW, Lee WL, Fernandez-Hernando C, Eichmann A, Sessa WC. Nat Cardiovasc Res. 2023 May; 2023 May 11. PMID: 39196046.
• Nanoparticle-mediated genome editing in single-cell embryos via peptide nucleic acids.Putman R, Ricciardi AS, Carufe KEW, Quijano E, Bahal R, Glazer PM, Saltzman WM. Bioeng Transl Med. 2023 May; 2022 Dec 2. PMID: 37206203.
• Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms.Stempel JM, Xie Z, Bewersdorf JP, Stahl M, Zeidan AM. Cancer J. 2023 May-Jun 01. PMID: 37195777.
• Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms.Xie Z, Chen EC, Mendez LM, Komrokji R, Zeidan AM. Cancer J. 2023 May-Jun 01. PMID: 37195768.
• Myelodysplastic Syndromes/Neoplasms-Insights Into Pathogenesis Leading to Improved Classification, Risk Stratification, and Treatments.Rose MG, Zeidan AM. Cancer J. 2023 May-Jun 01. PMID: 37195765.
• Comparison of Percutaneous Interventional Ablation-Osteoplasty-Reinforcement-Internal Fixation (AORIF), Long Intramedullary Nailing, and Hemiarthroplasty for the Treatment of Focal Metastatic Osteolytic Lesions in the Femoral Head and Neck.Jiang W, Friedlaender G, Lindskog D, Latich I, Lee FY. Cardiovasc Intervent Radiol. 2023 May; 2023 Apr 13. PMID: 37052716.
• Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.Ravi A, Hellmann MD, Arniella MB, Holton M, Freeman SS, Naranbhai V, Stewart C, Leshchiner I, Kim J, Akiyama Y, Griffin AT, Vokes NI, Sakhi M, Kamesan V, Rizvi H, Ricciuti B, Forde PM, Anagnostou V, Riess JW, Gibbons DL, Pennell NA, Velcheti V, Digumarthy SR, Mino-Kenudson M, Califano A, Heymach JV, Herbst RS, Brahmer JR, Schalper KA, Velculescu VE, Henick BS, Rizvi N, Jänne PA, Awad MM, Chow A, Greenbaum BD, Luksza M, Shaw AT, Wolchok J, Hacohen N, Getz G, Gainor JF. Nat Genet. 2023 May; 2023 Apr 6. PMID: 37024582.
• Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor.McNamara B, Harold J, Manavella D, Bellone S, Mutlu L, Hartwich TMP, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa MSZ, Yang K, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang GS, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz PE, Burton EA, Inagaki H, Albers A, Zhang C, Bollag G, Schlessinger J, Santin AD. Gynecol Oncol. 2023 May; 2023 Mar 21. PMID: 36958197.
• Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients.Boyiadzis M, Zhang MJ, Chen K, Abdel-Azim H, Abid MB, Aljurf M, Bacher U, Badar T, Badawy SM, Battiwalla M, Bejanyan N, Bhatt VR, Brown VI, Castillo P, Cerny J, Copelan EA, Craddock C, Dholaria B, Perez MAD, Ebens CL, Gale RP, Ganguly S, Gowda L, Grunwald MR, Hashmi S, Hildebrandt GC, Iqbal M, Jamy O, Kharfan-Dabaja MA, Khera N, Lazarus HM, Lin R, Modi D, Nathan S, Nishihori T, Patel SS, Pawarode A, Saber W, Sharma A, Solh M, Wagner JL, Wang T, Williams KM, Winestone LE, Wirk B, Zeidan A, Hourigan CS, Litzow M, Kebriaei P, de Lima M, Page K, Weisdorf DJ. Leukemia. 2023 May. PMID: 36949156.
• Percutaneous Ablation, Osteoplasty, Reinforcement, and Internal Fixation for Pain and Ambulatory Function in Periacetabular Osteolytic Malignancies.Dussik CM, Toombs C, Alder KD, Yu KE, Berson ER, Ibe IK, Li F, Lindskog DM, Friedlaender GE, Latich I, Lee FY. Radiology. 2023 May; 2023 Mar 14. PMID: 36916888.
• Melanoma in pregnancy.Czeyda-Pommersheim F, Kluger H, Langdon J, Menias C, VanBuren W, Leventhal J, Baumann R Jr, Revzin M. Abdom Radiol (NY). 2023 May; 2023 Jan 31. PMID: 36719425.
• Top advances of the year: Head and neck cancer.Verma A, Burtness B. Cancer. 2023 May 1; 2023 Jan 24. PMID: 36692372.
• In vivo imaging of cerebral glucose metabolism informs on subacute to chronic post-stroke tissue status - A pilot study combining PET and deuterium metabolic imaging.Meerwaldt AE, Straathof M, Oosterveld W, van Heijningen CL, van Leent MM, Toner YC, Munitz J, Teunissen AJ, Daemen CC, van der Toorn A, van Vliet G, van Tilborg GA, De Feyter HM, de Graaf RA, Hol EM, Mulder WJ, Dijkhuizen RM. J Cereb Blood Flow Metab. 2023 May; 2023 Jan 6. PMID: 36606595.
• Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time-varying clearance.Hwang M, Chia YL, Zheng Y, Chen CC, He J, Song X, Zhou D, Goldberg SB, Siu LL, Planchard D, Peters S, Mann H, Krug L, Even C. Br J Clin Pharmacol. 2023 May; 2022 Dec 25. PMID: 36454221.
• Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age.Xie Z, Chen EC, Stahl M, Zeidan AM. Blood Rev. 2023 May; 2022 Nov 5. PMID: 36357283.
• Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients.Boyiadzis M, Zhang MJ, Chen K, Abdel-Azim H, Abid MB, Aljurf M, Bacher U, Badar T, Badawy SM, Battiwalla M, Bejanyan N, Bhatt VR, Brown VI, Castillo P, Cerny J, Copelan EA, Craddock C, Dholaria B, Perez MAD, Ebens CL, Gale RP, Ganguly S, Gowda L, Grunwald MR, Hashmi S, Hildebrandt GC, Iqbal M, Jamy O, Kharfan-Dabaja MA, Khera N, Lazarus HM, Lin R, Modi D, Nathan S, Nishihori T, Patel SS, Pawarode A, Saber W, Sharma A, Solh M, Wagner JL, Wang T, Williams KM, Winestone LE, Wirk B, Zeidan A, Hourigan CS, Litzow M, Kebriaei P, de Lima M, Page K, Weisdorf DJ. Leukemia. 2023 May; 2022 Oct 30. PMID: 36310182.
• Mapping of exogenous choline uptake and metabolism in rat glioblastoma using deuterium metabolic imaging (DMI).Ip KL, Thomas MA, Behar KL, de Graaf RA, De Feyter HM. Front Cell Neurosci. 2023; 2023 Apr 28. PMID: 37187610.
• Sulfur-Arylation of Sulfenamides via Chan-Lam Coupling with Boronic Acids: Access to High Oxidation State Sulfur Pharmacophores.Greenwood NS, Ellman JA. Org Lett. 2023 Apr 28; 2023 Apr 12. PMID: 37042652.
• Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.Zeidan AM, Platzbecker U, Bewersdorf JP, Stahl M, Adès L, Borate U, Bowen D, Buckstein R, Brunner A, Carraway HE, Daver N, Díez-Campelo M, de Witte T, DeZern AE, Efficace F, Garcia-Manero G, Garcia JS, Germing U, Giagounidis A, Griffiths EA, Hasserjian RP, Hellström-Lindberg E, Iastrebner M, Komrokji R, Kulasekararaj AG, Malcovati L, Miyazaki Y, Odenike O, Santini V, Sanz G, Scheinberg P, Stauder R, van de Loosdrecht AA, Wei AH, Sekeres MA, Fenaux P. Blood. 2023 Apr 27. PMID: 36724453.
• Identification of Efflux Substrates Using a Riboswitch-Based Reporter in Pseudomonas aeruginosa.Urdaneta-Páez V, Hamchand R, Anthony K, Crawford J, Sutherland AG, Kazmierczak BI. mSphere. 2023 Apr 20; 2023 Mar 22. PMID: 36946743.
• First-Line Nivolumab Plus Ipilimumab in Recurrent/Metastatic Head and Neck Cancer-What Happened?Burtness B. J Clin Oncol. 2023 Apr 20; 2023 Mar 6. PMID: 36877893.
• Pleiotropic role of TRAF7 in skull-base meningiomas and congenital heart disease.Mishra-Gorur K, Barak T, Kaulen LD, Henegariu O, Jin SC, Aguilera SM, Yalbir E, Goles G, Nishimura S, Miyagishima D, Djenoune L, Altinok S, Rai DK, Viviano S, Prendergast A, Zerillo C, Ozcan K, Baran B, Sencar L, Goc N, Yarman Y, Ercan-Sencicek AG, Bilguvar K, Lifton RP, Moliterno J, Louvi A, Yuan S, Deniz E, Brueckner M, Gunel M. Proc Natl Acad Sci U S A. 2023 Apr 18; 2023 Apr 12. PMID: 37043537.
• What's Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach.Awada H, Gurnari C, Xie Z, Bewersdorf JP, Zeidan AM. Cancers (Basel). 2023 Apr 12; 2023 Apr 12. PMID: 37190176.
• Cross-feeding in the gut microbiome: Ecology and mechanisms.Culp EJ, Goodman AL. Cell Host Microbe. 2023 Apr 12. PMID: 37054671.
• Digital Spatial Profiling Links Beta-2-microglobulin Expression with Immune Checkpoint Blockade Outcomes in Head and Neck Squamous Cell Carcinoma.Gavrielatou N, Vathiotis I, Aung TN, Shafi S, Burela S, Fernandez AI, Moutafi M, Burtness B, Economopoulou P, Anastasiou M, Foukas P, Psyrri A, Rimm DL. Cancer Res Commun. 2023 Apr; 2023 Apr 11. PMID: 37057033.
• Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I.Unger JM, Qian L, Redman MW, Tavernier SS, Minasian L, Sigal EV, Papadimitrakopoulou VA, Leblanc M, Cleeland CS, Dzingle SA, Summers TJ, Chao H, Madhusudhana S, Villaruz L, Crawford J, Gray JE, Kelly KL, Gandara DR, Bazhenova L, Herbst RS, Gettinger SN, Moinpour CM. J Natl Cancer Inst. 2023 Apr 11. PMID: 36625510.
• Cost-Effectiveness Analyses in AML: What Have We Learned, How Should This Impact Patient Care, and What Needs to Be Done in the Future?Bewersdorf JP, Huntington SF, Zeidan AM. J Natl Compr Canc Netw. 2023 Apr 10; 2023 Apr 10. PMID: 37037494.
• Lenvatinib or anti-VEGF in combination with anti-PD-1 differentially augments antitumor activity in melanoma.Tran TT, Caulfield J, Zhang L, Schoenfeld D, Djureinovic D, Chiang VL, Oria V, Weiss SA, Olino K, Jilaveanu LB, Kluger HM. JCI Insight. 2023 Apr 10; 2023 Apr 10. PMID: 36821392.
• Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer.Hill BL, Graf RP, Shah K, Danziger N, Lin DI, Quintanilha J, Li G, Haberberger J, Ross JS, Santin AD, Slomovitz B, Elvin JA, Eskander RN. Int J Gynecol Cancer. 2023 Apr 3; 2023 Apr 3. PMID: 36750267.
• Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.Santin AD, Vergote I, González-Martín A, Moore K, Oaknin A, Romero I, Diab S, Copeland LJ, Monk BJ, Coleman RL, Herzog TJ, Siegel J, Kasten L, Schlicker A, Schulz A, Köchert K, Walter AO, Childs BH, Elbi C, Bulat I. Int J Gynecol Cancer. 2023 Apr 3; 2023 Apr 3. PMID: 36564099.
• Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG).Lee SM, Fan W, Wang A, Vaidya R, Redman MW, Gettinger SN, Bazhenova L, Herbst RS, Hershman DL, Unger JM. JCO Clin Cancer Inform. 2023 Apr. PMID: 37084329.
• NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023.Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Ng T, Otterson GA, Patel SP, Patil T, Polanco PM, Riely GJ, Riess J, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory KM, Hughes M. J Natl Compr Canc Netw. 2023 Apr. PMID: 37015337.
• Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.Ajani JA, D'Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Farjah F, Gerdes H, Gibson M, Grierson P, Hofstetter WL, Ilson DH, Jalal S, Keswani RN, Kim S, Kleinberg LR, Klempner S, Lacy J, Licciardi F, Ly QP, Matkowskyj KA, McNamara M, Miller A, Mukherjee S, Mulcahy MF, Outlaw D, Perry KA, Pimiento J, Poultsides GA, Reznik S, Roses RE, Strong VE, Su S, Wang HL, Wiesner G, Willett CG, Yakoub D, Yoon H, McMillian NR, Pluchino LA. J Natl Compr Canc Netw. 2023 Apr. PMID: 37015332.
• Surgical strategies for intracranial meningioma in the molecular era.Dincer A, Morales-Valero SF, Robert SM, Tabor JK, O'Brien J, Yalcin K, Fulbright RK, Erson-Omay Z, Dunn IF, Moliterno J. J Neurooncol. 2023 Apr; 2023 Apr 3. PMID: 37010677.
• Cell-matrix interactions control biliary organoid polarity, architecture, and differentiation.Fiorotto R, Mariotti V, Taleb SA, Zehra SA, Nguyen M, Amenduni M, Strazzabosco M. Hepatol Commun. 2023 Apr 1; 2023 Mar 24. PMID: 36972396.
• Protein degraders enter the clinic - a new approach to cancer therapy.Chirnomas D, Hornberger KR, Crews CM. Nat Rev Clin Oncol. 2023 Apr; 2023 Feb 13. PMID: 36781982.
• Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.Zeidan AM, Pollyea DA, Borate U, Vasconcelos A, Potluri R, Rotter D, Kiendrebeogo Z, Gaugler L, Prebet T, Strocchia M, Bonifacio G, Chen C. Ann Hematol. 2023 Apr; 2023 Feb 3. PMID: 36732419.
• Machine Learning Models for Predicting the Outcomes of Surgical Treatment of Colorectal Liver Metastases.Moaven O, Tavolara TE, Valenzuela CD, Cheung TT, Corvera CU, Cha CH, Stauffer JA, Niazi MKK, Gurcan MN, Shen P. J Am Coll Surg. 2023 Apr 1; 2023 Jan 19. PMID: 36727981.
• Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.Herbst RS, Wu YL, John T, Grohe C, Majem M, Wang J, Kato T, Goldman JW, Laktionov K, Kim SW, Yu CJ, Vu HV, Lu S, Lee KY, Mukhametshina G, Akewanlop C, de Marinis F, Bonanno L, Domine M, Shepherd FA, Urban D, Huang X, Bolanos A, Stachowiak M, Tsuboi M. J Clin Oncol. 2023 Apr 1; 2023 Jan 31. PMID: 36720083.
• Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma.Dizman N, Austin M, Considine B, Jessel S, Schoenfeld D, Merl MY, Hurwitz M, Sznol M, Kluger H. Clin Genitourin Cancer. 2023 Apr; 2023 Jan 12. PMID: 36681606.
• Associations of Early Completion of Advance Directives With Key End-of-Life Quality Measures: Analysis of an ASCO Quality Oncology Practice Initiative Patient Cohort.Power S, Bickel K, Chen RC, Chiang AC, Garrett-Mayer L, Makhoul I, Mougalian SS, Shapiro CL, Siegel R, Smith C, Rocque GB, Kozlik MM, Crist STS, Kamal A. JCO Oncol Pract. 2023 Apr; 2023 Jan 20. PMID: 36669136.
• Life mimics art.Venkatachalapathy M, Crews CM. Cell Res. 2023 Apr. PMID: 36646761.
• Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia.Guru Murthy GS, Logan BR, Bo-Subait S, Beitinjaneh A, Devine S, Farhadfar N, Gowda L, Hashmi S, Lazarus H, Nathan S, Sharma A, Yared JA, Stefanski HE, Pulsipher MA, Hsu JW, Switzer GE, Panch SR, Shaw BE. Am J Hematol. 2023 Apr; 2023 Jan 16. PMID: 36606713.
• Intervention Fidelity in Pain Pragmatic Trials for Nonpharmacologic Pain Management: Nuanced Considerations for Determining PRECIS-2 Flexibility in Delivery and Adherence.Kerns RD, Davis AF, Fritz JM, Keefe FJ, Peduzzi P, Rhon DI, Taylor SL, Vining R, Yu Q, Zeliadt SB, George SZ. J Pain. 2023 Apr; 2022 Dec 24. PMID: 36574858.
• Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, Schiller GJ, Martinelli G, Neubauer A, Sierra J, Montesinos P, Recher C, Yoon SS, Maeda Y, Hosono N, Onozawa M, Kato T, Kim HJ, Hasabou N, Nuthethi R, Tiu R, Levis MJ. Transplant Cell Ther. 2023 Apr; 2022 Dec 13. PMID: 36526260.
• Preface: Phyto-derived nanomedicines for therapeutics, imaging and drug delivery.Qiao H, Zhang J, Cheng YC. Adv Drug Deliv Rev. 2023 Apr; 2022 Dec 9. PMID: 36503066.
• HALO: A software tool for real-time head alignment in the MR scanner.Zhao Z, Galiana G, Zillo C, Camarro T, Qiu M, Papademetris X, Hampson M. Magn Reson Med. 2023 Apr; 2022 Nov 25. PMID: 36426774.
• Outcomes Stratification of Head and Neck Cancer Using Pre- and Post-treatment DNA Methylation From Peripheral Blood.Qian DC, Ulrich BC, Peng G, Zhao H, Conneely KN, Miller AH, Bruner DW, Eldridge RC, Wommack EC, Higgins KA, Shin DM, Saba NF, Smith AK, Burtness B, Park HS, Stokes WA, Beitler JJ, Xiao C. Int J Radiat Oncol Biol Phys. 2023 Apr 1; 2022 Nov 21. PMID: 36410685.
• Nanoparticle Targeting with Antibodies in the Central Nervous System.Lee JH, Chapman DV, Saltzman WM. BME Front. 2023; 2023 Mar 31. PMID: 37849659.
• Integrated Analysis of Tracheobronchial Fluid from Before and After Cardiopulmonary Bypass Reveals Activation of the Integrated Stress Response and Altered Pulmonary Microvascular Permeability.Habet V, Li N, Qi J, Peng G, Charkoftaki G, Vasiliou V, Sharma L, Pober JS, Dela Cruz C, Yan X, Pierce RW. Yale J Biol Med. 2023 Mar; 2023 Mar 31. PMID: 37009190.
• A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas.Gounder MM, Bauer TM, Schwartz GK, Weise AM, LoRusso P, Kumar P, Tao B, Hong Y, Patel P, Lu Y, Lesegretain A, Tirunagaru VG, Xu F, Doebele RC, Hong DS. J Clin Oncol. 2023 Mar 20; 2023 Jan 20. PMID: 36669146.
• Bacteria require phase separation for fitness in the mammalian gut.Krypotou E, Townsend GE, Gao X, Tachiyama S, Liu J, Pokorzynski ND, Goodman AL, Groisman EA. Science. 2023 Mar 17; 2023 Mar 16. PMID: 36927025.
• Surgery or Endovascular Therapy for Chronic Limb Ischemia.Roberts JD. N Engl J Med. 2023 Mar 16. PMID: 36920767.
• Design, synthesis, and biological testing of biphenylmethyloxazole inhibitors targeting HIV-1 reverse transcriptase.Carter ZJ, Hollander K, Spasov KA, Anderson KS, Jorgensen WL. Bioorg Med Chem Lett. 2023 Mar 15; 2023 Mar 3. PMID: 36871704.
• Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma.Potnis KC, Di M, Isufi I, Gowda L, Seropian SE, Foss FM, Forman HP, Huntington SF. Blood Adv. 2023 Mar 14. PMID: 36342852.
• Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea.Wang R, Shallis RM, Stempel JM, Huntington SF, Zeidan AM, Gore SD, Ma X, Podoltsev NA. Blood Adv. 2023 Mar 14. PMID: 35917456.
• Cross-platform analysis reveals cellular and molecular landscape of glioblastoma invasion.Chen AT, Xiao Y, Tang X, Baqri M, Gao X, Reschke M, Sheu WC, Long G, Zhou Y, Deng G, Zhang S, Deng Y, Bai Z, Kim D, Huttner A, Kunes R, Günel M, Moliterno J, Saltzman WM, Fan R, Zhou J. Neuro Oncol. 2023 Mar 14. PMID: 35901838.
• Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors.Gounder M, Ratan R, Alcindor T, Schöffski P, van der Graaf WT, Wilky BA, Riedel RF, Lim A, Smith LM, Moody S, Attia S, Chawla S, D'Amato G, Federman N, Merriam P, Van Tine BA, Vincenzi B, Benson C, Bui NQ, Chugh R, Tinoco G, Charlson J, Dileo P, Hartner L, Lapeire L, Mazzeo F, Palmerini E, Reichardt P, Stacchiotti S, Bailey HH, Burgess MA, Cote GM, Davis LE, Deshpande H, Gelderblom H, Grignani G, Loggers E, Philip T, Pressey JG, Kummar S, Kasper B. N Engl J Med. 2023 Mar 9. PMID: 36884323.
• Vascular steal and associated intratumoral aneurysms in highly vascular brain tumors: illustrative case.Hong CS, Marianayagam NJ, Morales-Valero SF, Barak T, Tabor JK, O'Brien J, Huttner A, Baehring J, Gunel M, Erson-Omay EZ, Fulbright RK, Matouk CC, Moliterno J. J Neurosurg Case Lessons. 2023 Mar 6; 2023 Mar 6. PMID: 36880509.
• The end of the beginning: progress and next steps in KRAS-mutant non-small-cell lung cancer.Goldberg SB, Herbst RS. Lancet. 2023 Mar 4; 2023 Feb 9. PMID: 36774937.
• STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2.Zeidan AM, Giagounidis A, Sekeres MA, Xiao Z, Sanz GF, Hoef MV, Ma F, Hertle S, Santini V. Future Oncol. 2023 Mar; 2023 Apr 21. PMID: 37083373.
• Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies.Atkins MB, Ascierto PA, Feltquate D, Gulley JL, Johnson DB, Khushalani NI, Sosman J, Yap TA, Kluger H, Sullivan RJ, Tawbi H. J Immunother Cancer. 2023 Mar. PMID: 36918225.
• Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors.Kluger H, Barrett JC, Gainor JF, Hamid O, Hurwitz M, LaVallee T, Moss RA, Zappasodi R, Sullivan RJ, Tawbi H, Sharon E. J Immunother Cancer. 2023 Mar. PMID: 36918224.
• Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy.Rizvi N, Ademuyiwa FO, Cao ZA, Chen HX, Ferris RL, Goldberg SB, Hellmann MD, Mehra R, Rhee I, Park JC, Kluger H, Tawbi H, Sullivan RJ. J Immunother Cancer. 2023 Mar. PMID: 36918220.
• Corrigendum to "Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma".Harold J, Bellone S, Manavell DD, Mutlu L, McNamara B, Hartwich TMP, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa MSZ, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang GS, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz PE, Santin AD. Gynecol Oncol. 2023 Mar. PMID: 36906375.
• Intrahepatic Cholangiocarcinoma Developing in Patients with Metabolic Syndrome Is Characterized by Osteopontin Overexpression in the Tumor Stroma.Cadamuro M, Sarcognato S, Camerotto R, Girardi N, Lasagni A, Zanus G, Cillo U, Gringeri E, Morana G, Strazzabosco M, Campello E, Simioni P, Guido M, Fabris L. Int J Mol Sci. 2023 Mar 1; 2023 Mar 1. PMID: 36902188.
• Comparing Detection Schemes for Adversarial Images against Deep Learning Models for Cancer Imaging.Joel MZ, Avesta A, Yang DX, Zhou JG, Omuro A, Herbst RS, Krumholz HM, Aneja S. Cancers (Basel). 2023 Mar 1; 2023 Mar 1. PMID: 36900339.
• Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors.Caulfield JI, Aizenbud L, Perdigoto AL, Meffre E, Jilaveanu L, Michalek DA, Rich SS, Aizenbud Y, Adeniran A, Herold KC, Austin MR, Kluger H. J Immunother Cancer. 2023 Mar. PMID: 36898736.
• NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023.Moses KA, Sprenkle PC, Bahler C, Box G, Carlsson SV, Catalona WJ, Dahl DM, Dall'Era M, Davis JW, Drake BF, Epstein JI, Etzioni RB, Farrington TA, Garraway IP, Jarrard D, Kauffman E, Kaye D, Kibel AS, LaGrange CA, Maroni P, Ponsky L, Reys B, Salami SS, Sanchez A, Seibert TM, Shaneyfelt TM, Smaldone MC, Sonn G, Tyson MD, Vapiwala N, Wake R, Washington S, Yu A, Yuh B, Berardi RA, Freedman-Cass DA. J Natl Compr Canc Netw. 2023 Mar. PMID: 36898362.
• Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer.McNamara B, Chang Y, Mutlu L, Harold J, Santin AD. Expert Opin Biol Ther. 2023 Mar; 2023 Feb 26. PMID: 36800548.
• The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.Han C, McNamara B, Bellone S, Harold J, Manara P, Hartwich TMP, Mutlu L, Yang-Hartwich Y, Zipponi M, Demirkiran C, Verzosa MSZ, Altwerger G, Ratner E, Huang GS, Clark M, Andikyan V, Azodi M, Dottino PR, Schwartz PE, Santin AD. Gynecol Oncol. 2023 Mar; 2023 Jan 25. PMID: 36706643.
• Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.Mauricio D, Bellone S, Mutlu L, McNamara B, Manavella DD, Demirkiran C, Verzosa MSZ, Buza N, Hui P, Hartwich TMP, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang GS, Clark M, Andikyan V, Azodi M, Schwartz PE, Santin AD. Gynecol Oncol. 2023 Mar; 2023 Jan 5. PMID: 36610380.
• Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.Shah MA, Kennedy EB, Alarcon-Rozas AE, Alcindor T, Bartley AN, Malowany AB, Bhadkamkar NA, Deighton DC, Janjigian Y, Karippot A, Khan U, King DA, Klute K, Lacy J, Lee JJ, Mehta R, Mukherjee S, Nagarajan A, Park H, Saeed A, Semrad TJ, Shitara K, Smyth E, Uboha NV, Vincelli M, Wainberg Z, Rajdev L. J Clin Oncol. 2023 Mar 1; 2023 Jan 5. PMID: 36603169.
• How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms.Gurnari C, Xie Z, Zeidan AM. Clin Hematol Int. 2023 Mar; 2022 Dec 27. PMID: 36574201.
• A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance.Yap TA, LoRusso PM, Wong DJ, Hu-Lieskovan S, Papadopoulos KP, Holz JB, Grabowska U, Gradinaru C, Leung KM, Marshall S, Reader CS, Russell R, Sainson RCA, Seal CJ, Shepherd CJ, Germaschewski F, Gliddon D, Stern O, Young L, Brewis N, Kayitalire L, Morrow M. Clin Cancer Res. 2023 Mar 1. PMID: 36342102.
• TP53-altered higher-risk myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a distinct genetic entity with unique unmet needs.Ball S, Loghavi S, Zeidan AM. Leuk Lymphoma. 2023 Mar; 2022 Nov 2. PMID: 36323304.
• Metastatic and multiply relapsed SDH-deficient GIST and paraganglioma displays clinical response to combined poly ADP-ribose polymerase inhibition and temozolomide.Singh C, Bindra RS, Glazer PM, Vasquez JC, Pashankar F. Pediatr Blood Cancer. 2023 Mar; 2022 Sep 24. PMID: 36151992.
• CHIPing away the progression potential of CHIP: A new reality in the making.Xie Z, Zeidan AM. Blood Rev. 2023 Mar; 2022 Aug 15. PMID: 35989137.
• Impact of radiotherapy delay following biopsy for patients with unresected glioblastoma.Gao S, Jin L, Moliterno J, Corbin ZA, Bindra RS, Contessa JN, Yu JB, Park HS. J Neurosurg. 2023 Mar 1; 2022 Jul 29. PMID: 35907197.
• Dose-Dependent Nuclear Delivery and Transcriptional Repression with a Cell-Penetrant MeCP2.Zhang X, Cattoglio C, Zoltek M, Vetralla C, Mozumdar D, Schepartz A. ACS Cent Sci. 2023 Feb 22; 2023 Feb 3. PMID: 36844491.
• Utility of promoter hypermethylation in malignant risk stratification of intraductal papillary mucinous neoplasms.Chhoda A, Sharma A, Sailo B, Tang H, Ruzgar N, Tan WY, Ying L, Khatri R, Narayanan A, Mane S, De Kumar B, Wood LD, Iacobuzio-Donahue C, Wolfgang CL, Kunstman JW, Salem RR, Farrell JJ, Ahuja N. Clin Epigenetics. 2023 Feb 20; 2023 Feb 20. PMID: 36803844.
• Fragment Coupling Approach to Diaporthein B.Hsu IT, Herzon SB. J Org Chem. 2023 Feb 17; 2023 Feb 3. PMID: 36737056.
• AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers.Abu-Khalaf MM, Alex Hodge K, Hatzis C, Baldelli E, El Gazzah E, Valdes F, Sikov WM, Mita MM, Denduluri N, Murphy R, Zelterman D, Liotta L, Dunetz B, Dunetz R, Petricoin EF, Pierobon M. NPJ Precis Oncol. 2023 Feb 16; 2023 Feb 16. PMID: 36797347.
• Glutathione supports lipid abundance in vivo.Asantewaa G, Tuttle ET, Ward NP, Kang YP, Kim Y, Kavanagh ME, Girnius N, Chen Y, Duncan R, Rodriguez K, Hecht F, Zocchi M, Smorodintsev-Schiller L, Scales TQ, Taylor K, Alimohammadi F, Sechrist ZR, Agostini-Vulaj D, Schafer XL, Chang H, Smith Z, O'Connor TN, Whelan S, Selfors LM, Crowdis J, Gray GK, Bronson RT, Brenner D, Rufini A, Dirksen RT, Hezel AF, Huber AR, Munger J, Cravatt BF, Vasiliou V, Cole CL, DeNicola GM, Harris IS. bioRxiv. 2023 Feb 11; 2023 Feb 11. PMID: 36798186.
• Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy.Wang Y, Malik S, Suh HW, Xiao Y, Deng Y, Fan R, Huttner A, Bindra RS, Singh V, Saltzman WM, Bahal R. Sci Adv. 2023 Feb 10; 2023 Feb 8. PMID: 36753549.
• Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab.Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS. J Clin Oncol. 2023 Feb 10. PMID: 36750016.
• Reply to S. Raoof.Dbouk M, Katona BW, Brand RE, Chak A, Syngal S, Farrell JJ, Kastrinos F, Stoffel EM, Canto MI, Goggins M. J Clin Oncol. 2023 Feb 10; 2022 Oct 31. PMID: 36315911.
• Targeted Dephosphorylation of Tau by Phosphorylation Targeting Chimeras (PhosTACs) as a Therapeutic Modality.Hu Z, Chen PH, Li W, Douglas T, Hines J, Liu Y, Crews CM. J Am Chem Soc. 2023 Feb 8; 2023 Feb 8. PMID: 36753634.
• Improving precision oncology through better designs and reporting of biomarker-driven randomized clinical trials.LoRusso PM, Freidlin B. J Natl Cancer Inst. 2023 Feb 8. PMID: 36448688.
• Atropisomers: Synthesis, Analysis, and Applications.Kozlowski MC, Miller SJ, Perreault S. Acc Chem Res. 2023 Feb 7. PMID: 36748251.
• Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti-PD-1 Immunotherapy in Endometrial Carcinoma.Chow RD, Michaels T, Bellone S, Hartwich TMP, Bonazzoli E, Iwasaki A, Song E, Santin AD. Cancer Discov. 2023 Feb 6. PMID: 36301137.
• Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma.Fanucci K, Pilat MJ, Shyr D, Shyr Y, Boerner S, Li J, Durecki D, Drappatz J, Puduvalli V, Lieberman FS, Gonzalez J, Giglio P, Ivy SP, Bindra RS, Omuro A, LoRusso P. Cancer Res Commun. 2023 Feb; 2023 Feb 2. PMID: 36968138.
• Implicit and Explicit Dehumanization of Older Family Members: Novel Determinants of Elder Abuse Proclivity.Chang ES, Monin JK, Isenberg N, Zelterman D, Levy BR. Stigma Health. 2023 Feb; 2022 Mar 17. PMID: 37092028.
• An overview of novel therapies in advanced clinical testing for acute myeloid leukemia.Venugopal S, Xie Z, Zeidan AM. Expert Rev Hematol. 2023 Feb; 2023 Feb 8. PMID: 36718500.
• Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update.Bhatia A, Burtness B. Drugs. 2023 Feb; 2023 Jan 16. PMID: 36645621.
• Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study.Germing U, Fenaux P, Platzbecker U, Buckstein R, Santini V, Díez-Campelo M, Yucel A, Tang D, Fabre S, Zhang G, Zoffoli R, Ha X, Miteva D, Hughes C, Komrokji RS, Zeidan AM, Garcia-Manero G. Ann Hematol. 2023 Feb; 2023 Jan 13. PMID: 36635381.
• Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor.Manavella DD, McNamara B, Harold J, Bellone S, Hartwich TMP, Yang-Hartwich Y, Mutlu L, Zipponi M, Demirkiran C, Verzosa MS, Altwerger G, Ratner E, Huang GS, Clark M, Andikyan V, Azodi M, Schwartz PE, Dottino PR, Choi J, Alexandrov LB, Buza N, Hui P, Santin AD. Gynecol Oncol. 2023 Feb; 2022 Dec 14. PMID: 36525930.
• Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia.Bewersdorf JP, Patel KK, Goshua G, Shallis RM, Podoltsev NA, Stahl M, Stein EM, Huntington SF, Zeidan AM. Leuk Lymphoma. 2023 Feb; 2022 Dec 9. PMID: 36493798.
• Advances in antibody-drug conjugates for gynecologic malignancies.Tymon-Rosario J, Gorman M, Richardson DL, Washington C, Santin AD. Curr Opin Obstet Gynecol. 2023 Feb 1; 2022 Dec 8. PMID: 36484278.
• Simulating time-to-event data subject to competing risks and clustering: A review and synthesis.Meng C, Esserman D, Li F, Zhao Y, Blaha O, Lu W, Wang Y, Peduzzi P, Greene EJ. Stat Methods Med Res. 2023 Feb; 2022 Nov 22. PMID: 36412111.
• A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.Zeidan AM, Borate U, Pollyea DA, Brunner AM, Roncolato F, Garcia JS, Filshie R, Odenike O, Watson AM, Krishnadasan R, Bajel A, Naqvi K, Zha J, Cheng WH, Zhou Y, Hoffman D, Harb JG, Potluri J, Garcia-Manero G. Am J Hematol. 2023 Feb; 2022 Nov 10. PMID: 36309981.
• Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.Kim JW, McKay RR, Radke MR, Zhao S, Taplin ME, Davis NB, Monk P, Appleman LJ, Lara PN Jr, Vaishampayan UN, Zhang J, Paul AK, Bubley G, Van Allen EM, Unlu S, Huang Y, Loda M, Shapiro GI, Glazer PM, LoRusso PM, Ivy SP, Shyr Y, Swisher EM, Petrylak DP. J Clin Oncol. 2023 Feb 1; 2022 Oct 18. PMID: 36256912.
• Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.Harrington KJ, Burtness B, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Lin J, Gumuscu B, Swaby RF, Rischin D. J Clin Oncol. 2023 Feb 1; 2022 Oct 11. PMID: 36219809.
• Clinical care in hepatocellular carcinoma: A mixed methods assessment of experiences and challenges of oncology professionals.Jacobs G, Boyle DA, El-Serag HB, Lewandowski RJ, Stein SM, Lazure P, McFadden P. Cancer Med. 2023 Feb; 2022 Sep 15. PMID: 36106593.
• An Appraisal of Immunohistochemical Stain Use in Hepatic Metastasis Highlights the Effectiveness of the Individualized, Case-Based Approach: Analysis of Data From a Tertiary Care Medical Center.Wang JD, Sebastian C, Walther Z, Suresh T, Lacy J, Zhang X, Jain D. Arch Pathol Lab Med. 2023 Feb 1. PMID: 35512224.
• Macrophage-Derived 25-Hydroxycholesterol Promotes Vascular Inflammation, Atherogenesis, and Lesion Remodeling.Canfrán-Duque A, Rotllan N, Zhang X, Andrés-Blasco I, Thompson BM, Sun J, Price NL, Fernández-Fuertes M, Fowler JW, Gómez-Coronado D, Sessa WC, Giannarelli C, Schneider RJ, Tellides G, McDonald JG, Fernández-Hernando C, Suárez Y. Circulation. 2023 Jan 31; 2022 Nov 23. PMID: 36416142.
• Cytochrome P450 3A4 suppression by epimedium and active compound kaempferol leads to synergistic anti-inflammatory effect with corticosteroid.Li K, Yu XH, Maskey AR, Musa I, Wang ZZ, Garcia V, Guo A, Yang N, Srivastava K, Dunkin D, Li JX, Guo L, Cheng YC, Yuan H, Tiwari R, Li XM. Front Pharmacol. 2022; 2023 Jan 30. PMID: 36793921.
• Epstein-Barr virus-associated primary intracranial leiomyosarcoma in an immunocompetent patient: illustrative case.Tabor JK, Lei H, Morales-Valero SF, O'Brien J, Gopal PP, Erson-Omay EZ, Fulbright RK, Moliterno J. J Neurosurg Case Lessons. 2023 Jan 23; 2023 Jan 23. PMID: 36692065.
• Generation of Stable Epithelial-Mesenchymal Hybrid Cancer Cells with Tumorigenic Potential.Tedja R, Alvero AB, Fox A, Cardenas C, Pitruzzello M, Chehade H, Bawa T, Adzibolosu N, Gogoi R, Mor G. Cancers (Basel). 2023 Jan 22; 2023 Jan 22. PMID: 36765641.
• Author Correction: Head and neck squamous cell carcinoma.Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Nat Rev Dis Primers. 2023 Jan 19; 2023 Jan 19. PMID: 36658129.
• Gut colonization by Bacteroides requires translation by an EF-G paralog lacking GTPase activity.Han W, Peng BZ, Wang C, Townsend GE 2nd, Barry NA, Peske F, Goodman AL, Liu J, Rodnina MV, Groisman EA. EMBO J. 2023 Jan 16; 2022 Dec 6. PMID: 36472247.
• TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity.Shallis RM, Daver NG, Altman JK, Hasserjian RP, Kantarjian HM, Platzbecker U, Santini V, Wei AH, Sallman DA, Zeidan AM. Cancer. 2023 Jan 15; 2022 Nov 17. PMID: 36397669.
• Genome-wide analysis of aberrant position and sequence of plasma DNA fragment ends in patients with cancer.Budhraja KK, McDonald BR, Stephens MD, Contente-Cuomo T, Markus H, Farooq M, Favaro PF, Connor S, Byron SA, Egan JB, Ernst B, McDaniel TK, Sekulic A, Tran NL, Prados MD, Borad MJ, Berens ME, Pockaj BA, LoRusso PM, Bryce A, Trent JM, Murtaza M. Sci Transl Med. 2023 Jan 11; 2023 Jan 11. PMID: 36630480.
• Predictive accuracy of elevated mitotic rate on lymph node positivity and recurrence in thin melanomas.Ly CL, Blaha O, Wei W, Galan A, Kluger H, Ariyan S, Olino K, Clune JE. Front Oncol. 2022; 2023 Jan 6. PMID: 36686728.
• Tumor treatment by pHLIP-targeted antigen delivery.DuPont M, Visca H, Moshnikova A, Engelman DM, Reshetnyak YK, Andreev OA. Front Bioeng Biotechnol. 2022; 2023 Jan 6. PMID: 36686229.
• Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial.Omuro A, Brandes AA, Carpentier AF, Idbaih A, Reardon DA, Cloughesy T, Sumrall A, Baehring J, van den Bent M, Bähr O, Lombardi G, Mulholland P, Tabatabai G, Lassen U, Sepulveda JM, Khasraw M, Vauleon E, Muragaki Y, Di Giacomo AM, Butowski N, Roth P, Qian X, Fu AZ, Liu Y, Potter V, Chalamandaris AG, Tatsuoka K, Lim M, Weller M. Neuro Oncol. 2023 Jan 5. PMID: 35419607.
• YIV-906 enhances nuclear factor of activated T-cells (NFAT) activity of T cells and promotes immune checkpoint blockade antibody action and CAR T-cell activity.Lam W, Hu R, Liu SH, Cheng P, Cheng YC. Front Pharmacol. 2022; 2023 Jan 4. PMID: 36686648.
• Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial.Huffman BM, Basu Mallick A, Horick NK, Wang-Gillam A, Hosein PJ, Morse MA, Beg MS, Murphy JE, Mavroukakis S, Zaki A, Schlechter BL, Sanoff H, Manz C, Wolpin BM, Arlen P, Lacy J, Cleary JM. JAMA Netw Open. 2023 Jan 3; 2023 Jan 3. PMID: 36602796.
• Regulated Induced Proximity Targeting Chimeras (RIPTACs): a Novel Heterobifunctional Small Molecule Therapeutic Strategy for Killing Cancer Cells Selectively.Raina K, Forbes CD, Stronk R, Rappi JP Jr, Eastman KJ, Gerritz SW, Yu X, Li H, Bhardwaj A, Forgione M, Hundt A, King MP, Posner ZM, Denny A, McGovern A, Puleo DE, Garvin E, Chenard R, Zaware N, Mousseau JJ, Macaluso J, Martin M, Bassoli K, Jones K, Garcia M, Howard K, Smith LM, Chen JM, De Leon CA, Hines J, Kayser-Bricker KJ, Crews CM. bioRxiv. 2023 Jan 2; 2023 Jan 2. PMID: 36711980.
• Imine Directed Cp*Rh(III) -Catalyzed N-H Functionalization and Annulation with Amino Amides, Aldehydes, and Diazo Compounds.Zoll AJ, Molas JC, Mercado BQ, Ellman JA. Angew Chem Int Ed Engl. 2023 Jan 2; 2022 Nov 30. PMID: 36331194.
• Platelet-derived TLT-1 promotes tumor progression by suppressing CD8+ T cells.Tyagi T, Jain K, Yarovinsky TO, Chiorazzi M, Du J, Castro C, Griffin J, Korde A, Martin KA, Takyar SS, Flavell RA, Patel AA, Hwa J. J Exp Med. 2023 Jan 2; 2022 Oct 28. PMID: 36305874.
• Impact of Prophylactic Antibacterials on Coagulation Profiles and Bleeding in Patients with Acute Myeloid Leukemia/Myelodysplastic Syndrome.Allen C, Gautam S, Cheng W, Pine AB, Podoltsev NA, Zeidan AM, Lee AI, Shallis RM. Acta Haematol. 2023; 2023 Apr 26. PMID: 37166332.
• Journal of Neuro-Oncology, Meningioma issue.Moliterno J, Brastianos PK. J Neurooncol. 2023 Jan. PMID: 36847897.
• Valproate-coenzyme A conjugate blocks opening of receptor binding domains in the spike trimer of SARS-CoV-2 through an allosteric mechanism.Maschietto F, Qiu T, Wang J, Shi Y, Allen B, Lisi GP, Lolis E, Batista VS. Comput Struct Biotechnol J. 2023; 2023 Jan 16. PMID: 36688026.
• 3D bioprinting of an implantable xeno-free vascularized human skin graft.Baltazar T, Jiang B, Moncayo A, Merola J, Albanna MZ, Saltzman WM, Pober JS. Bioeng Transl Med. 2023 Jan; 2022 Apr 21. PMID: 36684084.
• NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022.Horbinski C, Nabors LB, Portnow J, Baehring J, Bhatia A, Bloch O, Brem S, Butowski N, Cannon DM, Chao S, Chheda MG, Fabiano AJ, Forsyth P, Gigilio P, Hattangadi-Gluth J, Holdhoff M, Junck L, Kaley T, Merrell R, Mrugala MM, Nagpal S, Nedzi LA, Nevel K, Nghiemphu PL, Parney I, Patel TR, Peters K, Puduvalli VK, Rockhill J, Rusthoven C, Shonka N, Swinnen LJ, Weiss S, Wen PY, Willmarth NE, Bergman MA, Darlow S. J Natl Compr Canc Netw. 2023 Jan. PMID: 36634606.
• Advances in myelodysplastic syndromes: promising novel agents and combination strategies.Madanat YF, Xie Z, Zeidan AM. Expert Rev Hematol. 2023 Jan; 2023 Jan 12. PMID: 36620919.
• What role does adjuvant therapy play in the management of endometrial cancer?Huang GS, Tymon-Rosario J, Santin AD. Expert Opin Pharmacother. 2023 Jan; 2023 Jan 3. PMID: 36594708.
• The NLRP3 inflammasome in depression: Potential mechanisms and therapies.Xia CY, Guo YX, Lian WW, Yan Y, Ma BZ, Cheng YC, Xu JK, He J, Zhang WK. Pharmacol Res. 2023 Jan; 2022 Dec 21. PMID: 36563870.
• A comparison of simultaneous multislice and conventional diffusion tensor imaging techniques for ischemic stroke evaluation at 1.5T.Culleton S, Hashemizadeh Kolowori SK, Roberts J, de Havenon A, DiBella E, McNally JS. Br J Radiol. 2023 Jan 1; 2022 Dec 5. PMID: 36469531.
• Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma.Harold J, Bellone S, Manavella DD, Mutlu L, McNamara B, Hartwich TMP, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa MS, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang GS, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz PE, Santin AD. Gynecol Oncol. 2023 Jan; 2022 Nov 25. PMID: 36442427.
• Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy.Zeidan AM, Bewersdorf JP, Hasle V, Shallis RM, Thompson E, de Menezes DL, Rose S, Boss I, Halene S, Haferlach T, Fox B. Leukemia. 2023 Jan; 2022 Nov 27. PMID: 36437356.
• Alternative HCC prognostic biomarkers and use of artificial intelligence in the management of HCC.Jaffe A, Taddei TH, Giannini EG, Ilagan-Ying YC, Colombo M, Strazzabosco M. Liver Int. 2023 Jan; 2022 Dec 5. PMID: 36426717.
• Nanoparticle-based drug delivery for the treatment of traumatic brain injury.Mohammed FS, Omay SB, Sheth KN, Zhou J. Expert Opin Drug Deliv. 2023 Jan; 2022 Dec 6. PMID: 36420918.
• Hormone therapies in meningioma-where are we?Miyagishima DF, Moliterno J, Claus E, Günel M. J Neurooncol. 2023 Jan; 2022 Nov 23. PMID: 36418843.
• Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, Dinner SN, Pigneux A, Montesinos P, Wang ES, Seiter KP, Wei AH, De Botton S, Arnan M, Donnellan W, Schwarer AP, Récher C, Jonas BA, Ferrell PB Jr, Marzac C, Kelly P, Sweeney J, Forsyth S, Guichard SM, Brevard J, Henrick P, Mohamed H, Cortes JE. Lancet Haematol. 2023 Jan; 2022 Nov 10. PMID: 36370742.
• Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors.Bewersdorf JP, Shallis RM, Derkach A, Goldberg AD, Stein A, Stein EM, Marcucci G, Zeidan AM, Shimony S, DeAngelo DJ, Stone RM, Aldoss I, Ball BJ, Stahl M. Leuk Lymphoma. 2023 Jan; 2022 Oct 26. PMID: 36287540.
• BFAST but be smart: bTMB remains an exploratory biomarker in NSCLC.Kim SY, Herbst RS. Nat Rev Clin Oncol. 2023 Jan. PMID: 36271141.
• Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis.Kayali S, Pasta A, Plaz Torres MC, Jaffe A, Strazzabosco M, Marenco S, Giannini EG. Liver Int. 2023 Jan; 2022 Sep 27. PMID: 36102312.
• Deuterium metabolic imaging of the human brain in vivo at 7 T.Serés Roig E, De Feyter HM, Nixon TW, Ruhm L, Nikulin AV, Scheffler K, Avdievich NI, Henning A, de Graaf RA. Magn Reson Med. 2023 Jan; 2022 Sep 5. PMID: 36063499.
• The New England Neurosurgical Society: growth and evolution over 70 years.Wang AY, Sharma V, Bi WL, Curry WT, Florman JE, Groff MW, Heilman CB, Hong J, Kryzanski J, Lollis SS, McGillicuddy GT, Moliterno J, Ogilvy CS, Oh DS, Oyelese AA, Proctor MR, Shear PA, Wakefield AE, Whitmore RG, Riesenburger RI. J Neurosurg. 2023 Jan 1; 2022 May 6. PMID: 35523259.
• Neurogenic orthostatic hypotension after treatment with sorafenib.Wegner Wippel C, Deshpande H, Patwa H, Peixoto AJ. BMJ Case Rep. 2022 Dec 22; 2022 Dec 22. PMID: 36549761.
• Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404).Ho AL, Foster NR, Zoroufy AJ, Campbell JD, Worden F, Price K, Adkins D, Bowles DW, Kang H, Burtness B, Sherman E, Morton R, Morris LGT, Nadeem Z, Katabi N, Munster P, Schwartz GK. J Clin Oncol. 2022 Dec 20; 2022 Jul 22. PMID: 35867947.
• Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade.Vathiotis IA, Salichos L, Martinez-Morilla S, Gavrielatou N, Aung TN, Shafi S, Wong PF, Jessel S, Kluger HM, Syrigos KN, Warren S, Gerstein M, Rimm DL. NPJ Precis Oncol. 2022 Dec 15; 2022 Dec 15. PMID: 36522538.
• Three-component carboformylation: α-quaternary aldehyde synthesis via Co(iii)-catalysed sequential C-H bond addition to dienes and acetic formic anhydride.Tassone JP, Yeo J, Ellman JA. Chem Sci. 2022 Dec 14; 2022 Nov 21. PMID: 36545136.
• Longitudinal single-cell analysis of a patient receiving adoptive cell therapy reveals potential mechanisms of treatment failure.Qu R, Kluger Y, Yang J, Zhao J, Hafler DA, Krause DS, Bersenev A, Bosenberg M, Hurwitz M, Lucca L, Kluger HM. Mol Cancer. 2022 Dec 14; 2022 Dec 14. PMID: 36514045.
• Electronic Nicotine Delivery Systems: An Updated Policy Statement From the American Association for Cancer Research and the American Society of Clinical Oncology.Herbst RS, Hatsukami D, Acton D, Giuliani M, Moushey A, Phillips J, Sherwood S, Toll BA, Viswanath K, Warren NJH, Warren GW, Alberg AJ. J Clin Oncol. 2022 Dec 10; 2022 Oct 26. PMID: 36287017.
• Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.Rodriguez CP, Kang H, Geiger JL, Burtness B, Chung CH, Pickering CR, Fakhry C, Le QT, Yom SS, Galloway TJ, Golemis E, Li A, Shoop J, Wong S, Mehra R, Skinner H, Saba NF, Flores ER, Myers JN, Ford JM, Karchin R, Ferris RL, Kunos C, Lynn JM, Malik S. J Natl Cancer Inst. 2022 Dec 8. PMID: 36053203.
• Pentosinane, a Post-Translational Modification of Human Proteins with Underappreciated Stability.deRamon EA, Sabbasani VR, Streeter MD, Liu Y, Newhouse TR, McDonald DM, Spiegel DA. J Am Chem Soc. 2022 Dec 7; 2022 Nov 21. PMID: 36410375.
• Defining the structure-activity relationship for a novel class of allosteric MKP5 inhibitors.Gannam ZTK, Jamali H, Kweon OS, Herrington J, Shillingford SR, Papini C, Gentzel E, Lolis E, Bennett AM, Ellman JA, Anderson KS. Eur J Med Chem. 2022 Dec 5; 2022 Sep 2. PMID: 36116232.
• Polymer nanocarriers for targeted local delivery of agents in treating brain tumors.Josowitz AD, Bindra RS, Saltzman WM. Nanotechnology. 2022 Dec 2; 2022 Dec 2. PMID: 36179653.
• Mechanistic Considerations in 1,4-Dioxane Cancer Risk Assessment.Ginsberg G, Chen Y, Vasiliou V. Curr Opin Environ Sci Health. 2022 Dec; 2022 Oct 29. PMID: 37091947.
• Artificial turf and crumb rubber infill: An international policy review concerning the current state of regulations.Zuccaro P, Thompson DC, de Boer J, Watterson A, Wang Q, Tang S, Shi X, Llompart M, Ratola N, Vasiliou V. Environ Chall (Amst). 2022 Dec; 2022 Sep 16. PMID: 36644410.
• Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.Chesney J, Lewis KD, Kluger H, Hamid O, Whitman E, Thomas S, Wermke M, Cusnir M, Domingo-Musibay E, Phan GQ, Kirkwood JM, Hassel JC, Orloff M, Larkin J, Weber J, Furness AJS, Khushalani NI, Medina T, Egger ME, Graf Finckenstein F, Jagasia M, Hari P, Sulur G, Shi W, Wu X, Sarnaik A. J Immunother Cancer. 2022 Dec. PMID: 36600653.
• Comprehensive characterization of multiple components of Ziziphus jujuba Mill using UHPLC-Q-Exactive Orbitrap Mass Spectrometers.Qin SH, Yan F, E S, Xiong P, Tang SN, Yu KQ, Zhang M, Cheng YC, Cai W. Food Sci Nutr. 2022 Dec; 2022 Aug 9. PMID: 36514751.
• Targeted Therapies in the Treatment of Uterine Serous Carcinoma.Tymon-Rosario JR, Gorman M, Santin AD. Curr Treat Options Oncol. 2022 Dec; 2022 Nov 30. PMID: 36447064.
• Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms.Patnaik MM, Zeidan AM, Padron E, Platzbecker U, Sallman DA, DeZern AE, Bejar R, Sekeres M, Taylor J, Little RF, Bewersdorf JP, Kim TK, Kim N, Hourigan CS, Dela Porta MG, Stahl M, Steensma D, Xu ML, Odenike O, Carraway H, Fenaux P, Nazha A, Komrokji R, Loghavi S, Xie Z, Hasserjian R, Savona M, Bennett JM. Leukemia. 2022 Dec; 2022 Nov 5. PMID: 36335264.
• Author Correction: Total synthesis of structurally diverse pleuromutilin antibiotics.Goethe O, DiBello M, Herzon SB. Nat Chem. 2022 Dec. PMID: 36284148.
• A novel site on dual-specificity phosphatase MKP7/DUSP16 is required for catalysis and MAPK binding.Shillingford S, Zhang L, Surovtseva Y, Dorry S, Lolis E, Bennett AM. J Biol Chem. 2022 Dec; 2022 Oct 19. PMID: 36272649.
• Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes.Zeidan AM, Bewersdorf JP, Buckstein R, Sekeres MA, Steensma DP, Platzbecker U, Loghavi S, Boultwood J, Bejar R, Bennett JM, Borate U, Brunner AM, Carraway H, Churpek JE, Daver NG, Della Porta M, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Greenberg P, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim N, Kim TK, Komrokji RS, Kutchroo V, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Roboz GJ, Sallman DA, Sanz G, Stahl M, Starczynowski DT, Taylor J, Xie Z, Xu M, Savona MR, Wei AH, Abdel-Wahab O, Santini V. Leukemia. 2022 Dec; 2022 Oct 20. PMID: 36266326.
• Methodologic Concerns in Secondary Analysis of KEYNOTE-048.Burtness B, Lin J, Souliéres D. JAMA Oncol. 2022 Dec 1. PMID: 36264563.
• Locoregional Therapy in the Management of Intrahepatic Cholangiocarcinoma: Is There Sufficient Evidence to Guide Current Clinical Practice?Wang Y, Strazzabosco M, Madoff DC. Curr Oncol Rep. 2022 Dec; 2022 Oct 18. PMID: 36255606.
• How to correct relative voxel scale factors for calculations of vector-difference Fourier maps in cryo-EM.Wang J, Liu J, Gisriel CJ, Wu S, Maschietto F, Flesher DA, Lolis E, Lisi GP, Brudvig GW, Xiong Y, Batista VS. J Struct Biol. 2022 Dec; 2022 Oct 3. PMID: 36202310.
• Proteomic profiling reveals an association between ALDH and oxidative phosphorylation and DNA damage repair pathways in human colon adenocarcinoma stem cells.Wang Y, Chen Y, Garcia-Milian R, Golla JP, Charkoftaki G, Lam TT, Thompson DC, Vasiliou V. Chem Biol Interact. 2022 Dec 1; 2022 Sep 23. PMID: 36162455.
• Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook.Jaffe A, Taddei TH, Giannini EG, Ilagan-Ying YC, Colombo M, Strazzabosco M. Liver Int. 2022 Dec; 2022 Oct 11. PMID: 36161463.
• Bias Against International Medical Graduates in the Hematology/Oncology Fellowship Recruitment Process: Findings From a Nationwide Survey of Fellowship Program Directors.Butt A, Mankbadi M, Erikson C, Marshall A, Masselink LE, Tong G, Hafler J, Podoltsev N, Lee AI. JCO Oncol Pract. 2022 Dec; 2022 Sep 15. PMID: 36108253.
• Outcomes after repeat hepatectomy for colorectal liver metastases from the colorectal liver operative metastasis international collaborative (COLOMIC).Valenzuela CD, Moaven O, Gawdi R, Stauffer JA, Del Piccolo NR, Cheung TT, Corvera CU, Wisneski AD, Cha C, Pourhabibi Zarandi N, Dourado J, Perry KC, Russell G, Shen P. J Surg Oncol. 2022 Dec; 2022 Aug 15. PMID: 35969175.
• pHLIP Peptides Target Acidity in Activated Macrophages.Visca H, DuPont M, Moshnikova A, Crawford T, Engelman DM, Andreev OA, Reshetnyak YK. Mol Imaging Biol. 2022 Dec; 2022 May 23. PMID: 35604527.
• Cellular Stress-Induced Metabolites in Escherichia coli.Gatsios A, Kim CS, York AG, Flavell RA, Crawford JM. J Nat Prod. 2022 Nov 25; 2022 Nov 8. PMID: 36346625.
• Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses.Mao T, Israelow B, Peña-Hernández MA, Suberi A, Zhou L, Luyten S, Reschke M, Dong H, Homer RJ, Saltzman WM, Iwasaki A. Science. 2022 Nov 25; 2022 Nov 25. PMID: 36302057.
• N-Acyl Amides from Neisseria meningitidis and Their Role in Sphingosine Receptor Signaling.Cho W, York AG, Wang R, Wyche TP, Piizzi G, Flavell RA, Crawford JM. Chembiochem. 2022 Nov 18; 2022 Oct 13. PMID: 36112057.
• Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts.Zeidan AM, Platzbecker U, Garcia-Manero G, Sekeres MA, Fenaux P, DeZern AE, Greenberg PL, Savona MR, Jurcic JG, Verma AK, Mufti GJ, Buckstein R, Santini V, Shetty JK, Ito R, Zhang J, Zhang G, Ha X, Backstrom JT, Komrokji RS. Blood. 2022 Nov 17. PMID: 35797468.
• Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects.Mirza MR, Lindahl G, Mahner S, Redondo A, Fabbro M, Rimel BJ, Herrstedt J, Oza AM, Canzler U, Berek JS, González-Martín A, Follana P, Lord R, Azodi M, Estenson K, Wang Z, Li Y, Gupta D, Matulonis U, Feng B. Cancer Res Commun. 2022 Nov; 2022 Nov 15. PMID: 36970052.
• Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS).Brunner AM, Gavralidis A, Ali NA, Hunter A, Komrokji R, Zeidan A, Sallman DA. Blood Cancer J. 2022 Nov 15; 2022 Nov 15. PMID: 36379923.
• Electronic Nicotine Delivery Systems: An Updated Policy Statement from the American Association for Cancer Research and the American Society of Clinical Oncology.Herbst RS, Hatsukami D, Acton D, Giuliani M, Moushey A, Phillips J, Sherwood S, Toll BA, Viswanath K, Warren NJH, Warren GW, Alberg AJ. Clin Cancer Res. 2022 Nov 14. PMID: 36287033.
• Placing human gene families into their evolutionary context.Dornburg A, Mallik R, Wang Z, Bernal MA, Thompson B, Bruford EA, Nebert DW, Vasiliou V, Yohe LR, Yoder JA, Townsend JP. Hum Genomics. 2022 Nov 11; 2022 Nov 11. PMID: 36369063.
• Covalent Modification of the JH2 Domain of Janus Kinase 2.Henry SP, Liosi ME, Ippolito JA, Menges F, Newton AS, Schlessinger J, Jorgensen WL. ACS Med Chem Lett. 2022 Nov 10; 2022 Oct 24. PMID: 36385940.
• Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations.van Alderwerelt van Rosenburgh IK, Lu DM, Grant MJ, Stayrook SE, Phadke M, Walther Z, Goldberg SB, Politi K, Lemmon MA, Ashtekar KD, Tsutsui Y. Nat Commun. 2022 Nov 10; 2022 Nov 10. PMID: 36357385.
• Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab.Dey A, Austin M, Kluger HM, Trunova N, Mann H, Shire N, Morgan C, Zhou D, Mugundu GM. Front Immunol. 2022; 2022 Nov 3. PMID: 36405729.
• Asymmetric Photochemical [2 + 2]-Cycloaddition of Acyclic Vinylpyridines through Ternary Complex Formation and an Uncontrolled Sensitization Mechanism.Girvin ZC, Cotter LF, Yoon H, Chapman SJ, Mayer JM, Yoon TP, Miller SJ. J Am Chem Soc. 2022 Nov 2; 2022 Oct 20. PMID: 36264837.
• Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter.Lim M, Weller M, Idbaih A, Steinbach J, Finocchiaro G, Raval RR, Ansstas G, Baehring J, Taylor JW, Honnorat J, Petrecca K, De Vos F, Wick A, Sumrall A, Sahebjam S, Mellinghoff IK, Kinoshita M, Roberts M, Slepetis R, Warad D, Leung D, Lee M, Reardon DA, Omuro A. Neuro Oncol. 2022 Nov 2. PMID: 35511454.
• Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit.Hayes DF, Herbst RS, Myles JL, Topalian SL, Yohe SL, Aronson N, Bellizzi AM, Basu Roy U, Bradshaw G, Edwards RH, El-Gabry EA, Elvin J, Gajewski TF, McShane LM, Oberley M, Philip R, Rimm DL, Rosenbaum JN, Rubin EH, Schlager L, Sherwood SW, Stewart M, Taube JM, Thurin M, Vasalos P, Laser J. JCO Precis Oncol. 2022 Nov. PMID: 36446042.
• FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy.Choueiri TK, Kluger H, George S, Tykodi SS, Kuzel TM, Perets R, Nair S, Procopio G, Carducci MA, Castonguay V, Folefac E, Lee CH, Hotte SJ, Miller WH Jr, Saggi SS, Lee CW, Desilva H, Bhagavatheeswaran P, Motzer RJ, Escudier B. J Immunother Cancer. 2022 Nov. PMID: 36328377.
• Multiagent Chemotherapy Followed by Stereotactic Body Radiotherapy Versus Conventional Radiotherapy for Resected Pancreas Cancer.Mokhtech M, Miccio JA, Johung K, Cecchini M, Stein S, Narang AK, Herman JM, Kunstman J, Haddock MG, Anker CJ, Jabbour S, Hallemeier CL, Jethwa KR. Am J Clin Oncol. 2022 Nov 1; 2022 Oct 21. PMID: 36318696.
• Treatment Options for Recurrent Primary CNS Lymphoma.Kaulen LD, Baehring JM. Curr Treat Options Oncol. 2022 Nov; 2022 Oct 7. PMID: 36205806.
• Total synthesis of structurally diverse pleuromutilin antibiotics.Goethe O, DiBello M, Herzon SB. Nat Chem. 2022 Nov; 2022 Sep 26. PMID: 36163267.
• Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax.Bewersdorf JP, Shallis RM, Derkach A, Goldberg AD, Stein A, Stein EM, Marcucci G, Zeidan AM, Shimony S, DeAngelo DJ, Stone RM, Aldoss I, Ball BJ, Stahl M. Leuk Res. 2022 Nov; 2022 Aug 29. PMID: 36108424.
• Concealed by the convenient: acquired von Willebrand syndrome in myeloproliferative neoplasm requires a thorough evaluation.Stempel JM, Podoltsev NA, Zeidan AM, Lee AI, Shallis RM. Ann Hematol. 2022 Nov; 2022 Aug 19. PMID: 35984499.
• Effect of the STRIDE fall injury prevention intervention on falls, fall injuries, and health-related quality of life.Ganz DA, Yuan AH, Greene EJ, Latham NK, Araujo K, Siu AL, Magaziner J, Gurwitz JH, Wu AW, Alexander NB, Wallace RB, Greenspan SL, Rich J, Volpi E, Waring SC, Dykes PC, Ko F, Resnick NM, McMahon SK, Basaria S, Wang R, Lu C, Esserman D, Dziura J, Miller ME, Travison TG, Peduzzi P, Bhasin S, Reuben DB, Gill TM. J Am Geriatr Soc. 2022 Nov; 2022 Aug 6. PMID: 35932279.
• Engagement of older adults in STRIDE's multifactorial fall injury prevention intervention.McMahon SK, Greene EJ, Latham N, Peduzzi P, Gill TM, Bhasin S, Reuben DB. J Am Geriatr Soc. 2022 Nov; 2022 Aug 4. PMID: 35924574.
• Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities.Karz A, Dimitrova M, Kleffman K, Alvarez-Breckenridge C, Atkins MB, Boire A, Bosenberg M, Brastianos P, Cahill DP, Chen Q, Ferguson S, Forsyth P, Glitza Oliva IC, Goldberg SB, Holmen SL, Knisely JPS, Merlino G, Nguyen DX, Pacold ME, Perez-Guijarro E, Smalley KSM, Tawbi HA, Wen PY, Davies MA, Kluger HM, Mehnert JM, Hernando E. Pigment Cell Melanoma Res. 2022 Nov; 2022 Sep 1. PMID: 35912544.
• Association of iron infusion reactions with ABO blood type.Butt A, Muradashvili T, Soliman S, Li F, Burns AJ, Brooks A, Browning S, Bar N, Borgman G, Goshua G, Hwa J, Martin K, Rinder H, Tormey C, Pine AB, Bona RD, Lee AI, Neparidze N. Eur J Haematol. 2022 Nov; 2022 Aug 9. PMID: 35871468.
• A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome.Komrokji RS, Carraway HE, Germing U, Wermke M, Zeidan AM, Fu E, Rüter B, Burkard U, Osswald A, Foran JM. Haematologica. 2022 Nov 1; 2022 Nov 1. PMID: 35734924.
• Commensal microbiota from patients with inflammatory bowel disease produce genotoxic metabolites.Cao Y, Oh J, Xue M, Huh WJ, Wang J, Gonzalez-Hernandez JA, Rice TA, Martin AL, Song D, Crawford JM, Herzon SB, Palm NW. Science. 2022 Oct 28; 2022 Oct 28. PMID: 36302024.
• Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial.Cortes JE, Lin TL, Asubonteng K, Faderl S, Lancet JE, Prebet T. J Hematol Oncol. 2022 Oct 26; 2022 Oct 26. PMID: 36289532.
• Location, location, and activation of a channel by calcium.Kuo IY, Ehrlich BE. Proc Natl Acad Sci U S A. 2022 Oct 25; 2022 Oct 10. PMID: 36215521.
• Myasthenia Gravis in the Setting of Immune Checkpoint Inhibitor Therapy: Practical Considerations and Opinion-Based Approach to Acute Management.Zubair AS, Roy B, Baehring JM, Nowak RJ. Cureus. 2022 Oct; 2022 Oct 24. PMID: 36439604.
• ESOT Consensus Platform for Organ Transplantation: Setting the Stage for a Rigorous, Regularly Updated Development Process.Cillo U, Weissenbacher A, Pengel L, Jochmans I, Roppolo D, Amarelli C, Belli LS, Berenguer M, De Vries A, Ferrer J, Friedewald J, Furian L, Greenwood S, Monbaliu D, Nadalin S, Neyrinck A, Strazzabosco M, Toso C, Zaza G, Thuraisingham R, Berney T, Potena L, Montserrat N, Selzner N. Transpl Int. 2022; 2022 Oct 24. PMID: 36406781.
• Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies.Lidsky ME, Wang Z, Lu M, Liu A, Hsu SD, McCall SJ, Sheng Z, Granek JA, Owzar K, Anderson KS, Wood KC. NPJ Precis Oncol. 2022 Oct 23; 2022 Oct 23. PMID: 36274097.
• Endometrial Cancer in Reproductive Age: Fertility-Sparing Approach and Reproductive Outcomes.Mutlu L, Manavella DD, Gullo G, McNamara B, Santin AD, Patrizio P. Cancers (Basel). 2022 Oct 22; 2022 Oct 22. PMID: 36358604.
• Visible Light-Mediated, Diastereoselective Epimerization of Morpholines and Piperazines to More Stable Isomers.Shen Z, Vargas-Rivera MA, Rigby EL, Chen S, Ellman JA. ACS Catal. 2022 Oct 21; 2022 Oct 10. PMID: 36406894.
• Exploring ABOBEC3A and APOBEC3B substrate specificity and their role in HPV positive head and neck cancer.Papini C, Wang Z, Kudalkar SN, Schrank TP, Tang S, Sasaki T, Wu C, Tejada B, Ziegler SJ, Xiong Y, Issaeva N, Yarbrough WG, Anderson KS. iScience. 2022 Oct 21; 2022 Sep 5. PMID: 36164654.
• Eradication of tumors and development of anti-cancer immunity using STINGa targeted by pHLIP.Moshnikova A, DuPont M, Visca H, Engelman DM, Andreev OA, Reshetnyak YK. Front Oncol. 2022; 2022 Oct 18. PMID: 36330464.
• Effects of androgen deprivation on white matter integrity and processing speed in prostate cancer patients.Chaudhary S, Roy A, Summers C, Ahles T, Li CR, Chao HH. Am J Cancer Res. 2022; 2022 Oct 15. PMID: 36381311.
• Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance.Schoenfeld DA, Merkin RD, Moutafi M, Martinez S, Adeniran A, Kumar D, Jilaveanu L, Hurwitz M, Rimm DL, Kluger HM. Front Oncol. 2022; 2022 Oct 13. PMID: 36313654.
• COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer.Herbst RS, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, Sanchez-Hernandez A, Dakhil S, Camidge DR, Winzer L, Soo-Hoo Y, Cooper ZA, Kumar R, Bothos J, Aggarwal C, Martinez-Marti A. J Clin Oncol. 2022 Oct 10; 2022 Apr 22. PMID: 35452273.
• A preliminary, prospective study of peripheral neuropathy and cognitive function in patients with breast cancer during taxane therapy.Ibrahim EY, Munshani S, Domenicano I, Rodwin R, Nowak RJ, Pusztai L, Lustberg M, Ehrlich BE. PLoS One. 2022; 2022 Oct 7. PMID: 36206298.
• In vivo correction of cystic fibrosis mediated by PNA nanoparticles.Piotrowski-Daspit AS, Barone C, Lin CY, Deng Y, Wu D, Binns TC, Xu E, Ricciardi AS, Putman R, Garrison A, Nguyen R, Gupta A, Fan R, Glazer PM, Saltzman WM, Egan ME. Sci Adv. 2022 Oct 7; 2022 Oct 5. PMID: 36197984.
• Data Availability Statements in The Journal of Organic Chemistry, Organic Letters, and ACS Organic & Inorganic Au.Masson G, Kozlowski MC, Miller SJ. J Org Chem. 2022 Oct 7; 2022 Sep 12. PMID: 36094102.
• The Quest to Eradicate HPV-Related Oropharyngeal Carcinoma: An Opportunity Not to Miss.Lalonde CS, Teng Y, Burtness BA, Ferris RL, Ahmed R, Saba NF. J Natl Cancer Inst. 2022 Oct 6. PMID: 35567531.
• Data Availability Statements in The Journal of Organic Chemistry, Organic Letters, and ACS Organic & Inorganic Au.Masson G, Kozlowski MC, Miller SJ. ACS Org Inorg Au. 2022 Oct 5; 2022 Sep 12. PMID: 36855665.
• Taking out the trash: How misfolded proteins are removed from the endoplasmic reticulum.Brodsky JL, Engelman DM, Hendershot LM, Piana-Agostinetti S, Sommer T. Fac Rev. 2022; 2022 Oct 5. PMID: 36267301.
• Catalytic Enantioselective Sulfur Alkylation of Sulfenamides for the Asymmetric Synthesis of Sulfoximines.Greenwood NS, Champlin AT, Ellman JA. J Am Chem Soc. 2022 Oct 5; 2022 Sep 26. PMID: 36154032.
• Oxidative stress, glutathione, and CYP2E1 in 1,4-dioxane liver cytotoxicity and genotoxicity: insights from animal models.Wang Y, Charkoftaki G, Davidson E, Orlicky DJ, Tanguay RL, Thompson DC, Vasiliou V, Chen Y. Curr Opin Environ Sci Health. 2022 Oct; 2022 Aug 15. PMID: 37483863.
• Oral Chemotherapy Metric Performance in Quality Oncology Practice Initiative Practices: Updated Trends and Analysis.Blinder VS, Garrett-Mayer E, Jacobsen PB, Kozlik MM, Markham MJ, Siegel RD, Kamal AH, Crist STS, Rosenthal J, Chiang AC. J Natl Compr Canc Netw. 2022 Oct. PMID: 36240846.
• Synthetic biodegradable polyesters for implantable controlled-release devices.Pothupitiya JU, Zheng C, Saltzman WM. Expert Opin Drug Deliv. 2022 Oct; 2022 Oct 25. PMID: 36197839.
• Bespoke library docking for 5-HT(2A) receptor agonists with antidepressant activity.Kaplan AL, Confair DN, Kim K, Barros-Álvarez X, Rodriguiz RM, Yang Y, Kweon OS, Che T, McCorvy JD, Kamber DN, Phelan JP, Martins LC, Pogorelov VM, DiBerto JF, Slocum ST, Huang XP, Kumar JM, Robertson MJ, Panova O, Seven AB, Wetsel AQ, Wetsel WC, Irwin JJ, Skiniotis G, Shoichet BK, Roth BL, Ellman JA. Nature. 2022 Oct; 2022 Sep 28. PMID: 36171289.
• Coronavirus Lung Infection Impairs Host Immunity against Secondary Bacterial Infection by Promoting Lysosomal Dysfunction.Peng X, Kim J, Gupta G, Agaronyan K, Mankowski MC, Korde A, Takyar SS, Shin HJ, Habet V, Voth S, Audia JP, Chang D, Liu X, Wang L, Cai Y, Tian X, Ishibe S, Kang MJ, Compton S, Wilen CB, Dela Cruz CS, Sharma L. J Immunol. 2022 Oct 1; 2022 Sep 2. PMID: 36165196.
• Targeted Delivery of Chemo-Sonodynamic Therapy via Brain Targeting, Glutathione-Consumable Polymeric Nanoparticles for Effective Brain Cancer Treatment.Wu H, Gao X, Luo Y, Yu J, Long G, Jiang Z, Zhou J. Adv Sci (Weinh). 2022 Oct; 2022 Aug 15. PMID: 35971187.
• Molecular determinants of peri-apical targeting of inositol 1,4,5-trisphosphate receptor type 3 in cholangiocytes.Rodrigues MA, Gomes DA, Fiorotto R, Guerra MT, Weerachayaphorn J, Bo T, Sessa WC, Strazzabosco M, Nathanson MH. Hepatol Commun. 2022 Oct; 2022 Jul 19. PMID: 35852334.
• The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival.Dbouk M, Katona BW, Brand RE, Chak A, Syngal S, Farrell JJ, Kastrinos F, Stoffel EM, Blackford AL, Rustgi AK, Dudley B, Lee LS, Chhoda A, Kwon R, Ginsberg GG, Klein AP, Kamel I, Hruban RH, He J, Shin EJ, Lennon AM, Canto MI, Goggins M. J Clin Oncol. 2022 Oct 1; 2022 Jun 15. PMID: 35704792.
• Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer.Shafi S, Aung TN, Xirou V, Gavrielatou N, Vathiotis IA, Fernandez A, Moutafi M, Yaghoobi V, Herbst RS, Liu LN, Langermann S, Rimm DL. Lab Invest. 2022 Oct; 2022 May 17. PMID: 35581307.
• Brain-targeting, acid-responsive antioxidant nanoparticles for stroke treatment and drug delivery.Zhang S, Peng B, Chen Z, Yu J, Deng G, Bao Y, Ma C, Du F, Sheu WC, Kimberly WT, Simard JM, Coman D, Chen Q, Hyder F, Zhou J, Sheth KN. Bioact Mater. 2022 Oct; 2022 Mar 7. PMID: 35386312.
• Concurrent use of tumor necrosis factor inhibitor and tyrosine kinase inhibitor in ankylosing spondylitis and myeloid neoplasm.Gupta A, Afinogenova Y, Podoltsev NA, Danve A. Eur J Rheumatol. 2022 Oct. PMID: 35156633.
• Bayesian local exchangeability design for phase II basket trials.Liu Y, Kane M, Esserman D, Blaha O, Zelterman D, Wei W. Stat Med. 2022 Sep 30; 2022 Jul 1. PMID: 35777367.
• Data Availability Statements in The Journal of Organic Chemistry, Organic Letters, and ACS Organic & Inorganic Au.Masson G, Kozlowski MC, Miller SJ. Org Lett. 2022 Sep 23; 2022 Sep 12. PMID: 36094072.
• Structural Insights into Binding of Remdesivir Triphosphate within the Replication-Transcription Complex of SARS-CoV-2.Wang J, Shi Y, Reiss K, Maschietto F, Lolis E, Konigsberg WH, Lisi GP, Batista VS. Biochemistry. 2022 Sep 20; 2022 Aug 31. PMID: 36044776.
• Practical method for RF pulse distortion compensation using multiple square pulses for low-field MRI.Ha Y, Selvaganesan K, Wu B, Hancock K, Rogers C 3rd, Hosseinnezhadian S, Galiana G, Constable RT. PLoS One. 2022; 2022 Sep 16. PMID: 36112594.
• Chemoselective Acylation of Nucleosides.Tang Y, Grange RL, Engl OD, Miller SJ. Chemistry. 2022 Sep 16; 2022 Jul 26. PMID: 35730928.
• Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions.Fang AM, Shumaker LA, Martin KD, Jackson JC, Fan RE, Khajir G, Patel HD, Soodana-Prakash N, Vourganti S, Filson CP, Sonn GA, Sprenkle PC, Gupta GN, Punnen S, Rais-Bahrami S. Cancer. 2022 Sep 15; 2022 Jul 12. PMID: 35819253.
• Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy.Ueno D, Vasquez JC, Sule A, Liang J, van Doorn J, Sundaram R, Friedman S, Caliliw R, Ohtake S, Bao X, Li J, Ye H, Boyd K, Huang RR, Dodson J, Boutros P, Bindra RS, Shuch B. Oncotarget. 2022; 2022 Sep 14. PMID: 36128328.
• BRCA2 BRC missense variants disrupt RAD51-dependent DNA repair.Jimenez-Sainz J, Mathew J, Moore G, Lahiri S, Garbarino J, Eder JP, Rothenberg E, Jensen RB. Elife. 2022 Sep 13; 2022 Sep 13. PMID: 36098506.
• Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor-induced diabetes.Perdigoto AL, Deng S, Du KC, Kuchroo M, Burkhardt DB, Tong A, Israel G, Robert ME, Weisberg SP, Kirkiles-Smith N, Stamatouli AM, Kluger HM, Quandt Z, Young A, Yang ML, Mamula MJ, Pober JS, Anderson MS, Krishnaswamy S, Herold KC. JCI Insight. 2022 Sep 8; 2022 Sep 8. PMID: 35925682.
• Stereocontrolled Synthesis of the Fully Glycosylated Monomeric Unit of Lomaiviticin A.Xu Z, DiBello M, Wang Z, Rose JA, Chen L, Li X, Herzon SB. J Am Chem Soc. 2022 Sep 7; 2022 Aug 23. PMID: 35998350.
• Microfluidic immuno-serology assay revealed a limited diversity of protection against COVID-19 in patients with altered immunity.Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan JM, Buitrago-Pocasangre NC, Lele N, Asashima H, Racke MK, Wilson JE, Givens TS, Tomayko MM, Schulz WL, Longbrake EE, Hafler DA, Halene S, Fan R. bioRxiv. 2022 Sep 2; 2022 Sep 2. PMID: 36093346.
• Criteria for Cerebrospinal Fluid Diversion in Retractorless Sphenoid Wing Meningioma Surgery: A Technical Report.Vetsa S, Nadar A, Vasandani S, Gorelick E, Bungard J, Barak T, Fulbright RK, Marianayagam NJ, Moliterno J. J Neurol Surg Rep. 2022 Jul; 2022 Sep 2. PMID: 36060292.
• Alcohol Use and Use Disorder and Cancer Risk: Perspective on Causal Inference.Zhou H, Vasiliou V. Complex Psychiatry. 2022 Sep; 2022 Aug 9. PMID: 36601413.
• Prediction of Adverse Pathology at Radical Prostatectomy in Grade Group 2 and 3 Prostate Biopsies Using Machine Learning.Paulson N, Zeevi T, Papademetris M, Leapman MS, Onofrey JA, Sprenkle PC, Humphrey PA, Staib LH, Levi AW. JCO Clin Cancer Inform. 2022 Sep. PMID: 36179281.
• Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC).Atkins MB, Abu-Sbeih H, Ascierto PA, Bishop MR, Chen DS, Dhodapkar M, Emens LA, Ernstoff MS, Ferris RL, Greten TF, Gulley JL, Herbst RS, Humphrey RW, Larkin J, Margolin KA, Mazzarella L, Ramalingam SS, Regan MM, Rini BI, Sznol M. J Immunother Cancer. 2022 Sep. PMID: 36175037.
• Targeting Epidermal Growth Factor Receptor in Head and Neck Cancer.Bhatia A. Cancer J. 2022 Sep-Oct 01. PMID: 36165720.
• Integrating Targeted Therapies in the Management of Head and Neck Cancers.Burtness B. Cancer J. 2022 Sep-Oct 01. PMID: 36165719.
• Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.Gerds AT, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A, George TI, Gundabolu K, Hexner E, Hobbs GS, Jain T, Jamieson C, Kaesberg PR, Kuykendall AT, Madanat Y, McMahon B, Mohan SR, Nadiminti KV, Oh S, Pardanani A, Podoltsev N, Rein L, Salit R, Stein BL, Talpaz M, Vachhani P, Wadleigh M, Wall S, Ward DC, Bergman MA, Hochstetler C. J Natl Compr Canc Netw. 2022 Sep. PMID: 36075392.
• Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials.Gettinger SN, Huber RM, Kim DW, Bazhenova L, Hansen KH, Tiseo M, Langer CJ, Paz-Ares Rodríguez LG, West HL, Reckamp KL, Weiss GJ, Smit EF, Hochmair MJ, Kim SW, Ahn MJ, Kim ES, Groen HJM, Pye J, Liu Y, Zhang P, Vranceanu F, Camidge DR. JTO Clin Res Rep. 2022 Sep; 2022 Jul 31. PMID: 36065449.
• LACC1 bridges NOS2 and polyamine metabolism in inflammatory macrophages.Wei Z, Oh J, Flavell RA, Crawford JM. Nature. 2022 Sep; 2022 Aug 17. PMID: 35978195.
• APOBEC mutagenesis and selection for NFE2L2 contribute to the origin of lung squamous-cell carcinoma.Cannataro VL, Kudalkar S, Dasari K, Gaffney SG, Lazowski HM, Jackson LK, Yildiz I, Das RK, Gould Rothberg BE, Anderson KS, Townsend JP. Lung Cancer. 2022 Sep; 2022 Jul 9. PMID: 35872531.
• Addressing the diagnostic and therapeutic dilemmas of ovarian immature teratoma: Report from a clinicopathologic consensus conference.Pashankar F, Hanley K, Lockley M, Stoneham S, Nucci MR, Reyes-Múgica M, Elishaev E, Vang R, Veneris J, Rytting H, Olson T, Hazard K, Covens A, Arora R, Billmire D, Al-Ibraheemi A, Ulbright TM, Frazier L, Hirsch MS. Eur J Cancer. 2022 Sep; 2022 Jul 18. PMID: 35863107.
• Topical formulation based on disease-specific nanoparticles for single-dose cure of psoriasis.Mai Y, Ouyang Y, Yu M, Qin Y, Girardi M, Saltzman WM, Cocco E, Zhao C, Yu L, Jia Y, Xiao L, Dou L, Deng W, Liu Y, Xie J, Deng Y. J Control Release. 2022 Sep; 2022 Jul 12. PMID: 35817278.
• Clinical utility of MR/ultrasound fusion-guided biopsy in patients with lower suspicion lesions on active surveillance for low-risk prostate cancer.Lokeshwar SD, Nguyen J, Rahman SN, Khajir G, Ho R, Ghabili K, Leapman MS, Weinreb JC, Sprenkle PC. Urol Oncol. 2022 Sep; 2022 Jul 8. PMID: 35811206.
• Programmed Death-Ligand 1 and Programmed Death-Ligand 2 mRNAs Measured Using Closed-System Quantitative Real-Time Polymerase Chain Reaction Are Associated With Outcome and High Negative Predictive Value in Immunotherapy-Treated NSCLC.Fernandez AI, Gavrielatou N, McCann L, Shafi S, Moutafi MK, Martinez-Morilla S, Vathiotis IA, Aung TN, Yaghoobi V, Bai Y, Chan YG, Weidler J, Herbst R, Bates M, Rimm DL. J Thorac Oncol. 2022 Sep; 2022 Jun 25. PMID: 35764237.
• Patient Preferences for Benefits, Risks, and Administration Route of Hypomethylating Agents in Myelodysplastic Syndromes.Zeidan AM, Tsai JH, Karimi M, Schmier J, Jayade S, Zormpas E, Hassan A, Ruiters D, Anthony C, Hill K, Wert T, Botteman M. Clin Lymphoma Myeloma Leuk. 2022 Sep; 2022 May 2. PMID: 35729009.
• Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403).Mack PC, Miao J, Redman MW, Moon J, Goldberg SB, Herbst RS, Melnick MA, Walther Z, Hirsch FR, Politi K, Kelly K, Gandara DR. Clin Cancer Res. 2022 Sep 1. PMID: 35713632.
• Association Between Postdischarge Medical Oncology Follow-Up Appointments and Downstream Health Care Use: A Single-Institution Experience.Xiang J, Chow R, Reynoso A, Carafeno T, Deshpande H, Strait M, Prsic E. JCO Oncol Pract. 2022 Sep; 2022 Jun 13. PMID: 35696632.
• Association Between Private Equity Acquisition of Urology Practices and Physician Medicare Payments.Nie J, Hsiang W, Lokeshwar SD, McMahon G, Demkowicz PC, Kenney PA, Breyer BN, Leapman MS. Urology. 2022 Sep; 2022 Jun 6. PMID: 35680053.
• Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes.Zeidan AM, Joshi N, Kale H, Wang WJ, Corman S, Salimi T, Epstein RS. Clin Lymphoma Myeloma Leuk. 2022 Sep; 2022 Apr 22. PMID: 35614009.
• Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma.Avery J, Chandhok N, Rainey C, Torres R, Huntington S, Isufi I, Seropian S, Xu ML, Foss F. Clin Lymphoma Myeloma Leuk. 2022 Sep; 2022 Apr 22. PMID: 35568635.
• First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.Yap TA, Gainor JF, Callahan MK, Falchook GS, Pachynski RK, LoRusso P, Kummar S, Gibney GT, Burris HA, Tykodi SS, Rahma OE, Seiwert TY, Papadopoulos KP, Blum Murphy M, Park H, Hanson A, Hashambhoy-Ramsay Y, McGrath L, Hooper E, Xiao X, Cohen H, Fan M, Felitsky D, Hart C, McComb R, Brown K, Sepahi A, Jimenez J, Zhang W, Baeck J, Laken H, Murray R, Trehu E, Harvey CJ. Clin Cancer Res. 2022 Sep 1. PMID: 35511938.
• Cemiplimab for Orbital Squamous Cell Carcinoma in 11 Cases.Steren B, Burtness B, Bhatia A, Demirci H, Shinder R, Yoo D, Tse B, Pointdujour-Lim R. Ophthalmic Plast Reconstr Surg. 2022 Sep-Oct 01; 2022 May 3. PMID: 35502804.
• A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia.Prebet T, Goldberg AD, Jurcic JG, Khaled S, Dail M, Feng Y, Green C, Li C, Ma C, Medeiros BC, Yan M, Grunwald MR. Leuk Lymphoma. 2022 Sep; 2022 May 1. PMID: 35491816.
• The effects of androgen deprivation on working memory and quality of life in prostate cancer patients: The roles of hypothalamic connectivity.Chaudhary S, Zhornitsky S, Roy A, Summers C, Ahles T, Li CR, Chao HH. Cancer Med. 2022 Sep; 2022 Mar 22. PMID: 35315585.
• OligoTRAFTACs: A generalizable method for transcription factor degradation.Samarasinghe KTG, An E, Genuth MA, Chu L, Holley SA, Crews CM. RSC Chem Biol. 2022 Aug 31; 2022 Jul 26. PMID: 36128504.
• Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease.Mohty R, Al Hamed R, Bazarbachi A, Brissot E, Nagler A, Zeidan A, Mohty M. J Hematol Oncol. 2022 Aug 31; 2022 Aug 31. PMID: 36045390.
• Editorial for carbonyl metabolism.Petrash JM, Vasiliou V. Chem Biol Interact. 2022 Aug 25; 2022 May 31. PMID: 35662544.
• Synthesis of 2-Deoxyglycosides Bearing Free Hydroxyl Substituents on the Glycosyl Donor.Hoang KM, Zheng X, Herzon SB. J Org Chem. 2022 Aug 19; 2022 Aug 3. PMID: 35921523.
• RNA m(6)A demethylase ALKBH5 regulates the development of γδ T cells.Ding C, Xu H, Yu Z, Roulis M, Qu R, Zhou J, Oh J, Crawford J, Gao Y, Jackson R, Sefik E, Li S, Wei Z, Skadow M, Yin Z, Ouyang X, Wang L, Zou Q, Su B, Hu W, Flavell RA, Li HB. Proc Natl Acad Sci U S A. 2022 Aug 16; 2022 Aug 8. PMID: 35939687.
• Inflammatory stress signaling via NF-kB alters accessible cholesterol to upregulate SREBP2 transcriptional activity in endothelial cells.Fowler JWM, Zhang R, Tao B, Boutagy NE, Sessa WC. Elife. 2022 Aug 12; 2022 Aug 12. PMID: 35959888.
• Refinement of the Optimized Potentials for Liquid Simulations Force Field for Thermodynamics and Dynamics of Liquid Alkanes.Ghahremanpour MM, Tirado-Rives J, Jorgensen WL. J Phys Chem B. 2022 Aug 11; 2022 Aug 1. PMID: 35914179.
• Photocatalytic Reductive Olefin Hydrodifluoroalkylation Enabled by Tertiary Amine Reductants Compatible with Complex Systems.Ellefsen JD, Miller SJ. J Org Chem. 2022 Aug 5; 2022 Jul 13. PMID: 35829693.
• Cancer tracking system improves timeliness of liver cancer care at a Veterans Hospital: A comparison of cohorts before and after implementation of an automated care coordination tool.Zhang Y, Mezzacappa C, Shen L, Ivatorov A, Petukhova-Greenstein A, Mehta R, Ciarleglio M, Deng Y, Levin W, Steinhardt S, Connery D, Pineau M, Onyiuke I, Taylor C, Rose MG, Taddei TH. PLOS Digit Health. 2022 Aug; 2022 Aug 1. PMID: 36812575.
• Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer.Moutafi MK, Molero M, Martinez Morilla S, Baena J, Vathiotis IA, Gavrielatou N, Castro-Labrador L, de Garibay GR, Adradas V, Orive D, Valencia K, Calvo A, Montuenga LM, Ponce Aix S, Schalper KA, Herbst RS, Paz-Ares L, Rimm DL, Zugazagoitia J. J Immunother Cancer. 2022 Aug. PMID: 36002182.
• Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.Sanborn RE, Pishvaian MJ, Callahan MK, Weise A, Sikic BI, Rahma O, Cho DC, Rizvi NA, Sznol M, Lutzky J, Bauman JE, Bitting RL, Starodub A, Jimeno A, Reardon DA, Kaley T, Iwamoto F, Baehring JM, Subramaniam DS, Aragon-Ching JB, Hawthorne TR, Rawls T, Yellin M, Keler T. J Immunother Cancer. 2022 Aug. PMID: 35940825.
• Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer.Pichert MD, Canavan ME, Maduka RC, Li AX, Ermer T, Zhan PL, Kaminski M, Udelsman BV, Blasberg JD, Park HS, Goldberg SB, Boffa DJ. JAMA Netw Open. 2022 Aug 1; 2022 Aug 1. PMID: 35925606.
• Core packing of well-defined X-ray and NMR structures is the same.Grigas AT, Liu Z, Regan L, O'Hern CS. Protein Sci. 2022 Aug. PMID: 35900019.
• Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC.Kim DW, Gadgeel S, Gettinger SN, Riely GJ, Oxnard GR, Mekhail T, Schmid P, Dowlati A, Heist RS, Wozniak AJ, Singh J, Cha E, Spahn J, Ou SI. JTO Clin Res Rep. 2022 Aug; 2022 Jun 25. PMID: 35875467.
• Polyglycerol and Poly(ethylene glycol) exhibit different effects on pharmacokinetics and antibody generation when grafted to nanoparticle surfaces.Shin K, Suh HW, Grundler J, Lynn AY, Pothupitiya JU, Moscato ZM, Reschke M, Bracaglia LG, Piotrowski-Daspit AS, Saltzman WM. Biomaterials. 2022 Aug; 2022 Jul 11. PMID: 35849999.
• C-H bond activation and sequential addition to two different coupling partners: a versatile approach to molecular complexity.Brandes DS, Ellman JA. Chem Soc Rev. 2022 Aug 1; 2022 Aug 1. PMID: 35822540.
• Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period.Neparidze N, Wang R, Zeidan AM, Podoltsev NA, Shallis RM, Ma X, Davidoff AJ, Huntington SF. Leukemia. 2022 Aug; 2022 Jun 27. PMID: 35761025.
• Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database.Rippel N, Tremblay D, Zubizarreta N, Podoltsev N, Gotlib J, Heaney M, Kuykendall A, O'Connell C, Shammo JM, Fleischman A, Kremyanskaya M, Hoffman R, Mesa R, Yacoub A, Mascarenhas J. Leuk Res. 2022 Aug; 2022 Jun 16. PMID: 35717689.
• Short symmetric and highly selective asymmetric first and second order gradient modulated offset independent adiabaticity (GOIA) pulses for applications in clinical MRS and MRSI.Kumaragamage C, Coppoli A, Brown PB, McIntyre S, Nixon TW, De Feyter HM, Mason GF, de Graaf RA. J Magn Reson. 2022 Aug; 2022 Jun 3. PMID: 35691241.
• Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu.Yadav G, Roque DM, Bellone S, Manavella DD, Hartwich TMP, Zipponi M, Harold J, Tymon-Rosario J, Mutlu L, Altwerger G, Menderes G, Ratner E, Buza N, Hui P, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Alexandrov LB, Santin AD. Gynecol Oncol. 2022 Aug; 2022 May 28. PMID: 35641325.
• Microwave Ablation versus Stereotactic Body Radiotherapy for Stage I Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis.Wu X, Uhlig J, Blasberg JD, Gettinger SN, Suh RD, Solomon SB, Kim HS. J Vasc Interv Radiol. 2022 Aug; 2022 Apr 28. PMID: 35490932.
• Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling.Moutafi M, Martinez-Morilla S, Divakar P, Vathiotis I, Gavrielatou N, Aung TN, Yaghoobi V, Fernandez AI, Zugazagoitia J, Herbst RS, Schalper KA, Rimm DL. J Thorac Oncol. 2022 Aug; 2022 Apr 28. PMID: 35490853.
• A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.Sekeres MA, Schuster M, Joris M, Krauter J, Maertens J, Breems D, Gyan E, Kovacsovics T, Verma A, Vyas P, Wang ES, Ching K, O'Brien T, Gallo Stampino C, Ma WW, Kudla A, Chan G, Zeidan AM. Ann Hematol. 2022 Aug; 2022 Apr 30. PMID: 35488900.
• Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients.Forman R, Deshpande H, Burtness B, Bhatia AK. Head Neck. 2022 Aug; 2022 Apr 30. PMID: 35488876.
• Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.LoRusso P, Ratain MJ, Doi T, Rasco DW, de Jonge MJA, Moreno V, Carneiro BA, Devriese LA, Petrich A, Modi D, Morgan-Lappe S, Nuthalapati S, Motwani M, Dunbar M, Glasgow J, Medeiros BC, Calvo E. Invest New Drugs. 2022 Aug; 2022 Apr 25. PMID: 35467243.
• Perioperative chemotherapy for resectable colorectal liver metastases: Analysis from the Colorectal Operative Liver Metastases International Collaborative (COLOMIC).Gawdi R, Valenzuela CD, Moaven O, Stauffer JA, Del Piccolo NR, Cheung T, Corvera CU, Wisneski AD, Cha C, Russell G, Zarandi N, Dourado J, Shen P. J Surg Oncol. 2022 Aug; 2022 Apr 16. PMID: 35429409.
• Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.Gounder MM, Razak AA, Somaiah N, Chawla S, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Riedel RF, Stacchiotti S, Loggers ET, Ganjoo KN, Le Cesne A, Italiano A, Garcia Del Muro X, Burgess M, Piperno-Neumann S, Ryan C, Mulcahy MF, Forscher C, Penel N, Okuno S, Elias A, Hartner L, Philip T, Alcindor T, Kasper B, Reichardt P, Lapeire L, Blay JY, Chevreau C, Valverde Morales CM, Schwartz GK, Chen JL, Deshpande H, Davis EJ, Nicholas G, Gröschel S, Hatcher H, Duffaud F, Herráez AC, Beveridge RD, Badalamenti G, Eriksson M, Meyer C, von Mehren M, Van Tine BA, Götze K, Mazzeo F, Yakobson A, Zick A, Lee A, Gonzalez AE, Napolitano A, Dickson MA, Michel D, Meng C, Li L, Liu J, Ben-Shahar O, Van Domelen DR, Walker CJ, Chang H, Landesman Y, Shah JJ, Shacham S, Kauffman MG, Attia S. J Clin Oncol. 2022 Aug 1; 2022 Apr 8. PMID: 35394800.
• Relationship Between Participation in ASCO's Quality Oncology Practice Initiative Program and American Board of Internal Medicine's Maintenance of Certification Program.Siegel RD, Garrett-Mayer E, Lipner RS, Kozlik MMP, Vandergrift JL, Crist STS, Chen RC, Chiang AC, Kamal AH. JCO Oncol Pract. 2022 Aug; 2022 Apr 1. PMID: 35363501.
• Pre-Treatment Staging Imaging in Rectal Cancer: Results From the Quality Oncology Practice Initiative.Chen RC, Garrett-Mayer E, Kamal AH, Makhoul I, Kozlik MMP, Crist STS, Chiang AC. JCO Oncol Pract. 2022 Aug; 2022 Mar 30. PMID: 35353546.
• Association of primary tumor laterality with surgical outcomes for colorectal liver metastases: results from the Colorectal Liver Operative Metastasis International Collaborative (COLOMIC).Valenzuela CD, Moaven O, Gawdi R, Stauffer JA, Del Piccolo NR, Cheung TT, Corvera CU, Wisneski AD, Cha C, Mangieri CW, Zarandi NP, Dourado J, Perry KC, Russell G, Shen P. HPB (Oxford). 2022 Aug; 2022 Feb 28. PMID: 35289279.
• Mechanism-based design of agents that selectively target drug-resistant glioma.Lin K, Gueble SE, Sundaram RK, Huseman ED, Bindra RS, Herzon SB. Science. 2022 Jul 29; 2022 Jul 28. PMID: 35901163.
• Barriers and facilitators to lung cancer screening and follow-up.Bernstein E, Bade BC, Akgün KM, Rose MG, Cain HC. Semin Oncol. 2022 Jul 25; 2022 Jul 25. PMID: 35927099.
• Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy.Zeidan AM, Fenaux P, Gobbi M, Mayer J, Roboz GJ, Krauter J, Robak T, Kantarjian HM, Novák J, Jedrzejczak WW, Thomas X, Ojeda-Uribe M, Miyazaki Y, Min YH, Yeh SP, Brandwein JM, Gercheva L, Demeter J, Griffiths EA, Yee KWL, Issa JJ, Bewersdorf JP, Keer H, Hao Y, Azab M, Döhner H. Blood. 2022 Jul 21. PMID: 35507690.
• Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes.Abaza Y, Zeidan AM. Cells. 2022 Jul 20; 2022 Jul 20. PMID: 35883692.
• Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A.Reckamp KL, Redman MW, Dragnev KH, Minichiello K, Villaruz LC, Faller B, Al Baghdadi T, Hines S, Everhart L, Highleyman L, Papadimitrakopoulou V, Neal JW, Waqar SN, Patel JD, Gray JE, Gandara DR, Kelly K, Herbst RS. J Clin Oncol. 2022 Jul 20; 2022 Jun 3. PMID: 35658002.
• Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score.Burtness B, Rischin D, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Ge J, Swaby RF, Gumuscu B, Harrington K. J Clin Oncol. 2022 Jul 20; 2022 Mar 25. PMID: 35333599.
• Simultaneous microvascular decompression for trigeminal neuralgia and hemifacial spasm involving a dolichoectatic vertebral artery in an elderly patient: illustrative case.Marianayagam NJ, Qureshi HM, Vasandani S, Vetsa S, Jalal M, Wu K, Moliterno J. J Neurosurg Case Lessons. 2022 Jul 18; 2022 Jul 18. PMID: 36046706.
• Targeted Degradation of mRNA Decapping Enzyme DcpS by a VHL-Recruiting PROTAC.Swartzel JC, Bond MJ, Pintado-Urbanc AP, Daftary M, Krone MW, Douglas T, Carder EJ, Zimmer JT, Maeda T, Simon MD, Crews CM. ACS Chem Biol. 2022 Jul 15; 2022 Jun 24. PMID: 35749470.
• RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition.Hunihan L, Zhao D, Lazowski H, Li M, Qian Y, Abriola L, Surovtseva YV, Muthusamy V, Tanoue LT, Rothberg BEG, Schalper KA, Herbst RS, Wilson FH. Clin Cancer Res. 2022 Jul 15. PMID: 35247929.
• Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer.Silk AW, Barker CA, Bhatia S, Bollin KB, Chandra S, Eroglu Z, Gastman BR, Kendra KL, Kluger H, Lipson EJ, Madden K, Miller DM, Nghiem P, Pavlick AC, Puzanov I, Rabinowits G, Ruiz ES, Sondak VK, Tavss EA, Tetzlaff MT, Brownell I. J Immunother Cancer. 2022 Jul. PMID: 35902131.
• Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects.Peters S, Paz-Ares L, Herbst RS, Reck M. J Immunother Cancer. 2022 Jul. PMID: 35858709.
• Visible Light-Mediated, Highly Diastereoselective Epimerization of Lactams from the Most Accessible to the More Stable Stereoisomer.Kazerouni AM, Brandes DS, Davies CC, Cotter LF, Mayer JM, Chen S, Ellman JA. ACS Catal. 2022 Jul 1; 2022 Jun 16. PMID: 35832573.
• Brief Report: Implementation of a Universal Prescreening Protocol to Increase Recruitment to Lung Cancer Studies at a Veterans Affairs Cancer Center.Xiang JJ, Roy A, Summers C, Delvy M, O'Donovan J, Christensen J, Dwy C, Perry L, Connery D, Rose MG, Sheehan K, Chao HH. JTO Clin Res Rep. 2022 Jul; 2022 Jun 8. PMID: 35815320.
• Quantitative tissue analysis and role of myeloid cells in non-small cell lung cancer.Henick BS, Villarroel-Espindola F, Datar I, Sanmamed MF, Yu J, Desai S, Li A, Aguirre-Ducler A, Syrigos K, Rimm DL, Chen L, Herbst RS, Schalper KA. J Immunother Cancer. 2022 Jul. PMID: 35793873.
• Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML.Albert DH, Goodwin NC, Davies AM, Rowe J, Feuer G, Boyiadzis M, Dorritie KA, Mancini M, Gandour-Edwards R, Jonas BA, Borthakur G, Aldoss I, Rizzieri DA, Odenike O, Prebet T, Singh S, Popovic R, Shen YU, McDaniel KF, Kati WM, Modi DA, Motwani M, Wolff JE, Frost DJ. In Vivo. 2022 Jul-Aug. PMID: 35738590.
• Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities.Kim TK, Vandsemb EN, Herbst RS, Chen L. Nat Rev Drug Discov. 2022 Jul; 2022 Jun 14. PMID: 35701637.
• A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer.Cho BC, Goldberg SB, Kim DW, Socinski MA, Burns TF, Lwin Z, Pathan N, Ma WD, Masters JC, Cossons N, Wilner K, Nishio M, Husain H. Expert Opin Investig Drugs. 2022 Jul; 2022 Jun 3. PMID: 35657653.